Section |
Name |
Details |
06.01.02.03 |
Exenatide (Immediate-release) Byetta® |
Bath
Salisbury and Swindon
- Existing patients only.
- 5 microgram, 10 microgram - 60 dose pre-filled pen (250 microgram/ml)
- Dose: 5mg BD for one month, increase to 10 micrograms BD if response insufficient and patient tolerating medication.
|
14.04 |
23-valent pneumococcal polysaccharide vaccine Previously known as Pneumovax® II |
- Primary Care: at NHS expense for patients in accordance with the national immunisation programme. Adults over 65 years and at risk groups, as listed in the Green Book, chapter 25.
- Use practice stock and claim on FP34 appendix form.
|
05.03.01 |
Abacavir |
- Tablets 300mg
- Oral solution 20mg/ml
|
05.03.01 |
Abacavir and Lamivudine Tablet |
- 600 mg of abacavir (as sulfate) and 300 mg lamivudine
|
10.01.03 |
Abatacept Orencia® |
- 250mg vial, powder for reconstitution. Injection 125mg pre-filled syringe
- Commissioned by CCG for:
- The treatment of rheumatoid arthritis in line with NICE TA195, TA375.
- Commissioned by NHS England From Specialist Centres Only for:
- Juvenile idiopathic arthritis in line with NICE TA373.
- Paediatric indications where an adult NICE TA is available.
- Check individual Trust contracting arrangements.
|
02.09 |
Abciximab |
- GWH and SFT only
- Non formulary at RUH
- 10mg in 5ml
- Adjunct in percutaneous coronary intervention
|
08.01.05 |
Abemaciclib |
- 50mg, 100mg, 150mg film coated tablets
|
08.03.04.02 |
Abiraterone |
|
04.10.01 |
Acamprosate |
- Tablets e/c 333mg
- Use only in the context of supervised withdrawal regime with psychosocial recovery programme. For maintenance of abstinence in alcohol dependent patients.
- See shared care guidelines below for maintenance of abstinence.
- Acamprosate is supported by NICE (CG115) following assisted withdrawal or for harmful drinkers and people with mild alcohol dependence who have requested a pharmacological intervention in combination with an individual psychological intervention.
|
11.06 |
Acetazolamide |
 BaNES and Salisbury for glaucoma
 Swindon for glaucoma
- 250mg tablets and 250mg MR capsules (NB capsules more costly and stock shortages until at least July 2020)
- Note: at RUH and GWH, acetazolamide is included on the formulary for idiopathic intracranial hypertension as
Unlicensed indication
- Note - Private prescription only for prophylaxis of mountain sickness. Not licensed and NOT for prescribing on NHS. For further information see link below
|
11.06 |
Acetazolamide Injection |
|
12.01.01 |
Acetic Acid 2% |
- Please note: Patients should self-care in the first instance
|
20 |
Acetic acid 5% |
- GWH Obstetric and Gynae OP stock
|
11.08.02 |
Acetylcholine |
- 20mg powder and solvent for solution for intraocular irrigation
|
03.11 |
Acetylcysteine |
- 600mg effervescent tablets (licensed) (Swindon only)
- 600mg Tablets (unlicensed)
- 200mg/1ml 10ml ampoules Infusion (Also used for treatment of poisoning)
- Interstitial pneumonia (unlicensed)/ Idiopathic Pulmonary Fibrosis (unlicensed)
- Also used as renal protection before CT scan with contrast agent
- NHS England Specialised Commissioning - Respiratory Interstital Lung Disease Adults
|
11.08.01 |
Acetylcysteine |
- Acetylcysteine eye drops 5%, hypromellose 0.35% 10ml (includes benzalkonium chloride, disodium edetate)
- Specialist initiation - Only if filamentary keratitis present.
|
18 |
Acetylcysteine Parvolex |
|
05.03.02.01 |
Aciclovir |

- 200mg
- 400mg
- 800mg
- During Varicella Zoster Immunoglobulin Shortage (Aug 2018):
 "off label" use during the shortage of Varicella Zoster Immunoglobulin (VZIG)in patients who are 20+ weeks pregnant.Only to be used as AMBER on specialist advice.
- Dose 800mg four times a day from day 7 to 14 after exposure
|
05.03.02.01 |
Aciclovir |
- 250mg/10ml IV infusion
- 500mg/20ml IV infusion
- 1g/40ml IV infusion
|
13.10.03 |
Aciclovir 5% |
- Cream 5% 2g, 10g
- Apply to lesions every 4 hours (5 times a day) for 5-10 days
|
13.05.02 |
Acitretin |
- Capsules 10mg, 25mg
- Consultant Dermatologist Only
- For severe resistant or complicated psoriasis,- not recommended in women of child bearing age.
- Pregnancy Prevention Scheme applies if prescribed in women of child bearing age. Acitretin is highly teratogenic and must not be used by women who are pregnant. The same applies to women of childbearing potential unless strict contraception is practiced 4 weeks before, during and for 3 years after treatment
|
03.01.02 |
Aclidinium Eklira Genuair® |
- For patients with manual dexterity problems or an eGFR<30ml/min.
- Inhalation powder 322 microgram/dose aclidinium
|
03.01.04 |
Aclidinium and formoterol inhaler Duaklir Genuair ® |
- Combination of Formoterol fumarate / Aclidinium (as bromide)
- Breath actuated dry powder MDI 12/340 Genuair device
|
18 |
Activated charcoal |
|
01.05.03 |
Adalimumab Imraldi®Amgevita®Humira® |
- 40mg pre-filled pens or pre-filled syringes.
- Prescribe BY BRAND. Biosimilar first-line option. Imraldi® first-line biosimilar.
- Please note: Adalimumab should be prescribed in accordance with either the BSW STP Ulcerative Colitis Biologic / Biosimilar Commissioning Pathway or the BSW STP Crohn's Disease Biologic / Biosimilar Commissioning Pathway.
|
10.01.03 |
Adalimumab Imraldi®Amgevita®Humira® |
- Injection 40mg prefilled syringe, prefilled pen
- Prescribe by brand. Biosimilar first-line option. Imraldi® first line biosimilar across BSW
- For rheumatoid arthritis in accordance with NICE TA375.
- Commissioned by NHS England From Specialist Centres Only for:
- Juvenile idiopathic arthritis in line with NICE TA373.
- Paediatric indications where an adult NICE TA is available
- Check Trust contracting arrangements.
|
13.05.03 |
Adalimumab Imraldi® Amgevita® Humira® |
- Prescribe by brand. Biosimilar first-line option. Imraldi® first line biosimilar across BSW
- Injection 40mg pre-filled syringe
- Commissioned by CCG for psoriasis in accordance with NICE TA146.
Commissioned by NHS England via specialist centres only for treating moderate to severe hidradenitis suppurativa in accordance with NICE TA392.
|
13.06.01 |
Adapalene |
- Cream 0.1% 45g
- Gel 0.1% 45g
- For the prevention of relapse.
|
13.06.01 |
Adapalene + Benzoyl peroxide Topical gel |
- Gel Adapalene 0.1% and Benzoyl Peroxide 2.5% 45g
- Gel Adapalene 0.3% and Benzoyl Peroxide 2.5% 45g
|
09.05.01.01 |
Adcal ® |
- Swindon only
- BaNES and Salisbury - not on formulary
- 1500mg chewable tablets, each containing 1.5g calcium carbonate.
|
05.03.03.01 |
Adefovir Dipivoxil Hepsera® |
|
02.03.02 |
Adenosine |
|
03.04.03 |
Adrenaline / epinephrine EpiPen® Jext® |
Epipen® brand (150 microgram and 300microgram devices) is considered the first line Adrenaline Auto Injector (AAI) across BSW.
Jext® brand (150 microgram and 300microgram devices) may also be used across BSW if supply issues necessitate.
Emerade ® brand (150microgram, 300microgram and 500microgram devices) were previously included on the formulary but NOT currently available. See further information below.
Injection technique is device specific. To ensure patients receivethe AAI that they have been trained to use, prescribers should prescribe by brand. Resources to support initial training, or when switching device:
Epipen demo video; Epipen prescriber checklist; Jext demo video;
Additional notes:
All healthcare professionals in primary, secondary or specialist healthcare services who prescribe, supply or administer AAIs, or who advise patients and carers should ensure that:
- When patients next request a prescription, they are reviewed to ensure their AAI prescription is still appropriate.
- Prescribers issue no more than TWO AAIs per patient (exceptions suggested to this in a 2019 DHSC supply disruption alert are ▪ where schools require separate AAI(s) to be kept on the school premises (e.g. in a medical room) in which case prescribers may need to consider issuing more than two but no more than four AAIs per child; ▪ for the rare scenario where patients might need more than two AAIs prescribed (for example, prior severe reaction resistant to treatment with adrenaline), the prescriber may issue additional AAIs).
- Patients are aware to not expose any brand of AAI to temperatures above 25°C. Storage above 25°C may increase the likelihood of a fault occurring with AAIs.
- Patients use their device(s) as instructed until the expiry date/extended expiry date. N.B. a device expiring in ‘March 2020’ does not expire until 31 March 2020.
- Patients are aware of the signs of anaphylaxis and the actions they should immediately take.
June 2020 -AAIs Supply Issues.
Emerade® 150, 300 and 500 microgram AAI devices will be
unavailable for the foreseeable future. Patient and/or carers
should return Emerade AAIs to their local pharmacy once they have
obtained a prescription for, and been supplied with, an alternative brand.
While Emerade® remains unavailable, alternative devices should be considered
- Emerade® is the only AAI available in 500microgram formulation but The MHRA note that there is evidence to suggest that a single EpiPen® (300 microgram) or Jext® (300 microgram) device will be a suitable replacement for a single Emerade® 500 microgram device.
|
03.04.03 |
Adrenaline / Epinephrine Adrenaline 1 in 1000 |
|
03.04.03 |
Adrenaline / Epinephrine Adrenaline 1 in 1000 |
 - GWH
- Non-formulary - RUH
- Non-formulary - SFT
|
02.07.03 |
Adrenaline / Epinephrine 1 in 10,000 |
- Injection 100 micrograms/ml, 1ml amp, 10ml amp,
- Injection 100 micrograms/ml 3ml, 10ml prefilled syringes
|
03.04.03 |
Adrenaline / epinephrine 1 in 10,000 |
- 1 in 10, 000 ampoules and minijet.
- Slow IV inj reserved for severely ill patients where there is doubt about adequacy of the circulation and absorption from the IM site with ECG monitoring.
- Ensure that the correct strength of adrenaline injection is used.
|
03.01.05 |
AeroChamber Plus ® |
- Aerochamber Plus standard with mask cannot be used without the mask.
- Please prescribe standard device with mouthpiece if the mask is not required.
|
08.01.05 |
Afatinib |
- 20mg, 30mg, 40mg and 50mg tablets
|
11.08.02 |
Aflibercept Eylea® |
|
20 |
Ajmaline |
- For use within RUH
- Approved for use in the diagnosis of Brugada syndrome (unlicensed) by Consultant Cardiologists (for diagnostic use only).
|
05.05.08 |
Albendazole |
- Eskazole 400mg tablets (Imported (France)
- Zentel 200mg chewable tablets (Imported (Australia)
- Zentel 400mg chewable tablets (Imported (United States)
- Dermatology use for cutaneous larva migrans
|
09.02.02.02 |
Albumin Solution |
- GWH and SFT
- RUH - Non formulary
- 4.5% & 20% infusions
|
08.02.03 |
Alemtuzumab |
|
06.06.02 |
Alendronic Acid |
- Tablets 70mg weekly
- Oral Solution 70mg/100ml (for patients with NG or PEG tubes)
|
09.06.04 |
Alfacalcidol One-Alpha® |
 Salisbury
 Swindon and BaNES
- Capsules 250 nanograms, 500 nanograms, 1 microgram
- Oral drops- 2 micrograms/mL, one drop contains approximately 100 nanograms
- BaNES : Recommended brand - One- Alpha
- Note: Patients receiving alfacalcidol or calcitriol should have their plasma calcium levels checked regularly (at intervals recommended by specialist, usually evey 3-6 months)
|
15.01.04.03 |
Alfentanil |
- 1mg in 2ml amp
- 5mg in 10ml amp
- 5mg in 1ml amp intensive care injection
Note - also included as an AMBER TLS drug in SWINDON ONLY for use in palliative care. See here
|
21.02.01 |
Alfentanil |
Alfentanil is only included on the BSWformulary for palliative care use in primary care when prescribed in SWINDON under specialist recommendation (AMBER TLS).
SAFETY NOTE - Alfentanil is a potent opioid anaesthetic agent that has a lower analgesic potency than fentanyl, but a much more rapid onset of action. Peak analgesic and respiratory depressant effects occur within 90 seconds. Use care when prescribing to ensure the dose is correct as severe harm and death has occurred from dose errors.
Preparations available:
- 500micrograms in 1mL (available as 1mg/2ml and 5mg/10ml ampoules)
- 5mg in 1ml (THIS IS TEN TIMES THE STRENGTH OF PREPARATION ABOVE. This higher strength preparation will not be widely stocked in clinical settings)
All alfentanil preparations are RED TLS drugs in Wiltshire ans BaNES. |
07.04.01 |
Alfuzosin |
- Tablets 2.5mg
- Modified-release tablets 10mg
|
02.12 |
Alirocumab Praluent® |
- 75mg/ml, 150mg/ml solution for injection in a pre filled pen
- Consultant Lipid specialist only.
- As an adjunct to diet in primary hypercholesterolaemia or mixed dyslipidaemia: with a statin when LDL-C response to a statin alone is insufficient, and alone or with other lipid-lowering treatments if statins are contraindicated or not tolerated.
|
13.05.01 |
Alitretinoin |
- Oral alitretinoin is licensed for the treatment of severe chronic hand eczema unresponsive to potent topical corticosteroids, in adults.
- Alitretinoin should ONLY be prescribed by dermatologists.
- Prescriptions of alitretinoin for women of childbearing potential should be limited to 30 days of treatment and continuation of treatment requires a new prescription. Ideally, pregnancy testing, issuing a prescription and dispensing of alitretinoin should occur on the same day. Dispensing of alitretinoin should occur within a maximum of 7 days of the prescription.
- Pregnancy is an absolute contraindication to treatment with alitretinoin.
- A treatment course of alitretinoin may be given for 12 to 24 weeks depending on response.
- Discontinuation of therapy should be considered for patients who still have severe disease after the initial 12 weeks of treatment. In the event of relapse, patients may benefit from further treatment courses of alitretinoin. Patients should still be advised to use daily emollients during therapy and once the eczema has cleared.
- Capsules 10mg; 30mg
- Please see links below to risk materials on generic and branded alitretinoin forms
- Use for other indications is via IFR application only to CCG
|
10.01.04 |
Allopurinol |
- 100mg and 300mg tablets
- The dose of allopurinol should be reduced in patients with renal failure.
|
04.07.04.01 |
Almotriptan |
- Swindon only
- Tablets 12.5mg
- The maximum recommended dose is two doses in 24 hours.
|
06.01.02.03 |
Alogliptin |
- 6.25mg, 12.5mg, 25mg
- Not licensed for monotherapy and no data to support the use of alogliptin with metformin & a sulphonylurea in triple oral therapy
- First line DPP-4 for all new patients who fulfil criteria in accordance with NICE guidance NG28 December 2015
- Most cost-effective gliptin
- Renal Impairment: See SPC for dose adjustments
|
09.06.05 |
Alpha Tocopheryl Acetate Vitamin E Oral |
 SFT
 GWH
 RUH
unlicensed tablets 100mg - Available on a names patient basis only and therefore are considerably more expensive than the suspension.
- Suspension 500mg in 5ml
|
07.01.01.01 |
Alprostadil Prostin VR® |
- RUH only
- Non formulary at GWH and SFT
- 500 micrograms/ml solution for infusion
|
07.04.05 |
Alprostadil Vitaros® |
- 3mg/g cream for application to tip of penis.
- GWH and SFT only
- Non formulary at RUH
|
07.04.05 |
Alprostadil Caverject® |
- 10 microgram, 20 microgram, 40 microgram intracavernosal injection.
- Please note patients will be taught, in clinic, how to administer the dual chamber system. If this form of Caverject is unavailable, patients should not be switched to other Caverject preparations, unless advised by a specialist, as they will need to be re-trained in how to use the new device.
|
07.04.05 |
Alprostadil Viridal® Duo |
- 10 microgram, 20 microgram, 40 microgram intracavernosal injection.
|
07.04.05 |
Alprostadil MUSE® |
- 125 microgram, 250 microgram, 500 microgram, 1000 microgram transurethral delivery system.
|
02.10.02 |
Alteplase |
|
02.10.02 |
Alteplase |
 - GWH - For use by GWH Ophthalmologists for the treatment of submacular haemorrhage, following appropriate training. **Please note this is an off-label indication**.
- Non-formulary - Bath & Salisbury.
- Vial: 10mg
|
16.02 |
Alteplase Actilyse Cathflo |
- 1 vial with powder contains: 2 mg alteplase (corresponding to 1,160,000 IU)
- Paediatric central venous catheter management
|
09.04.02 |
Altrajuce |
- Not suitable for people with diabetes, COPD and wounds due to carbohydrate:protein ratio
- 200ml bottle
- See ONS guidance for full product details (link at top)
|
09.04.02 |
Altraplen Compact |
- For those who require smaller volumes or with fluid restrictions
- 125ml bottle
- See ONS guidance for full product details (link at top)
|
A2.02.02.03 |
Altraplen Compact ® |
125 ml fluid
28 day supply = 56 bottles, 7000 ml
300 kcals, 12 g protein, 125 ml fluid
IDDSI Level 1 - Slightly thick fluids |
A2.04.01.02 |
Altrashot® |
120 ml bottle
28 day supply = 28 bottles, 3360 ml
420 kcal, 6 g protein
Recommended dose = 4 x 30 ml / day
IDDSI level 2 - Mildly thick |
09.05.02.02 |
Aluminium Hydroxide Alu-Cap® |
 Banes and Wiltshire
 Swindon
|
13.12 |
Aluminium Salts |
- 20% aluminium chloride hexahydrate in an alcoholic basis
- Anhydrol Forte®, 60ml
- Driclor® 60ml, 75ml
- Notes: Aluminium chloride is a potent antiperspirant used in the treatment of severe hyperhidrosis.
|
04.09.01 |
Amantadine |
- Capsules 100mg
- Syrup 50mg in 5ml
- For Parkinsons Disease
- 'Off label' for the treatment of fatigue in Multiple Sclerosis according to NICE CG186 Oct14
|
11.03.01 |
Amikacin |
- 500mg/2ml solution for injection
- GWH only. For treatment of Acanthamoeba keratitis.
- Non formulary at RUH and SFT
|
16.15 |
Amikacin |
Swindon only
- Paediatric consultant/microbiology advice only
- Monitoring of drug levels required - NOT ROUTINELY STOCKED AT GWH
Non-formulary at BaNES and Salisbury |
02.02.03 |
Amiloride Hydrochloride Tablet |
- Tablets 5mg
- Note: Amiloride is a weak diuretic, but is useful for potassium conservation and is the most appropriate alternative to potassium supplements
|
03.01.03 |
Aminophylline Phyllocontin Continus® |
- Modified release tablets 225mg (Phyllocontin®) m/r
- In asthma - use only at Step 4, after long acting β2 agonists,leukotriene antagonist and high dose steroids. Referral may be preferable.
- In COPD - Not recommended for routine use. Referral may be preferable.
|
03.01.03 |
Aminophylline IV |
- Aminophylline Injection 250 mg/10ml
- For selected patients with acute severe asthma or severe exacerbations of COPD.
|
02.03.02 |
Amiodarone |
- Injection 150mg in 3ml
- Pre-filled syringe 300mg in 10ml
- Note: Should only be used where facilities for cardiac monitoring, defibrillation and cardiac pacing exist.
|
02.03.02 |
Amiodarone Hydrochloride Oral |
- Tablets 100mg, 200mg
- A Shared Care Document is in the process of being written for BSW in line with NHSE guidance (June 2019) that prescribers should not initiate amiodarone in primary care for any new patient and that if, in exceptional circumstances, there is a clinical need for amiodarone to be prescribed, this should be undertaken in a cooperation arrangement with a multi-disciplinary team and/or other healthcare professional.
|
04.02.01 |
Amisulpride |
- Tablets 50mg, 100mg, 200mg, 400mg
- Oral Solution
|
04.03.01 |
Amitriptyline |
- Tablets 10mg, 25mg, 50mg
- Oral solution 25mg in 5ml
- Not recommended for the treatment of depression – see BNF. A sedating TCA with a high incidence of side-effects and can be fatal in overdose. Low dose useful for neuropathic pain.
|
04.07.03 |
Amitriptyline |
- Tablet 10mg, 25mg, 50mg
- 'Off label' use for pain
|
04.07.04.02 |
Amitriptyline |
- Tablet 10mg, 25mg, 50mg
- Notes: Initial dose 10mg nocte gradually increasing up to 75mg nocte if necessary (max 150mg nocte).
- Amitriptyline is not included in NICE CG150, but local neurologists recommend considering as a first line option if migraine co-exists with depression, disturbed sleep, chronic pain condition or troublesome tension-type headache. However, amitriptyline is highly anticholinergic. Avoid if >65 years or frail and inform patient of risk of serious side effects including cognitive impairment
- Trial at maximum tolerated dose for 6-8 weeks. Review/stop if not effective.
|
21.01.01.03 |
Amitriptyline |
- Tablet 10mg, 25mg, 50mg
- 'Off label' use for neuropathic pain
|
02.06.02 |
Amlodipine |
- Tablets 5mg, 10mg
- Amlodipine is for angina and hypertension, has a longer duration of action and can be given once a day. The besilate salt should NOT be prescribed as is more costly.
|
13.10.02 |
Amorolfine |
- Nail lacquer 5% 5ml , 3ml
- Apply once or twice a week to affected nail for 6 months for fingernails and 12 months for toenails.
|
05.01.01.03 |
Amoxicillin |
- Capsules 250mg, 500mg.
- Oral suspension (SF) 125mg/1.25ml, 125mg/5ml, 250mg/5ml
|
05.01.01.03 |
Amoxicillin |
|
16.09 |
Amoxycillin |
- Capsules 250mg, 500mg
- Suspension 125mg/5ml and 250mg/5ml
|
05.02 |
Amphotericin |
- Infusion 50mg
- The National Patient Safety Agency has advised all healthcare staff involved in the use of intravenous amphotericin of the potentially lethal results if non-lipid and lipid formulations of the drug are confused. Caution: double check.
|
11.03.02 |
Amphotericin |
- GWH only - Only for treatment of fungal endophthalmitis after consultant or senior ophthalmologist approval. See information sheet for dilution instructions.
- Non formulary at RUH and SFT
|
05.02 |
Amphotericin liposomal Ambisome ® |
- Infusion 50mg.
- The National Patient Safety Agency has advised all healthcare staff involved in the use of intravenous amphotericin of the potentially lethal results if non-lipid and lipid formulations of the drug are confused. Caution: double check.
|
08.01.05 |
Amsacrine |
- 75mg/1.5ml solution for infusion ampoules and diluent
|
09.01.04 |
Anagrelide |
- 500 microgram
- For the treatment of essential thrombocythaemia
|
08.03.04.01 |
Anastrozole |
|
05.02.04 |
Anidulafungin |
- 100mg powder for concentrate for solution for IV infusion
- Treatment of invasive candidiasis in adult non-neutropaenic patients who are unable to tolerate fluconazole or have invasive candidiasis that is resistant to fluconazole as per acute trust guidance.
|
21.01.06 |
Antacid and Oxetacaine |
- Oxetacaine 10mg/5ml with aluminium and magnesium hydroxides Suspension
- For palliative care use
|
12.03.01 |
Antacid with Oxetacaine (Magnesium Hydroxide & Aluminium Hydroxide) |
- Oral suspension: Each 5ml contains 10mg Oxetacaine, Aluminium hydroxide equivalent to 200mg aluminium oxide + 100mg magnesium hydroxide 150ml bottle.
- Not on formulary in GWR and SFT
- RUH only - Antacid and anaesthetic relief of oesophageal pain in palliative care patients (unlicensed)
|
14.05.03 |
Anti-D (Rh0) Immunoglobulin |
|
01.07.01 |
Anusol® |
- Cream, ointment & suppositories.
|
01.07.02 |
Anusol-HC® Rectal |
- Ointment & suppositories.
|
02.08.02 |
Apixaban Eliquis® |
- Tablets 2.5mg, 5mg
- The Traffic Light Status for apixaban depends on the prescribed indication:
Prevention of stroke and systemic embolism in NVAF. (TA275)
Treatment and secondary prevention of DVT and/or PE. (TA341)
OFF-LABEL treatment of cancer associated thrombosis NOTE: Only for patients seen at the RUH. At other trusts, this would be a RED TLS indication currently. See SCA below.
Prevention of VTE after elective hip or knee replacement. (TA245)
Following total hip replacement 2.5mg BD for 28 days post op then stop.
Following knee replacement 2.5mg BD for 14 days post op then stop.
|
04.09.01 |
Apomorphine |
- Injection 20mg/2ml, 50mg/5ml
- APO-go® pen 10mg/ml 3ml pen injector
- APO-go® PFS 5mg/ml 10ml prefilled syringe
- Supply of Neria lines and ancillaries available via homecare (contact RUH pharmacy homecare team) for BaNES patients. Neria lines via FP10 from GP for all other CCGs.
- Note: Apomorphine is sometimes helpful in stabilising patients experiencing unpredictable "off" periods with levodopa treatment. It is essential to stabilise patients on domperidone for at least 2 days before starting treatment with apomorphine.
|
11.08.02 |
Apraclonidine |
|
10.01.03 |
Apremilast Otezla® |
- Titration pack, tablets, f/c, 14-day starter pack of apremilast 4 x 10 mg (pink) with 4 x 20 mg (brown) and 19 x 30 mg (beige).
- Tablet, f/c, apremilast 30 mg (beige) for maintenance treatment.
|
13.05.03 |
Apremilast |
- Titration pack, tablets, f/c, 14-day starter pack of apremilast 4 x 10 mg (pink) with 4 x 20 mg (brown) and 19 x 30 mg (beige). Otelza
- Tablet, f/c, apremilast 30 mg (beige) x 56 Otelza
|
04.06 |
Aprepitant |
- Capsules 80mg, 125mg
- As an adjunct to dexamethasone and a 5HT3 antagonist in preventing nausea and vomiting associated with moderately and highly emetogenic chemotherapy
|
13.02.01 |
Aproderm colloidal ® oat cream |
- VERY LIGHT MOISTURISER FOR VERY SENSITIVE MILD DRY SKIN, IF ISOMOL GEL HAS BEEN TRIED AND FAILED.
- Branded generic version of Aveeno (cheaper than Aveeno)
- Patients requiring an emollient who are using medical oxygen therapy should use Aproderm Colloidal as this is a non-paraffin based emollient.
|
13.02.02 |
Aproderm® Barrier cream |
- Cream 30g, 100g
- Dimethicone and Trimethylsiloxysilicate (4%)
|
A2.03.01 |
Aptamil Pepti 1 |
'1' from birth, '2' from 6 months |
13.02.01 |
Aquamax ® |
- SFT only for in-patients
- NOT for use in primary care
|
01.06.03 |
Arachis Oil |
- 130ml enema.
- Avoid the use of arachis oil in patients with a known nut allergy.
|
02.08.01 |
Argatroban |
- 1mg/ml soultion for infusion vials
- Restricted for use on the advice of a Haematologist for the treatment/prophylaxis of thromboembolic disease in patients with a history of heparin-induced thrombocytopenia
- Used in preference to danaparoid in patients with moderate renal impairment
|
09.08.01 |
Arginine |
- GWH and RUH only
unlicensed
- SFT - non formulary
- Tablets: 500 mg
- Oral solution: 50mg/ml
- Powder:100g
- Injection: 500mg/ml
- For paediatric prescribing only.
- Restricted - to initiation by Consultant Paediatricians for the treatment of metabolic disorders on the advice of tertiary centres in accordance with NHS England commissioning of highly specialised metabolic disorder services.
|
04.02.01 |
Aripiprazole |
- Tablets 5mg, 10mg, 15mg, 30mg
- Orodispersible tablet 10mg, 15mg
- Oral solution 1mg/ml
|
08.01.05 |
Arsenic Trioxide |
|
15.02 |
Articaine Hydrochloride with Adrenaline injection |
- Articaine hydrochloride 40mg/ml, adrenaline 1 in 100,000 (10 micrograms/ml), 2.2ml cartridge for dental use
|
09.06.03 |
Ascorbic Acid Vitamin C |
- Salisbury not on formulary
- BaNES not on formulary and not stocked at RUH. Only ordered in for medically diagnosed deficiency (i.e. treatment and prevention of scurvy)
- Tablets 50mg, 100mg, 500mg. Effervescent 1g (Not prescribable on NHS)
- Notes: Deficiency is rare and ascorbic acid is not recommended
- Vitamins should not be routinely prescribed in primary care due to limited evidence of clinical effectiveness.
- The only exception is medically diagnosed deficiency, including for those patients who may have a lifelong or chronic condition or have undergone surgery that results in malabsorption. Continuing need should however be reviewed on a regular basis
|
09.06.03 |
Ascorbic Acid Vitamin C |
- GWH - For use in Ophthalmology for severe corneal burns.
- Non-formulary - SFT & RUH.
- Tablets: 500mg.
- Effervescent tablets 1g. (Not presribeable on the NHS).
|
04.07.01 |
Aspirin |
- Tablets 300mg
- Included on formulary for the relief of headache and migraine
- 1-2 tablets (300-600mg) every 3-4 hours as required, to a maximum of 12 tablets (3.6g) daily in divided doses.
|
02.09 |
Aspirin (antiplatelet) |
- Dispersible tablets 75mg
- Dispersible tablets 300mg
- Suppositories 300mg
|
05.03.01 |
Atazanavir Reyataz® |
|
05.03.01 |
Atazanavir + Cobicistat Evotaz® |
- Atazanavir sulphate corresponding to 300 mg atazanavir and 150 mg of cobicistat
|
02.04 |
Atenolol Oral |
- Tablets 25mg, 50mg, 100mg
- SyrupSF 25mg/5ml
|
02.04 |
Atenolol Injection |
- 500micrograms per 1mL injection
|
04.07.04.02 |
Atenolol |
- Tablets 25mg, 50mg, 100mg
- SyrupSF 25mg/5ml
- Note: Atenolol 25mg once daily increasing to 50mg once daily (unlicensed for this indication, atenolol may be better tolerated than propranolol. Not included in NICE CG150)
|
08.01.05 |
Atezolizumab |
|
04.04 |
Atomoxetine |
- Capsules 10mg, 18mg, 25mg, 40mg, 60mg, 80mg, 100mg
Note: SCA for Adults link below. SCA for Paeds see Chapter 16 |
16.05 |
Atomoxetine |
- 10mg, 18mg, 25mg, 40mg, 60mg, 80mg, 100mg capsules
- 4mg/1ml oral solution
|
02.12 |
Atorvastatin |
|
07.01.03 |
Atosiban |
- Injection 7.5mg/mL (6.75mg/0.9mL vial)
- Concentrate for IV infusion 7.5mg/mL (37.5mg/5mL vial)
|
05.04.08 |
Atovaquone |
- GWH use for the treatment of PJP (Pneumocystis jirovecii pneumonia)
|
05.04.01 |
Atovaquone with proguanil hydrochloride Malarone® |
- Proguanil 100mg/ atovaquone 250mg tablets
- Treatment for Malaria is available on the NHS.
- Patients requiring Malaria prevention must acquire this on a private prescription
|
15.01.05 |
Atracurium Besilate injection |
- 25mg in 2.5ml amp
- 50mg in 5ml amp
- 250mg in 25ml vial
|
11.05 |
Atropine |
|
18 |
Atropine |
|
11.05 |
Atropine Sulphate |
|
15.01.03 |
Atropine Sulphate |
 for use within secondary care
 very rarely some GPs need to use this for emergencies in primary care.
- 600 micrograms in 1ml amp
- 1mg in 1ml amp
- 1mg in 10ml PFS
|
08.01.05 |
Avelumab |
- 200mg/10ml concentrate for solution for infusion vials
- For use in combination with axitinib in line with NICE TA645 [Not at SFT]
|
07.04.05 |
Aviptadil + phentolamine Invicorp® |
- Solution for intracavernosal injection.
- GWH and SFT only
- Non formulary at RUH
|
08.01.05 |
Axitinib |
- 1mg, 3mg, 5mg and 7mg tablets
|
09.04.02 |
Aymes ActaGain 2.4 Maxi |
- 200ml bottle
- See ONS guidance for full product details (link at top)
|
09.04.02 |
Aymes ActaSolve Smoothie Juice style ONS |
- Not suitable for people with diabetes, COPD and wounds - due to carbohydrate:protein ratio
- 66g sachet
- See ONS guidance for full product details (link at top)
|
09.04.02 |
Aymes Shake Powdered MILKSHAKE style ONS |
- 57g sachets
- See ONS guidance for full product details (link at top)
|
A2.02.01.02 |
AYMES Shake Compact |
Made with 100 ml whole milk.
316 Calories, 12.6g Protein, 12.5g fat and 27 vitamins and minerals.
IDDSI level 1 - Slightly Thick |
08.01.03 |
Azacitidine |
|
01.05.03 |
Azathioprine |
 - BaNES & Wiltshire patients
 - GWH - Swindon DAWN patients.
- 25mg & 50mg tablets.
- Please refer to our DMARD Shared Care and Monitoring Guidance below for further information.
|
08.02.01 |
Azathioprine |
- 25mg and 50mg tablets
- Chemotherapy/post transplant
|
10.01.03 |
Azathioprine |
-
 - BaNES & Wiltshire
-
 - Swindon DAWN patients
- Please refer to our DMARD Shared Care and Monitoring Guidance for further information (link below)
- 25mg and 50mg tablets
|
13.05.03 |
Azathioprine |
- Severe refractory eczema or as a steroid sparing agent (unlicensed use)
- Tablets 25mg; 50mg
|
13.06 |
Azelaic Acid |
- Non-antibiotic treatment option for rosacea (adults only) and mild to moderate papular-pustular acne of the facial area (age 12 upwards).
- Gel 15% 30g
- Apply twice daily discontinue if no improvement after 1 month (acne) or 2 months (rosacea)
|
12.02.01 |
Azelastine |
- 140micrograms/dose nasal spray 22ml
- Useful option for patients who do not want to try a corticosteroid or have contra-indications to them
|
05.01.05 |
Azithromycin |
- Tablets 250mg
- Oral suspension 200mg/5ml
- Included for primary care use only as an option for the treatment of chlamydia, travellers diarrhoea (private prescription) and certain types of Lyme diease.
- See primary care antibiotic guidance for further advice.
 For COPD prophylaxis (off-label use), the decision to start azithromycin for several months at a time should be initiated by secondary care once the diagnosis of COPD has been confirmed and all the necessary preliminary investigations (eg CT and sputum cultures) has been done. NOT to be initiated by GPs without specialist input.
|
16.09 |
Azithromycin |
- 250mg and 500mg
- 200mg/5ml
|
05.01.02.03 |
Aztreonam |
|
10.02.02 |
Baclofen |
- Tablets 10mg
- Liquid 5mg in 5ml
- Serious side-effects can follow abrupt withdrawal of baclofen; therapy should be discontinued by gradual dose reduction over at least 1-2 weeks (longer if symptoms occur)
- Bath only - Intrathecal Baclofen - Refer to the NHS Commissioning Board Clinical Policy D04/P/c: Intrathecal baclofen (ITB)
|
01.05.01 |
Balsalazide |
- 750mg capsules.
- Please note: Balsalazide is indicated for the treatment of mild to moderate ulcerative colitis and maintenace of remission, but should ONLY be prescribed for patients not responding to other aminosalicylates.
|
10.01.03 |
Baricitinib Olumiant® |
- 2mg and 4mg tablets
- CCG commissioned as per NICE TA466
|
13.02.02 |
Barrier preparation Cavilon®Film |
- Use within GWH ONLY, not for use by primary care
|
14.04 |
BCG vaccine diagnostic agent |
- Tuberculline purified protein derivative (PPD) (Mantoux test) - named patient.
|
14.04 |
BCG vaccine Intradermal |
- Bacillus calmette-guerin vaccine
- The BCG vaccine (which stands for Bacillus Calmette-Guérin vaccine) is not given as part of the routine NHS vaccination schedule. It's given on the NHS only when a child or adult is thought to have an increased risk of coming into contact with TB
|
06.01.01.03 |
BD Safe-Clip ® Needle clipping device |
|
06.01.01.03 |
BD Viva ® Pen needles |
- Second line to GlucoRx
- 4mm/32G, 5mm/31G and 8mm/31G sizes only
|
03.02 |
Beclometasone Qvar®, Kelhale® |
|
03.02.02 |
Beclometasone and formoterol Fostair NEXThaler® |
- First choice ICS/LABA DPI for asthma and COPD.
- Combination of beclometasone and formoterol
- For asthma: dry powder inhaler; beclometasone 100 micrograms,formoterol 6 micrograms dose and beclometasone 200 micrograms,formoterol 6 micrograms dose
- For COPD with FEV1<50%: dry powder inhaler; beclometasone100 micrograms, formoterol 6 micrograms dose only in line with the product guidance
|
03.02.02 |
Beclometasone and formoterol Fostair® |
|
03.02 |
Beclometasone Dipropionate Clenil Modulite®, Soprobec® |
- Prescribe by brand name
- Clenil® Modulite aerosol inhalation MDI 50, 100, 200, 250 micrograms/dose
- Soprobec® aerosal inhalation MDI 50, 100, 200, 250 micrograms/dose
- Soprobec® is directly equivalent to Clenil Modulite®
- Clenil® and Kelhale®/Qvar® are first line pMDI low dose ICS for asthma.
|
12.02.01 |
Beclometasone Dipropionate spray |
- 200 dose nasal spray, 50 micrograms per spray
- Beclomethasone is licensed for the prophylaxis and treatment of allergic and vasomotor rhinitis.
- First line for treatment of allergic rhinits . OTC for over 18 years.
|
10.01.03 |
Belimumab Benlysta® |
- Intravenous infusion, powder for reconstitution 120mg vial; 400mg vial
- Commissioned by NHSE at specialist centres e.g RUH
- Non Formulary at GWH and SFT
|
08.01.01 |
Bendamustine |
|
02.02.01 |
Bendroflumethiazide Tablet |
- Tablets 2.5mg
- Note: 2.5mg produces a maximal blood pressure lowering effect, with very little biochemical disturbance.
|
13.06.01 |
Benzoyl Peroxide |
|
13.06.01 |
Benzoyl Peroxide 5% with Clindamycin 1% Topical gel |
- Gel benzoyl peroxide 5%, clindamycin 1% 25g, 50g
- Apply once daily in the evening.
|
12.03.01 |
Benzydamine |
- oral rinse 0.15% 300ml
- oromucosal spray 0.15% 30ml
|
05.01.01.01 |
Benzylpenicillin |
-
 for emergency treatment of meningitis
-
 for all other indications
- 600mg vials
- 1.2g vials
|
05.01.01.01 |
Benzylpenicillin Benzathine Injection |
- GWH use to treat syphilis in HIV patients by the sexual health team.
- RUH sexual health specialists use this as well for syphilis
- A long acting form of benzylpenicillin administered by deep intramuscular injection. It is usually given as a single dose or weekly for the treatment of syphilis depending on the disease stage and guidelines used.
- 600,000 units or 1.2 MU Injection
|
04.06 |
Betahistine Dihydrochloride Tablet |
|
06.03.02 |
Betamethasone |
 Salisbury
 RUH
 GWH For use as a mouthwash: dissolve betamethasone (as betamethasone sodium phosphate) 500 microgram soluble tablet in 10ml of water and use as a mouthbath up to five times a day.
|
06.03.02 |
Betamethasone |
|
11.04.01 |
Betamethasone |
|
13.04 |
Betamethasone (as Dipropionate) 0.05% with Salicylic Acid 2% Diprosalic® |
- Potent steroid for scalps with salicylic acid
- Scalp Application Betamethasone valerate 0.05% & Salicylic Acid 2% 100ml
- For very scaly scalps.
|
13.04 |
Betamethasone (as Valerate) 0.025% Betnovate-RD® |
- Moderate potency steroid
- Cream, Ointment 0.025% 100g
- Apply sparingly once or twice daily
|
13.04 |
Betamethasone (as Valerate) 0.1% Betnovate® |
- Potent steroid
- Cream, Ointment 0.1% 30g, 100g
|
13.04 |
Betamethasone (as Valerate) 0.1% with Clioquinol |
- Potent steroid
- Cream, Ointment Betamethasone (as valerate) 0.1% clioquinol 3% 30g
- Was Betnovate C (discontinued)
|
13.04 |
Betamethasone (as Valerate) 0.1% with Fucidic Acid 2% Fucibet® |
- Potent steroid
- Cream, Betamethasone 0.1%, fusidic acid 2% 30g, 60g
|
12.01.01 |
Betamethasone 0.1% with Neomycin 0.5% Betnesol N® |
|
13.04 |
Betamethasone Dipropionate 0.05% w/w plus Salicylic Acid 3.00% w/w Diprosalic® |
|
13.04 |
Betamethasone Dipropionate 0.064% with Clotrimazole 1% Lotriderm® |
- Potent steroid
- Cream Betamethasone diproprionate 0.05%, clotrimazole 1% 30g
|
13.04 |
Betamethasone Esters Bettamousse® |
|
13.04 |
Betamethasone Esters Betacap® |
- Potent steroid
- Scalp application 0.1% 100ml water miscible in basis containing coconut oil derivative.
- Well-tolerated if scalp stings easily.
|
12.02.01 |
Betamethasone Sodium Phosphate 0.1% nasal drops |
|
12.01.01 |
Betamethasone sodium phosphate drops 0.1% Ear drops |
- Ear drops 0.1%
- Prolonged use of topical corticosteroids should be avoided.
- Betamethasone products for use in nasal allergy please refer to 12.2.1
|
11.04.01 |
Betamethasone with Neomycin |
- Betamethasone sodium phosphate 0.1% with Neomycin sulfate 0.5% eye drops
|
11.06 |
Betaxolol |
- 0.5% ophthalmic drops and 0.25% ophthalmic solution
|
11.08.02 |
Bevacizumab Avastin® |
|
02.12 |
Bezafibrate |
- Only to be prescribed after having had a telephone consultation with a specialist
- 200mg, modified release tablets 400mg (Bezalip mono®)
- NICE. Do not do recomendation: Do not routinely offer fibrates for the prevention of CVD to any of the following: -people who are being treated for primary prevention -people who are being treated for secondary prevention -people with CKD -people with type 1 diabetes -people with type 2 diabetes.
|
08.03.04.02 |
Bicalutamide |
|
05.03.01 |
Bictegravir, Emtricitabine, Tenofovir alafenamide Biktarvy® |
- Tablets containing bictegravir sodium equivalent to 50 mg of bictegravir, 200 mg of emtricitabine, and tenofovir alafenamide fumarate equivalent to 25 mg of tenofovir alafenamide
- For treatment of HIV-1 in adults in line with NHSE CCP
|
11.06 |
Bimatoprost |
- 100microgram/ml ophthalmic drops
- 300microgram/ml preservative free single use eyedrops available where indicated as per BSW glaucoma guidance
|
11.06 |
Bimatoprost with Timolol |
- 300micrograms and 5mg/ml combination ophthalmic drops
|
20 |
Biolon / Haelonid AV |
|
12.03.05 |
Biotene Oralbalance ® oral gel |
- Saliva replacement oral gel
- 50g
- ACBS
|
09.08.01 |
Biotin |
unlicensed GWH only
- SFT and RUH Non formulary
- Tablets: 5mg
- Injection: 5mg/ml
- Restricted - to prescribing by Consultant Paediatricians on the recommendation of tertiary Paediatric Specialists only.
|
06.01.01.02 |
Biphasic Insulin Aspart NovoMix® 30 |
 Salisbury
 Bath and Swindon
- Type 2 diabetes only
|
06.01.01.02 |
Biphasic Insulin Lispro Humalog® Mix |
 Salisbury
 Bath and Swindon
- Type 2 diabetes only
|
06.01.01.02 |
Biphasic Isophane Insulin Insuman® Comb |
- Type 2 diabetes only
- NOTE - Insuman Comb 15 cartridge is being discontinued.
- NOTE - Insuman Comb 25 vial is being discontinued.
|
06.01.01.02 |
Biphasic Isophane Insulin Humulin® M3 |
|
01.06.02 |
Bisacodyl |
- 5mg tablets.
- 5mg & 10mg suppositories.
|
12.02.03 |
Bismuth + iodoform impregnated gauze (BIPP) |
- A paste of composition Iodoform 40% w/w, Bismuth Subnitrate 20% w/w and Paraffin Liquid 40% w/w. presented in a labelled aluminium laminated pouch.
|
01.03.03 |
Bismuth subsalicylate Pepto-Bismol® |
 - Salisbury & Swindon.
- Non-formulary - BaNES
- 262.5mg chewable tablets.
- Please note: This is ONLY included for use as part of H.pylori eradication therapy, as described above in Section 01.03 Helicobacter pylori infection.
- When used as the bismuth element of H. pylori eradication therapy, the dose of bismuth subsalicylate is 525mg four times daily (prescribe generically).
|
02.04 |
Bisoprolol |
- Tablets 1.25mg, 2.5mg, 3.75mg, 5mg, 7.5mg, 10mg
- Note: For heart failure, use should be initiated cautiously, titrated slowly and adequately monitored.
|
02.08.01 |
Bivalirudin |
- Injection, powder for reconstitution 250mg vial
- Anticoagulation during PCI
|
08.01.02 |
Bleomycin |
- 15,000 unit powder for injection
|
08.02 |
Blinatumomab |
|
14.04 |
Boostrix IPV ® |
- Boostrix-IPV suspension for injection in pre-filled syringe
- Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content) (schedule between 3yrs & 4/12 to 5 years)
|
08.01.05 |
Bortezomib |
|
02.05.01 |
Bosentan |
- Formulary at RUH and SFT (under shared care with Southampton)
- Tablets 62.5mg, 125mg
- For digitial ischaemia and ulceration in Raynaud's Disease and scleroderma as per NHSE policy below within Specialist Centres
|
08.01.05 |
Bosutinib |
|
04.07.04.02 |
Botulinum A toxin botox® |
- Powder for reconstitution 50 unit vial, 100 unit vial, 200 unit vial
- If effective repeat 12 weekly, if ineffective discontinue after 2 cycles.
- See BSW policy and prior approval form for chronic migraine below.
|
04.09.03 |
Botulinum A toxin |
- Dysport® injection 300 or 500 unit vial
- Botox® Injection powder for reconstitution 50 unit vial, 100 unit vial, 200 unit vial
- Xeomin® Injection powder for reconstitution 50 unit vial, 100 unit vial, 200 unit vial.
- See BSW CCG Botulinum commissioning policy for approved indications on the link below.
- Botox can also be used for migraine in accordance with recommendations of NICE TA 260.
- Xeomin® may be used for chronic sialorrhoea associated with chronic neurological conditions in line with licences and with NICE TA605
- Preparations are not interchangeable and should be used under specialist supervision.
- Commissioned by NHS England for use in focal spasticity in children according to set criteria.
|
13.12 |
Botulinum A toxin |
- GWH.
- A specific commissioning policy for the use of this for hyperhydrosis is under development (August 19). Current botulinum policy is found below.
- Botulinum toxin units are not interchangeable from one product to another. Prescribe by brand as advised by hospital pharmacy department.
|
07.04.03 |
Botulinum toxin |
- See BSW CCG Botulinum commissioning policy for approved indications:
- Management of bladder dysfunction in adults not adequately managed with anticholinergics for: Overactive bladder with symptoms of urinary incontinence, urgency and frequency.
- Neurogenic detrusor over-activity with urinary incontinence due to sub-cervical spinal cord injury or MS.
|
08.01.05 |
Brentuximab |
|
08.01.05 |
Brigatinib |
|
11.06 |
Brimonidine Tartrate |
- 0.2% ophthalmic eye drops
- Note - higher risk of side-effects and sensitivity.
|
11.06 |
Brinzolamide |
|
11.06 |
Brinzolamide 1% with Timolol 0.5% |
- Brinzolamide 1% with Timolol 0.5%
|
11.06 |
Brinzolamide 10mg/ml & brimonidine 2mg/ml |
- ophthalmic drops containing 10 mg/mL of brinzolamide and 2 mg/mL of brimonidine tartrate equivalent to 1.3 mg of brimonidine.
BaNES/Wilts - For use as per Glaucoma guidance Swindon - Not on formulary |
04.08.01 |
Brivaracetam |
- Tablets 10mg, 25mg, 50mg, 75mg, 100mg
- Liquid 10mg/1ml
- IV 10mg/1ml 5ml ampoule
- Brivaracetam recommended as an adjunctive AED treatment for adult patients (≥16 years) with focal-onset seizures.
- Only to be used when first or second line treatments have failed.
|
13.05.03 |
Brodalumab |
- 210 mg solution for injection in pre-filled syringe
- Use as per NICE TA
|
06.07.01 |
Bromocriptine |
|
01.05.02 |
Budesonide Jorveza® |
- 1mg oro-dispersible tablets.
- For treatment of eosinophlic oesophagitis.
- Please prescribe BY BRAND.
|
01.05.02 |
Budesonide Budenofalk® |
- 2mg per actuation white foam, 1 canister (14 days treatment).
- Please note: Budesonide foam enema is ONLY indicated for use second line in patients unable to use / tolerate Colifoam® enema.
|
01.05.02 |
Budesonide Budenofalk® |
- 3mg gastro-resistant capsules.
- Please note: Budenofalk capsules are available for use for their licensed indications of:
- induction of remission in patients with mild to moderate Crohn's disease affecting the ileum and/or ascending colon,
- induction of remmission in patients with active collagenous colitis.
- Please prescribe BY BRAND.
|
01.05.02 |
Budesonide Cortiment® |
- 9mg prolonged-release tablets.
- Note not on formulary at SFT.
- For induction of remission in patients with mild to moderate ulcerative colitis, where 5-ASA treatment is not sufficient.
- Please prescribe BY BRAND.
|
03.02 |
Budesonide Pulmicort®, Easyhaler® |
- Prescribe by brand name
- Easyhaler dry powder for inhalation MDI
- 100 micrograms/dose, 200 micrograms/dose, 400 micrograms/dose
- Turbohaler dry powder inhaler MDI 100 microgram/dose,
- 200 micrograms/dose, 400 micrograms/dose
- Easyhaler Budesonide® and Pulmicort® are the first line DPI low dose ICS for asthma.
|
12.02.01 |
Budesonide Nasal spray |
- Budesonide nasal spray 64micrograms / spray 120 dose
- Second line for the treatment of allergic rhinitis
- Licensed for nasal polyps.
|
03.02.02 |
Budesonide and formoterol Symbicort® |
- No new prescribing. Existing patients only.
- Can be used in a MART regime.
- Prescribe by brand.
- Combination of budesonide and formoterol
- Turbohaler dry powder inhaler DPI 100/6; 200/6; 400/12
- Notes: Symbicort Turbohaler is licensed for both asthma and COPD;
|
03.02.02 |
Budesonide and formoterol DuoResp Spiromax® |
- No new prescribing. Existing patients only.
- Low strength can be used in a MART regime.
- Prescribe by brand.
- Combination of budesonide and formoterol fumarate dihydrate
- Dry Powder Inhaler 320micrograms/9 micrograms (equivalent to 400/12)and 160micrograms/4.5 micrograms (equivalent to 200/6)
- For the treatment of asthma and COPD within product licence
|
03.02.02 |
Budesonide and formoterol Fobumix Easyhaler® |
- First choice ICS/LABA DPI for asthma.
- Can be used in a MART regime.
- Prescribe by brand
- Combination of budesonide and formoterol fumarate dihydrate
- Breath-actuated dry powder inhaler 80 micrograms/4.5micrograms,160 micrograms/ 4.5 micrograms and 320 micrograms/9 micrograms
- For the treatment of asthma and COPD within product licence
- Most cost effective option July 2018
|
03.02 |
Budesonide Nebuliser Suspension |
- Respiratory solution 500 micrograms per 2ml, 1mg per 2ml
|
02.02.02 |
Bumetanide |
- Tablets 1mg, 5mg
- Bumetanide is significantly more expensive than Furosemide in primary care.
|
15.02 |
Bupivacaine and Adrenaline injection |
- 0.25% w/v
- 0.5% w/v
- 1 in 200,000
|
15.02 |
Bupivacaine Hydrochloride injection |
- 25mg in 10ml (0.25%) amp
- 50mg in 10ml (0.5%) amp
- 75mg in 10ml (0.75%) amp
- GWH only: 0.1% and 0.125% epidural infusion bags used.
|
15.02 |
Bupivacaine Hydrochloride with Glucose injection |
- 0.5% solution for injection, 4ml ampoule
- Not routinely stocked at RUH
|
04.07.02 |
Buprenorphine |
- HIGH STRENGTH PATCHES
- Patch 35 microgram/ hour, for 4 days
- Patch 52.5 microgram/ hour, for 4 days
- Patch 70 microgram/ hour, for 4 days
- Only to be used in patients with cognitive deficit or swallowing difficulties, after a trial of soluble/liquid medication. Zomorph capsules can be opened for ease of swallowing.
- Buprenorphine patches are not suitable for management of acute / intermittent pain.
- Patients and/or their carers need to be aware that these patches need to be applied at appropriate 96 hour intervals (or 4 days). Remember to remove the old patch before application of new patch. Avoid use of multiple patches.
|
04.07.02 |
Buprenorphine |
- LOW STRENGTH PATCHES
- Patch 5 microgram/hour for 7 days
- Patch 10 microgram/hour for 7 days
- Patch 15 micrograms/hour for 7 days
- Patch 20 microgram/hour for 7 days
- Only to be used in patients with cognitive deficit or swallowing difficulties, after a trial of soluble/liquid medication. Zomorph capsules can be opened up for ease of swallowing.
- Buprenorphine patches are NOT suitable, or licensed, for management of acute / intermittent pain.
- Patients and/or their carers neeed to be aware that these patches need to be applied at appropriate seven-day intervals. Remember to remove the old patch before application of new patch. Avoid use of multiple patches.
|
04.10.03 |
Buprenorphine |
 BaNES
 Swindon/North Wilts: Under review
- Sublingual Tablets 400micrograms, 2mg, 8mg
- For treatment of substance misuse
- See BaNES CCG shared care for substance misuse on link above
- The recommended criteria for generalist prescribers to prescribe in the field of opioid dependence is that they have completed the RCGP Certificate in the Management of Drug Misuse (part one) and be part of the Local Enhanced Service (LES) for substance misuse
- GPs with Specialist Interest (GPwSI) in substance misuse and specialist prescribers in the field of substance misuse (not LES prescribers) are "secondary care prescribers" for the purpose of these guidelines.
- Supervised Consumption through an accredited pharmacy should be undertaken for a minimum of twelve weeks at the start of methadone and buprenorphine treatment in line with DOH and NICE
|
21.01.01.02 |
Buprenorphine |
- HIGH STRENGTH PATCH
- Patch 35 microgram/ hour, for 4 days
- Patch 52.5 microgram/ hour, for 4 days
- Patch 70 microgram/ hour, for 4 days
- Only to be used in patients with cognitive deficit or swallowing difficulties, after a trial of soluble/liquid medication. Zomorph capsules can be opened for ease of swallowing.
- Buprenorphine patches are not suitable for management of acute / intermittent pain.
- Patients and/or their carers need to be aware that these patches need to be applied at appropriate 96 hour intervals (or 4 days). Remember to remove the old patch before application of new patch. Avoid use of multiple patches.
|
21.01.01.02 |
Buprenorphine |
- LOW STRENGTH PATCH
- 7 day patch of choice for consistency and safety
- Patch 5 microgram/hour for 7 days
- Patch 10 microgram/hour for 7 days
- Patch 15 micrograms/hour for 7 days
- Patch 20 microgram/hour for 7 days
- Only to be used in patients with cognitive deficit or swallowing difficulties, after a trial of soluble/liquid medication. Zomorph capsules can be opened up for ease of swallowing.
- Buprenorphine patches are NOT suitable, or licensed, for management of acute / intermittent pain.
- Patients and/or their carers neeed to be aware that these patches need to be applied at appropriate seven-day intervals. Remember to remove the old patch before application of new patch. Avoid use of multiple patches.
|
04.10.02 |
Bupropion Hydrochloride |
- Tablets m/r, f/c 150mg
- CSM advice: Bupropion is contra-indicated in patients with a history of seizures or of eating disorders, a CNS tumour, or who are experiencing acute symptoms of alcohol or benzodiazepine withdrawal.
June 2020 - Out of stock until end November 2020. See MHRA Supply Disruption Alert |
06.07.02 |
Buserelin |
- For fertility treatment
- 150 micrograms / metered spray
|
08.03.04.02 |
Buserelin |
- 100microgram and 150microgram nasal spray
|
04.01.02 |
Buspirone Hydrochloride Tablets |
- Tablets 5mg
- No withdrawal effects but response to treatment may take up to 2 weeks
|
08.01.01 |
Busulfan |
|
08.01.01 |
Busulfan |
|
03.04.03 |
C1 esterase inhibitor Cinryze® /Berinert® |
|
08.01.05 |
Cabazitaxel |
|
06.07.01 |
Cabergoline |
- 500 micrograms
- Shared care agreement in development
|
08.01.05 |
Cabozantinib |
|
08.01.05 |
Cabozantinib |
- 20mg, 40mg and 60mg tablets
|
09.05.01.01 |
Calcichew ® Tablet |
- BaNES and Salisbury only
- Swindon - not on formulary
- 500mg chewable tablets, each containing 1.25g calcium carbonate.
|
13.05.02 |
Calcipotriol 50mcg/g Topical |
|
13.05.02 |
Calcipotriol 50micrograms/g with Betamethasone 0.05% Dovobet |
- Ointment Calcipotriol 50mcg/g betamethasone diproprionate 500mcg/g 120g
- Contains a potent steroid which may destabilise psoriasis and increase its severity due to rebound pustulation and inflammation.
- Usual max duration of treatment is 4 weeks.
- Max 15g daily to no more than 30% of body surface area; max 100g weekly; 75g weekly (child >12 yrs)
|
13.05.02 |
Calcipotriol and betamethasone 50 microgram/g + 0.5 mg/g Dovobet |
- Indications: Topical treatment of scalp psoriasis in adults. Topical treatment of mild to moderate “non-scalp” plaque psoriasis vulgaris in adults.
- Contains a potent steroid which may destabilise psoriasis and increase its severity due to rebound pustulation and inflammation.
- The recommended treatment period is 4 weeks for scalp areas and 8 weeks for “non-scalp” areas. If it is necessary to continue or restart treatment after this period, treatment should be continued after medical review and under regular medical supervision.
- The maximum daily dose should not exceed 15 g. The body surface area treated with calcipotriol containing medicinal products should not exceed 30 %
|
13.05.02 |
Calcipotriol and Betamethasone cutaneous foam Enstilar® |
- One gram of cutaneous foam contains 50 micrograms of calcipotriol (as monohydrate) and 0.5 mg of betamethasone (as dipropionate).
- Contains a potent steroid which may destabilise psoriasis and increase its severity due to rebound pustulation and inflammation.
- Usual max duration of treatment is 4 weeks.
- Max 15g daily to no more than 30% of body surface area; max 100g weekly; 75g weekly (child >12 yrs)
|
09.06.04 |
Calcitriol |
- 250 nanograms, 500 nanograms
- For renal indication only.
- Note: Patients receiving alfacalcidol or calcitriol should have their plasma calcium levels checked regularly (at intervals recommended by specialist, usually every 3-6 months)
|
13.05.02 |
Calcitriol 3micrograms/g Silkis® |
- Can be used on the face (with caution) and flexures unlike Dovonex.
- It is recommended that not more than 35% of the body surface be exposed to daily treatment. Not more than 30 g of ointment should be used per day. There is limited clinical experience available for the use of this dosage regimen of more than 6 weeks.
|
09.05.01.01 |
Calcium 5.1mmol/10ml Syrup Alliance Calcium Syrup® |
- Replaces Calcium Sandoz syrup (discontinued)
|
09.05.02.02 |
Calcium Acetate |
 Swindon
 BaNES, Wiltshire
- Phosex Calcium acetate 1g tablets
- Each 1g tablet contains 250mg calcium or 6.2mmol Ca2+.
Usual dose 4-6 tablets daily according to phosphate levels.
- For use as a phosphate binder according to NICE CG 157
|
09.05.02.02 |
Calcium Carbonate Calcichew® |
- Salisbury and BaNES
- Calcichew chewable tablet containing 500mg calcium/12.5mmol Ca2+
|
09.05.01.01 |
Calcium Carbonate with Calcium Lactate Gluconate Calvive-1000® |
- Effervescent tablets containing calcium lactate gluconate & calcium carbonate, 1000mg calcium per tablet
- Rebranded April 2020, formerly Sandocal 1000 effervescent tablets. No change to drug composition.
|
09.05.01.01 |
Calcium Chloride |
- Parental preparation - Calcium Chloride Injection
- Min-I-jet 10ml
|
08.01 |
Calcium Folinate |
- Folinic acid (as Calcium folinate) 7.5mg per 1ml
- Chemotherapy induced mucositis and myelosuppression
|
09.05.01.01 |
Calcium Gluconate 10% Injection |
- 10ml ampoule
- Infusion 50ml
|
18 |
Calcium gluconate gel |
please note, may not be stocked at RUH but can be ordered through supplies |
06.01.02.03 |
Canagliflozin |
- 100mg and 300mg
 FOR USE IN COMBINATION WITH OTHER ORAL PRODUCTS FOR THE TREATMENT ON TYPE 2 DIABETES
 IF USED IN COMBINATION WITH INSULIN IN TYPE 2 DIABETES FOLLOWING NICE GUIDANCE ONLY
|
02.05.05.02 |
Candesartan |
- Tablets 2mg, 4mg, 8mg, 16mg, 32mg
|
04.07.04.02 |
Candesartan |
- Tablets 2mg, 4mg, 8mg, 16mg, 32mg
Candesartan has been approved for prophylaxis of chronic migraine (unlicensed indication) only when recommended by a specialist. Recommended dose 2mg daily increased by 2mg weekly if needed to max 8mg BD. Patient information leaflet here. See BSW migraine pathway below. |
13.05.02 |
Capasal ® Shampoo |
- Coal tar distilled 10 mg per 1 gram
- Coconut oil 10 mg per 1 gram
- Salicylic acid 5 mg per 1 gram
- 250ml
|
08.01.03 |
Capecitabine |
|
12.03.01 |
Caphosol ® Medical Device |
- GWH only: Restricted for use in patients undergoing autologous stem cell transplant only. Consultant haematologist prescription only.
|
04.07.03 |
Capsaicin |
- Cream containing 0.075% capsaicin (Axsain®)
- For the treatment of post herpetic neuralgia (after lesions have healed) & painful diabetic peripheral neuropathy sparingly up to 3-4 times a day.
- The recommended duration of use in the first instance is 8 weeks, since there is no clinical trial evidence of efficacy for treatment of more than 8 weeks duration. After this time, it is recommended that the patient's condition should be fully clinically assessed prior to continuation of treatment, and regularly re-evaluated thereafter, by the supervising consultant.
|
10.03.02 |
Capsaicin Zacin® |
 Swindon only - for painful diabetic peripheral polyneuropathy (off-label)
- Cream containing 0.025% capsaicin (Zacin®)
- For symptomatic relief in osteoarthritis. It may need to be used for 1-2 weeks before pain is relieved
|
10.03.02 |
Capsaicin Qutenza® |
- Pain clinic use only as per local policy below.
|
10.03.02 |
Capsaicin Axsain® |
 Swindon only - for painful diabetic peripheral polyneuropathy.
- Cream containing 0.075% capsaicin (Axsain®)
- For treatment of post herpetic neuralgia (after lesions have healed) & painful diabetic peripheral neuropathy
|
16.01 |
Captopril |
- 12.5mg, 25mg and 50mg
- 5mg/5ml and 25mg/5ml SF solution
Swindon only
Non-formulary in BaNES and Salisbury |
04.02.03 |
Carbamazepine |
- Tablet 100mg, 200mg, 400mg
- Tegretol® m/r tablet 200mg, 400mg. Prescribe M/R tablet by brand
- LiquidSF 100mg/ml
- Suppository 125mg, 250mg
- Prescribe generically for non epilepsy indications.
- Carbamazepine may be used for the prophylaxis of bipolar disorder in patients unresponsive to lithium; it seems to be particularly more effective in patients with rapid cycling manic-depressive illness (4 or more episodes per year).
|
04.07.03 |
Carbamazepine |
- Tablets 100mg, 200mg, 400mg
|
04.08.01 |
Carbamazepine |
- Tablet 100mg, 200mg, 400mg
- Tegretol® m/r tablet 200mg, 400mg. Prescribe M/R tablet by brand (Category 1 MHRA)
- LiquidSF 100mg/ml
- Suppository 125mg, 250mg
- Prescribe generically for non epilepsy indications.
|
06.02.02 |
Carbimazole |
- 5mg, 20mg
- CSM warning: Neutropenia and agranulocytosis. Doctors are reminded of the importance of recognising bone marrow suppression induced by carbimazole and the need to stop treatment promptly.
- Initiate following discussion with/at the point of referral to a specialist.
- Monitor for signs of infection and warn patients to report sore throat or other signs of infection. Counsel patient of possible risk of skin rash or agranulocytosis.
- Discuss any course of treatment over 3 years with a specialist.
- 5mg carbimazole is equivalent to 50mg propylthiouracil
|
03.07 |
Carbocisteine |
- Capsules 375mg
- Oral liquid 250mg/5ml
- Sachets 750mg/10ml Sugar free oral solution
- Note: liquid must still be used in patients with feeding tubes
|
11.08.01 |
Carbomer |
|
11.08.01 |
Carbomer 980 eye drops |
- 0.2% gel 10g
- Suitable for contact lense wearers
|
08.01.05 |
Carboplatin |
- 150mg/15ml, 450mg/45ml, 50mg/5ml and 600mg/60ml infusion
|
07.01.01 |
Carboprost Hemabate® |
- 250micrograms/1ml solution for injection ampoules
- Indicated for postpartum haemorrhage due to uterine atony in patients unresponsive to ergometrine and oxytocin.
|
11.08.01 |
Carboxymethylcellulose, glycerine & castor oil eye drops |
- Carmellose 0.5ml, glycerol 1%, castor oil 0.25% 10ml
|
08.01.05 |
Carfilzomib |
- 10mg, 30mg and 60mg infusion
|
11.08.01 |
Carmellose |
- 1% drop 10ml
- VIZcellulose® is the most cost-effective preservative-free carmellose preparation in primary care
- Swindon only - Use Celluvisc SDUs in secondary care.
|
12.03.01 |
Carmellose Sodium Orabase® |
- Please note: Patients should self-care in the first instance
|
09.08.01 |
Carnitine |
- GWH only
- RUH and SFT non formulary
- 100mg / ml (10 x 10ml single dose)
- Commissioned by NHS England for carnitine deficiency when supplied in secondary care, as per NHS England service specification. For initiation by specialist centres only.
|
02.04 |
Carvedilol |
- Tablets 3.125mg,6.25mg,12.5mg,25mg
Salisbury and BaNES
Swindon
|
05.02.04 |
Caspofungin |
- 50mg Powder for conc for soln for infusion
- 70mg Powder for conc for soln for infusion
- Indicated for the treatment of invasive candidiasis. Treatment of invasive aspergillosis in patients refractory to or intolerant of amphotericin and/or itraconazole. Empirical therapy for presumed fungal infections in febrile neutropenic patients. Used as per microbiology advice only.
|
07.04.04 |
Catheter Patency Solutions |
|
07.04.04 |
Catheter Patency Solutions |
|
07.04.04 |
Catheter Patency Solutions |
|
07.04.04 |
Catheter Patency Solutions |
|
13.09 |
Ceanel Concentrate® Liquid |
- Cetrimide 100 mg per 1 ml
- Phenylethyl alcohol 75 mg per 1 ml
- Undecenoic acid 10 mg per 1ml
- 150ml,500ml
|
05.01.02 |
Cefalexin |
- Capsules 250mg, 500mg
- Tablets 250mg, 500mg.
- Oral suspension 125mg/5ml and 250mg/5ml
- For use in UTIs please see local Primary Care Antibiotic Guidance
|
05.01.02.01 |
Cefixime Suprax® |
 - GWH - For use by Sexual Health team, as a stat dose in combination with azithromycin, for the treatment of gonorrhoea in patients declining IM injection.
- Non-formulary - Bath & Salisbury.
- 200mg tablets.
|
05.01.02 |
Cefotaxime |
 for meningococcal disease for Penicillin allergic patients
 for all other indications
- 500mg
- 1g
- 2g
|
05.01.02 |
Ceftazidime |
- 250mg
- 500mg
- 1g
- 2g
- 2000mg surefuser device over 24hrs via local Outpatient Parenteral Antibiotic Treatment (OPAT) services (acute trusts).
|
05.01.02 |
Ceftriaxone |
 for use in acute trusts
 for use in primary care as follows:
- for treatment of cellulitis in the community in BaNES via Virgin Care primary care services
- 1g IM STAT used for treatment of pelvic inflammatory disease with high risk of gonococcal infection in conjunction with oral antibiotics as per local primary care antibiotic guidance.
- 250mg, 1g and 2g
|
05.01.02 |
Cefuroxime |
|
11.03.01 |
Cefuroxime |
- 5% eye drops
- 5% preservative-free eyedrops (GWH only)
|
11.08.02 |
Cefuroxime intracameral injection Aprokam® |
- 3mg in 0.3ml pre-prepared injection.
- 50mg vial.
|
10.01.01 |
Celecoxib Celebrex® |
- Salisbury only
- Non formulary in BaNES and Swindon
- 100mg and 200mg capsules
|
08.01.05 |
Ceritinib |
|
13.05.03 |
Certolizumab 200mg |
- 200mg pre-filled pen or syringe
- For people whose psoriasis has partially responded to the lowest licensed maintenance dose, increasing to the highest licensed dose (400 mg) is not cost effective compared with switching to an alternative biological treatment. Hence only the 200mg maintenance dose has been approved by NICE.
|
10.01.03 |
Certolizumab Pegol Cimzia® |
- Prefilled syringe 200mg.
- Use in accordance with NICE guidance and local pathways for RA, AS or PSA.
- Not routinely commissioned by NHS England for paediatric indications - see NHS England drugs list.
|
03.04.01 |
Cetirizine |
 Self Care Medicine for primary care.
- Tablets 10mg
- Oral solutionSF 5mg in 5ml
|
08.01.05 |
Cetuximab |
|
04.01.01 |
Chloral Hydrate |
- 143mg/5ml oral solution
- GWH: Paediatric use only
- SFT: used for pre-procedure sedation only.
- Short-term use only. License is for severe insomnia which is interfering with normal daily life and where other therapies have failed.
- Not to be initiated in primary care.
|
05.01.07 |
Chloramphenicol |
|
11.03.01 |
Chloramphenicol |
- 0.5% eye drops
- 0.5% minims available for patients allergic to preservatives, administering more than 6 times a day, undergoing eye surgery
- Eye drops available OTC for adults and children over 2 years
|
11.03.01 |
Chloramphenicol |
- 1% eye ointment
- Eye ointment available OTC for adults and children over 2 years
|
04.10.01 |
Chlordiazepoxide |
- Capsule 5mg, 10mg
- Use only in the context of supervised withdrawal regime over a period of 5-10 days, with psychosocial recovery programme.
|
13.11.02 |
Chlorhexidine 0.05% Topical |
- Surgical scrub 4% w/v in surfactant solution (pink)
- Obstetric Cream , chlorhexidine gluconate solution 5%
- Hard surface wipes
- Sterile topical solution sachets for irrigation
- 0.5% w/v in 70% industrial methylated spirits for preop skin use.
- Hand Rub
- Sterile 0.015% w/v with cetrimide 0.15% (yellow) 25ml sachets
- Chlorhexidine gluconate 4% surgical scrub is used for pre-operative hand and skin preparation and for general hand disinfection.
- A 5-7 day course of mupirocin 2% ointment or cream and chlorhexidine wash is used to decolonise patients with MRSA.
|
12.03.04 |
Chlorhexidine gluconate 1% dental gel |
|
12.02.03 |
Chlorhexidine Hydrochloride 0.1%, Neomycin Suphate 0.5% Naseptin® |
- Contains arachis oil: Should be avoided in peanut or soya allergy
- To avoid the development of resistance, the treatment course should not exceed 7 days and the course not repeated on more than one occasion
|
12.03.04 |
Chlorhexidine mouthwash 0.2% |
|
08.01.01 |
Chlormethine Hydrochloride (Mustine) Injection |
- 10mg powder for reconstitution
|
05.04.01 |
Chloroquine phosphate |
- Treatment of non-falciparum malaria is available on the NHS.
- Patients requiring Malaria prevention must acquire this on a private prescription or can buy it OTC
- Tablets 250mg (equivalent to 155mg chloroquine base)
- Syrup 68mg/5ml (equivalent to 50mg chloroquine base per 5ml)
25th March 2020 - MHRA statement on chloroquine for COVID-19 - Chloroquine is not licensed to treat COVID-19 related symptoms or prevent infection. Clinical trials are ongoing to test chloroquine as an agent in the treatment of COVID-19 or to prevent COVID-19 infection. These clinical trials are still not completed, so no conclusions have been reached on the safety and effectiveness of this medicine to treat or prevent COVID-19. Until we have clear, definitive evidence that these treatments are safe and effective for the treatment of COVID-19, chloroquine should only be used for this purpose within a clinical trial. |
16.01 |
Chlorothiazide |
- Only available as an unlicensed preparation for specialist initiation only.
Swindon only
Non-formulary in BaNES and Salisbury |
03.04.01 |
Chlorphenamine |
- Tablets 4mg
- Oral solution 2mg/5ml
- Injection 10mg/ml
|
04.02.01 |
Chlorpromazine |
- 25mg,50mg,100mg tablets
- 25mg/5ml solution SF
- 25mg/5ml syrup
- 100mg/5ml solution
|
11.03.01 |
Chlortetracycline |
- 1% eye ointment
- RUH only. Non formulary at GWH and SFT
|
14.04 |
Cholera vaccine Dukoral® |
- This vaccine is not indicated for most travellers
|
12.03.01 |
Choline Salicylate |
- Please note: Patients should self-care in the first instance
- 8.7% dental gel 15g
|
06.05.01 |
Choriogonadotropin Alfa Ovitrelle® |
- Not on formulary GWH
- prefilled syringe 6500 unit/0.5ml (250 micrograms/0.5ml)
- Female infertility
|
06.05.01 |
Chorionic Gonadotrophin Pregnyl ® |
- Not on formulary RUH
- 5000 I.U. powder for solution for injection.
|
03.02 |
Ciclesonide Alvesco® |
 Salisbury ONLY
- Non-formulary BaNEs & Swindon
- For persistent asthma in exceptional cases e.g in patients withpoor compliance or patients having side effects on standard inhaledcorticosteroids. For initiation by Respiratory consultant and ongoingprescription by GP
|
01.05.03 |
Ciclosporin |
- 10mg, 25mg, 50mg & 100mg capsules.
- 250mg in 5ml ampoules for intravenous infusion.
- Please refer to our DMARD Shared Care and Monitoring Guidance below for monitoring information (not applicable to GWH gastroenterology).
|
08.02.02 |
Ciclosporin Capimune ®Deximune®Neoral® |
- 25mg, 50mg and 100mg capsules
- For SOLID organ transplant patients continue on brand specifed by the specialist.
- Preparations are not interchangeable.
- NHSE commissioner when ciclosporin used for solid organ transplants. Available from Specialist Centres ONLY.
|
08.02.02 |
Ciclosporin Sandimmun® |
|
08.02.02 |
Ciclosporin |
- 25mg, 50mg and 100mg capsules
- Indicated for bone marrow stem cell transplant.
- The brand to be dispensed should be specified by the prescriber due to differences in bioavailability.
- Preparations are not interchangeable.
- RUH and SFT - Neoral
|
10.01.03 |
Ciclosporin |
- 10mg, 25mg, 50mg and 100mg capsules
|
11.08.01 |
Ciclosporin Ikervis® |
- 0.1% drops (1 mg/mL eye drops, emulsion)
- Note - Ensure correct product is prescribed; available products have different licensing information and TLS.
- Ikervis ® is licensed for the treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes.
- Verkazia® is licensed for the treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents. See here
|
11.08.01 |
Ciclosporin |
- 0.2% eye ointment - Unlicensed preparation
- GWH only - ONLY for patients who respond to ciclosporin but fail to tolerate Ikervis presentation. Only to be prescribed on yellow GWH hospital outpatient prescription and NOT FP10
- Non formulary in RUH and SFT
|
13.05.03 |
Ciclosporin |
 GWH ONLY: for licensed indications: Treatment of severe psoriasis in patients in whom conventional therapy is inappropriate or ineffective and for patients with severe atopic dermatitis when systemic therapy is required
 for SFT/RUH and for use in all unlicensed indications
- Capsules 10mg; 25mg; 50mg;
|
16.15 |
Ciclosporin Verkazia® |
- 0.1% drops (1 mg/mL eye drops, emulsion)
- Verkazia® is licensed for the treatment of severe vernal keratoconjunctivitis in children from 4 years of age and adolescents.
- Ensure correct product is prescribed. Other ciclosporin eyedrops are available but have different licensing information and TLS. Ikervis® contains the same ingredient but is not licensed in paediatrics.
|
05.03.02.02 |
Cidofovir |
- IV infusion 75mg/ml, 5ml vial
|
09.05.01.02 |
Cinacalcet |
- For initiation and follow-on prescribing by an Endocrinology Specialist for the treatment of complex primary hyperparathyroidism
- 30mg, 60mg, 90mg
|
09.05.01.02 |
Cinacalcet |
- Renal Specialist use for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on dialysis, in line with NICE TA 117
- Non formulary at RUH for this indication
- Amber shared care at QAH Portsmouth for SFT patients.
- 30mg, 60mg, 90mg
|
04.06 |
Cinnarizine |
|
05.01.12 |
Ciprofloxacin |
- Only to be used in line with local primary care antibiotic guidance indications.
- The EMA’s Pharmacovigilence Risk Assessment Committee has recommended restricting fluoroquinolones following a review of disabling & potentially long-lasting side-effects. See link above for further information.
- Tablets 250mg, 500mg
- Oral suspension 250mg/5ml
|
05.01.12 |
Ciprofloxacin |
- The EMA’s Pharmacovigilence Risk Assessment Committee has recommended restricting fluoroquinolones following a review of disabling & potentially long-lasting side-effects. See link above for further information.
- IV infusion 100mg/50ml, 200mg/100ml, 400mg/200ml
|
11.03.01 |
Ciprofloxacin |
- 0.3% eye drops
 Salisbury
 RUH and GWH - For corneal crystallisation and endophthalmitis
|
12.01.01 |
Ciprofloxacin |
- 2 mg/ml ear drops solution in single-dose container
- Licensed for the treatment of acute otitis externa in adults and children older than 1 year with an intact tympanic membrane
- The ampoule contents should be used immediately after opening the single dose ampoule.
- Each pack contains 15 ampoules
- Used at SFT only
|
12.01.01 |
Ciprofloxacin 0.3% |
- GWH ENT use eye drops in the ear (off-label)
|
15.01.05 |
Cisatracurium |
- SFT only
- 2mg/ml or 5mg/ml
|
08.01.05 |
Cisplatin |
- 10mg/10ml, 50mg/50ml and 100mg/100ml infusion
|
04.03.03 |
Citalopram |
- Tablets 10mg, 20mg, 40mg
- Oral dropsSF 40mg in 1ml–8mg (4 drops may be considered equivalent to 10mg tablet)
- Note: Fewer drug interactions than fluoxetine or paroxetine.
- For citalopram, new restrictions on the maximum daily doses now apply:
- 40 mg for adults;
- 20 mg for patients older than 65 years;
- 20 mg for those with hepatic impairment.
- Citalopram has been found to cause a dose-dependent prolongation of the QT-interval. Cases of QT interval prolongation and ventricular arrhythmia including torsade de pointes have been reported during the post-marketing period, predominantly in patients of female gender, with hypokalemia, or with pre-existing QT prolongation or other cardiac diseases. See SPC for further detail.
|
01.06.05 |
Citramag ® Sachet |
- Sachet containing citric acid anhydrous 17.79 gram & magnesium carbonate heavy 11.57 gram.
|
08.01.03 |
Cladribine |
- 10mg tablet
- 10mg/10ml solution for infusion
- 10mg/5ml solution for injection
- For specialist use only in accordance with guidance from cancer network or NICE
|
05.01.05 |
Clarithromycin |
- Tablets 250mg, 500mg
- Oral suspension (SF) 125mg/5ml, 250mg/5ml
|
05.01.05 |
Clarithromycin |
- IV infusion -used by BaNES community IV service
|
08.02.04 |
Clarithromycin |
- RUH only
- Used in combination with lenalidomide and pomalidomide as per DTC899
- 250mg and 500mg tablets
|
05.01.06 |
Clindamycin |
- 600mg/4ml
- GWH use as part of treatment protocol for PCP (Pneumocystis jirovecii pneumonia)
|
05.01.06 |
Clindamycin |
- 75mg
- 150mg
- For use in primary care as per local antibiotic guidance for unresolving cellulitis.
- GWH use as part of treatment protocol for PCP (Pneumocystis jirovecii pneumonia)
- High risk for clostridium difficile disease. Clindamycin is associated with Clostridium difficile diarrhoea, which limits its use. Patients should discontinue treatment immediately if diarrhoea develops.
|
07.02.02 |
Clindamycin Dalacin® |
|
13.06.01 |
Clindamycin 1% |
- 10% aqueous Solution
- Topical antibiotics should not be used in isolation; use in combination with retinoids or benzoyl peroxide topically if possible.
- Resistance is more likely with topical antibiotics and topical clindamycin can cause resistance to oral erythromycin. Only use topical clindamycin if retinoids/BPO aren't tolerated and the patient does not want to take an oral antibiotic (or has contra-indications).
|
13.06.01 |
Clindamycin/ tretinoin Gel |
- Gel Tretinoin 0.025% and Clindamycin 1% 30g
|
04.08.01 |
Clobazam |
- 10mg (Category 2 MHRA)
- Endorse SLS when used for epilepsy.
- Clobazam oral suspension 5mg or 10mg/5ml is available but is expensive. Use only if no other option is suitable and there are significant swallowing problems.
|
13.04 |
Clobetasol propionate Etrivex® |
- Very potent steroid
- 125ml shampoo 500mcg/g
|
13.04 |
Clobetasol Propionate 0.05% Dermovate® |
- Very potent steroid
- Cream 0.0525%, Ointment 0.05375% 30g, 100g
- Scalp Application 0.05% 30ml, 100ml
|
13.04 |
Clobetasol Propionate with neomycin and nystatin 0.5mg/5mg/100,000 IU/g Ointment |
- Very potent steroid
- SFT and GWH only
- NOT for primary care use.
- £87 a pack in primary care (Feb 2020)
- Only available generically. Dermovate NN has been discontinued.
|
13.04 |
Clobetasone Butyrate 0.05% Eumovate® |
- Moderate potency steroid
- Cream, Ointment 0.05% 30g, 100g
- Apply sparingly up to twice a day
- Note: Clobetasone butyrate (Eumovate®) cream can be sold over the counter for short-term symptomatic treatment & control of patches of eczema & dermatitis (but not seborrhoeic dermatitis) in adults and children over 12 years.
|
08.01.03 |
Clofarabine |
- 20mg/20ml infusion
- ONLY Approved for use in acute myeloblastic leukaemia in accordance with the criteria set out by the NHS England Cancer Drugs Fund
|
06.05.01 |
Clomifene Citrate |
- 50mg
- Note: Clomifene is only indicated for patients in whom ovulatory dysfunction has been demonstrated and other causes of infertility have been excluded or adequately treated.
Prescribing should fall within NICE CG156: • Do not offer oral ovarian stimulation agents(such as clomifene citrate, anastrozole or letrozole) to women with unexplained infertility, and • For women who are taking clomifene citrate, do not continue treatment for longer than 6 months. In accordance with the product SPC, 3 courses should constitute an adequate trial. Due to the limited length of time it is used and that patients are likely to be receiving ongoing care in a specialist setting the number of requests to pick up this prescribing in primary care should be minimal. |
04.03.01 |
Clomipramine |
- Capsule 10mg, 25mg, 50mg
- Note: Also used in phobic and obsessional states
|
04.08.01 |
Clonazepam |
- Tablet 500 microgram, 2mg (Category 2 MHRA)
- For injection see 4.8.2
|
04.08.02 |
Clonazepam |
- 1mg/ml or infusion of 1mg
- Discontinued in the UK however an unlicensed import is used by acute trusts.
|
06.04.01 |
Clonidine Tablet |
- Clonidine 25microgram tablets (central acting alpha adrenergic agonist) for the management of vasomotor symptoms in menopause, particularly flushing.
- Designated less suitable for prescribing in the BNF because of significant side effects.
|
16.15 |
Clonidine |
GWH only
- Treatment resistant ADHD and severe Tic disorder. Paediatric consultant only.
Non-formulary at RUH/SFT |
02.09 |
Clopidogrel |
|
07.02.02 |
Clotrimazole |
- 1% cream 20g
- 10% vaginal cream 5g
- 500mg pessary
- Patients should be advised that clotrimazole products might damage latex condoms and diaphragms.
|
12.01.01 |
Clotrimazole 1% |
- 1% solution is licensed to be used as ear drops
|
13.10.02 |
Clotrimazole 1% |
|
04.02.01 |
Clozapine Zaponex® |
- Tablets 25mg, 100mg
- Note: Patients must be registered with the Zaponex® Treatment Access System (ZTAS). Licensed for treatment resistant schizophrenia.
- The patient, the supervising consultant and the dispensing pharmacy must all be registered with ZTAS. In this formulary area the AWP internal pharmacy is the primary supplier for clozapine for almost all patients.
- Regular (minimum monthly) full blood counts are required prior to and during clozapine treatment, if these are not up-to-date then medication cannot be dispensed.
See link below for AWP Procedure for the care of patients taking clozapine in primary care settings during the COVID-19 pandemic |
13.05.02 |
Coal Tar Extract 5% (Alcoholic) Shampoo |
|
13.05.02 |
Coal tar lotion 5% Exorex® |
- Coal Tar solution 5% emulsion 100ml, 250ml
- Useful for guttate psoriasis. Dilute with water to form an emulsion. Apply a thin layer twice or three times a day. Also useful applied to scaly scalps overnight.
|
02.02.04 |
Co-amilofruse (furosemide and amiloride) |
- 2.5mg/20mg, 5mg/40mg, (amiloride/furosemide)
- Note: Combination diuretics are not generally recommended, as the individual components cannot be adjusted independently. Restrict use to patients at risk of hypokalaemia, or if compliance problems.
|
02.02.04 |
Co-amilozide |
- 2.5mg /25mg (amiloride /hydroclorothiazide)
- Note: Combination diuretics are not generally recommended, as the individual components cannot be adjusted independently. Restrict use to patients at risk of hypokalaemia, or if compliance problems.
- Note: BaNES only - Co-amilozide included for ENT indications relating to balance e.g Menieres
|
05.01.01.03 |
Co-Amoxiclav |
- 500/100
- 1000/200
- Do not prescribe with metronidazole, unless very significant faecal contamination of abdominal cavity identified during surgery.
- Cholestatic jaundice can occur either during or shortly after
the use of co-amoxiclav. The risk of acute liver toxicity is about 6 times greater with co-amoxiclav than with amoxicillin. Cholestatic jaundice is more common in patients above the age of 65 years and in men.
- The duration of treatment should not usually
exceed 14 days.
|
05.01.01.03 |
Co-Amoxiclav |
- Tablets 250/125, 500/125.
- Oral suspension (SF) 125/31 in 5ml, 250/62 in 5ml.
- Do not prescribe with metronidazole, unless very significant faecal contamination of abdominal cavity identified during surgery.
- Cholestatic jaundice can occur either during or shortly after use of
co-amoxiclav. The risk of acute liver toxicity was about 6 times greater with co-amoxiclav than wth amoxicillin. Cholestatic jaundice is more common in patients above the age of 65 years and in men.
- The duration of treatment should not usually exceed 14 days.
|
04.09.01 |
Co-Beneldopa |
- Capsule 62.5mg, 125mg, 250mg
- Dispersible tablet 62.5mg, 125mg
- M/R capsule 125mg.
|
15.02 |
Cocaine 5% with adrenaline 1:2000 |
|
15.02 |
Cocaine HCl |
- GWH only
- Sterile oromucosal solution 10%
- For topical use only. Not for injection or to be taken.
- Cocaine Hydrochloride Solution is indicated to provide local anaesthesia and vasoconstriction of accessible mucous membranes prior to surgery especially in the oral, laryngeal, and nasal cavities.
|
04.09.01 |
Co-Careldopa |
- Sinemet-62.5, Sinemet 110 (10/100) Sinemet Plus (25/100), Sinemet-275 tablet
- Half Sinemet CR m/r tablet 25/100
- Sinemet CR m/r tablet 50/200.
|
04.09.01 |
Co-Careldopa and Entacapone Sastravi® |
- Prescribe as Sastravi® brand (Bioequivalent and more cost effective). Sastravi exactly the same strengths as Stalevo - see below:
- Tablets 50mg levodopa, 12.5mg carbidopa, 200mg entacapone
- Tablets 75mg levodopa, 18.75mg carbidopa, 200mg entacapone
- Tablets 100mg levodopa, 25mg carbidopa, 200mg entacapone
- Tablets 125mg levodopa, 31.25mg carbidopa, 200mg entacapone
- Tablets 150mg levodopa, 37.5mg carbidopa, 200mg entacapone
- Tablets 175mg levodopa, 43.75mg carbidopa, 200mg entacapone
- Tablets 200mg levodopa, 50mg carbidopa, 200mg entacapone
|
13.05.02 |
Cocois® |
- Coal tar solution 120 mg per 1 gram
- Salicylic acid 20 mg per 1 gram
- Sulfur precipitated 40 mg per 1 gram
- 40g,100g
|
13.06.02 |
Co-Cyprindiol 2000/35 (Cyproterone Acetate 2mg with Ethinylestradiol 35micrograms) Tablet |
- Tablets cyproterone 2000mcg ethinyl estradiol 35mcg per tablet (prescribe generically, previous brand name Dianette)
|
01.04.02 |
Codeine phosphate |
- 15mg & 30mg tablets.
- 60mg tablets (Salisbury & Swindon ONLY).
- Please note: Codeine can cause sedation and constipation, and there is a risk of dependence with long term use. It should be reserved for short courses, and is best avoided in stoma patients.
|
04.07.02 |
Codeine Phosphate |
- Tablet 15mg, 30mg, 60mg
- Oral solution 25mg in 5ml
- Useful for the relief of mild to moderate pain but is too constipating for long-term use
|
21.01.01.02 |
Codeine Phosphate |
- Tablet 15mg, 30mg, 60mg
- Useful for the relief of mild to moderate pain but is too constipating for long-term use
|
10.01.04 |
Colchicine |
- 500 microgram tablets
- The dose of colchicine in acute gout is 1mg initially followed by 500 micrograms every 2-3 hours until relief of pain is obtained or vomiting or diarrhoea occurs or until a total dose of 6mg (12 tablets) has been reached. The course should not be repeated within 3 days.
|
09.06.04 |
Colecalciferol Stexerol D3® |
- 25,000 unit or 1,000 unit.
- Tablets containing 25,000 units vitamin D3 (625 micrograms) colecalciferol
- Loading Dose: TWO tablets (50,000 units) per week for 6 weeks
- Maintenance dose: ONE tablet (25,000 units) monthly (packs of 12)
- Tablets containing 1,000 units Vitamin D3 ( 25 micrograms) colecalciferol
- Maintenance dose: ONE tablet (1,000 units) daily
- Stexerol film-coated tablets are suitable for vegetarians, certified halal & kosher, peanut oil free, soya oil free, gelatine free, & gluten free. The tablets can be crushed or swallowed whole and can be taken with food. The vitamin D is derived from sheep’s wool so they may not be suitable for vegans but they are suitable for vegetarians.
- Use as per local vitamin D guidance above.
|
09.06.04 |
Colecalciferol Fultium D3® |
- Note: These are not included in the BSW Vitamin D guidance but may be in use in acute trusts in line with hospital contract
- 20,000 unit, 3200 unit, 800 unit available
- Licensed for use in children 12-18 years old and adults.
- Please note capsules contain gelatin
|
09.06.04 |
Colecalciferol 25,000 unit Invita D3 |
- Licensed for use in children 0-18 years old and adults with swallowing difficulties.
- May be mixed with a small amount of cold or lukewarm food immediately before administration.
- Use as per local vitamin D guidance above.
|
09.06.04 |
Colecalciferol and calcium carbonate Accrete D3® |
- First line for primary care across BSW
- Tablet 1.5g (equiv to calcium 600mg)/400iu Dose: 1 tablet twice daily
- Tablet chewable 2.5g (equiv to calcium 1g)/880iu Dose: 1 tablet once daily
- Cost effective alternative to Calceos
|
09.06.04 |
Colecalciferol and calcium carbonate Adcal-D3® |
- Caplets containing 300mg/ 7.5mmol calcium and 200 units/5micrograms of vitamin D (as vitamin D3/coleclciferol. Dose: 2 caplets twice daily
- Chewable tablets containing 600mg/15 mmol calcium and 400 units/ 10micrograms of Vitamin D (as vitamin D3/colecaciferol). Dose: 1 tablet twice daily.
- Dissolve, effervescent tablets containing 600mg calcium and 400 units of vitamin D (as vitamin D3). Dose: 1 tablet twice daily.
- Swindon: FIRST LINE IN SECONDARY CARE
|
09.06.04 |
Colecalciferol and calcium carbonate Calceos® |
- Chewable tablets containing 500mg/12.5mmol calcium and 400 units/ 10micrograms of Vitamin D (as Vitamin D3/colecalciferol)
- Dose: 1 tablet twice daily.
|
09.06.04 |
Colecalciferol and Calcium carbonate Calcichew-D3® Forte |
- Not on Swindon formulary
- Chewable tablets containing 500mg / 12.5mmol calcium and 400 units /10micrograms of vitamin D (as vitamin D3) Dose: 1 tablet twice a day
|
09.06.04 |
Colecalciferol and calcium carbonate Calfovit D3® |
- For patients unable to take chewable tablets or capsules.
- Powder- calcium phosphate (calcium 1.2g/ 30mmmol) and 800 units/20micrograms colecalciferol per sachet.
- For patients requiring calcium and vitamin D via enteral feeding. Calcium phosphate 1.2g or 30mmmol calcium and colecalciferol 20micrograms or 800 units per sachet.
- CALFOVIT D3 is indicated in adults and elderly. The safety and efficacy of CALFOVIT D3 in children has not been established; therefore, CALFOVIT D3 should not be used in this population. No data are available.
|
01.09.02 |
Colesevelam |
- 625mg tablets.
- Please note: Colesevelam is included for the treatment of diarrhoea associated with bile salt malabsorption (off label) only in patients unable to tolerate colestyramine. Please refer to our Colesevelam Shared Care Agreement for further information.
- Please note: Colesevelam has not been approved for the treatment of hypercholesterolaemia.
SUPPLY ISSUES WITH COLESTYRAMINE
Jan 2020 - BaNES, West Wilts and Swindon patients - Temporary change in TLS from AMBER with SCA to GREEN While Colestyramine is unavailable, RUH gastroenterologists have provided interim advice and guidance for local GPs to prescribe suitable alternatives in primary care for patients with bile acid malabsorption disorders. Gastroenterology recommends GPs consider prescribing one of the two following options:
- Colesevelam 625mg tablets - One capsule OD or
- Colestipol 5g sachet - 1 sachet OD
as per BNF instructions, particularly around timings of other medications. Then increase the dose incrementally at weekly intervals to control symptoms up to the maximum dose as recommended in the BNF. If the alternatives aren’t effective, then GP should consider prescribing Loperamide and consider alternative diagnoses +/- secondary care referral where appropriate. |
01.09.02 |
Colestipol Hydrochloride Sachet |
SUPPLY ISSUES WITH COLESTYRAMINE
Jan 2020 - BaNES, West Wilts and Swindon patients - Temporary change in TLS from AMBER to GREEN While Colestyramine is unavailable, RUH gastroenterologists have provided interim advice and guidance for local GPs to prescribe suitable alternatives in primary care for patients with bile acid malabsorption disorders. Gastroenterology recommends GPs consider prescribing one of the two following options:
- Colesevelam 625mg tablets - One tablet OD or
- Colestipol 5g sachet - 1 sachet OD
as per BNF instructions, particularly around timings of other medications. Then increase the dose incrementally at weekly intervals to control symptoms up to the maximum dose as recommended in the BNF. If the alternatives aren’t effective, then GP should consider prescribing Loperamide and consider alternative diagnoses +/- secondary care referral where appropriate. |
01.09.02 |
Colestyramine Sachet |
- 4g sachet.
- Please note: Sugar- fee sachets are more expensive.
SUPPLY ISSUES WITH COLESTYRAMINE
Jan 2020 - BaNES, West Wilts and Swindon patients - While Colestyramine is unavailable, RUH gastroenterologists have provided interim advice and guidance for local GPs to prescribe suitable alternatives in primary care for patients with bile acid malabsorption disorders. Gastroenterology recommends GPs consider prescribing one of the two following options:
- Colesevelam 625mg tablets - One capsule OD or
- Colestipol 5g sachet - 1 sachet OD
as per BNF instructions, particularly around timings of other medications. Then increase the dose incrementally at weekly intervals to control symptoms up to the maximum dose as recommended in the BNF. If the alternatives aren’t effective, then GP should consider prescribing Loperamide and consider alternative diagnoses +/- secondary care referral where appropriate. |
02.12 |
Colestyramine |
- Powder 4g sachet (Note: The sugar free sachet is less cost effective)
- Should only be used for lipid-lowering in exceptional circumstances and be initiated by a consultant. It remains useful in the small number of patients for whom statins cannot be used.
|
05.01.07 |
Colistimethate Colobreathe® |
- Dry powder for inhaler and hard capsule 1.66 million units/capsule
|
05.01.07 |
Colistimethate |
 RUH CF patients (seen at BRI hospital) TLS Red for management of acute and chronic CF infections
 RUH only: Nebulised- NON-CF patients chronically colonised with P.aeruginosa Prescribe as Colomycin® brand along with sodium chloride ampoules for reconstitution as detailed in SCA (below)
 GWH for use in bronchiectasis and existing CF patients (usually nebulised).
 GWH for use in new CF patients (usually nebulised).
 GWH use IV for treatment of carbapenemase-producing Enterobacteriaceae
- 500,000 units
- 1 million units
- 2 million units
|
16.08 |
Colistimethate Sodium Promixin® |
- 1million-units
- For use in paediatrics only following initiation by specialist
|
01.01.01 |
Co-magaldrox |
- SuspensionSF 195/220 (low sodium, bowel neutral).
|
06.04.01.01 |
Combined continuous HRT Kliovance |
- estradiol 1mg and norethisterone acetate 500micrograms
|
06.04.01.01 |
Combined continuous HRT Kliofem |
- 2mg estradiol and 1mg norethisterone
- 1 prescription charge.
|
06.04.01.01 |
Combined continuous HRT Premique low dose |
- 300 micrograms conj. oestrogens and 1.5mg medroxyprogesterone acetate
|
06.04.01.01 |
Combined continuous HRT Femoston Conti |
- 1mg estradiol + 5mg dydrogesterone
- 0.5mg estradiol + 2.5mg dydrogesterone (low dose)
|
06.04.01.01 |
Combined continuous HRT Evorel® Conti |
- Patches 50 micrograms estradiol 170 micrograms norethisterone
- Change Twice a week
|
06.04.01.01 |
Combined cyclical HRT Evorel® Sequi |
- Patches 50 micrograms estradiol and 170 micrograms norethisterone acetate
- Change patch Twice a week
|
06.04.01.01 |
Combined cyclical HRT Elleste-Duet® |
- Tablets estradiol (1mg, 2mg) with 1mg norethisterone acetate
- 2 prescription charges
|
06.04.01.01 |
Combined cyclical HRT Femoston® |
- Tablets (1mg or 2mg) estradiol with 10mg dydrogesterone
|
07.03.01 |
Combined Hormonal Contraceptives Evra |
- Transdermal patch containing 6 mg norelgestromin and 600 micrograms ethinyl estradiol
- Restricted for use in women who are likely to comply poorly with combined oral contraceptives
|
07.03.01 |
Combined Hormonal Contraceptives Logynon ED® |
- Multiphasic pills containing ethinylestradiol 30 micrograms, levonorgestrel 50 micrograms; ethinylestradiol 40 micrograms, levonorgestrel 75 micrograms; ethinylestradiol 30 micrograms, levonorgestrel 125 micrograms; 7 inactive lactose tablets. 3 x 28 tablets.
|
07.03.01 |
Combined Hormonal Contraceptives Microgynon 30 ED® |
- Tablets containing ethinylestradiol 30 micrograms and levonorgestrel 150 micrograms (21 beige tabs); lactose (7 white tabs) 3 x 28 £2.99 December 2018.
|
07.03.01 |
Combined Hormonal Contraceptives NuvaRing® |
- Ethinylestradiol 15 micrograms/24 hours with Etonogestrel 120micrograms/24 hours. 3 ring pack. 1 ring to be inserted into the vagina, removed on day 22; subsequent courses after 7 day ring-free interval.
- May be considered in women:
- with GI disturbance /malabsorption.
- getting persistent breakthrough bleeding with COCP (good cycle control).
- who have difficulties swallowing pills, and are not keen on other methods of contraception.
- getting hormonal side effects with COCP (relatively low oestrogen exposure).
|
09.02.02.01 |
Compound Sodium Lactate Intravenous Infusion Hartmann's solution |
- Calcium chloride0.027%, Potassium chloride 0.04% Sodium chloride 0.06% and Sodium lactate 0.25%
|
13.02.02 |
Conotrane® Barrier cream |
- 100g, 500g
- Benzalkonium chloride, cetrimide
- Nappy rash or for use in elderly in nursing homes
|
06.05.01 |
Corticorelin |
- Not on formulary Salisbury or Swindon
- For Corticotrophin releasing Hormone (CRH) test which is a dynamic endocrine test
- Powder and solvent
- 100microgram used as an intravenous injection as a single dose
|
05.01.08 |
Co-trimoxazole |
|
05.01.08 |
Co-trimoxazole |
- Tablets 480mg, 960mg
- Suspension 240mg/5ml, 480mg/5ml
- Included in primary care antibiotic guidance as an alternative option for the treatment of acute exacerbations of COPD
- Otherwise used as recommended by a microbiologist.
|
05.04.08 |
Co-trimoxazole |
|
13.08.02 |
Covermark ® |
- Classic Foundation and Finishing Powder
|
08.01.05 |
Crizotinib |
|
13.03 |
Crotamiton Eurax® |
- Eurax Cream 10% , 30g, 100g
- Apply twice or three times daily.
|
20 |
Cyanoacrylate glue N-butyl-2-cyanoacrylate |
- For use within the RUH
- For treatment of gastric variceal bleeding
|
09.01.02 |
Cyanocobalamin Oral Vitamin B12 |
- 50microgram, 100microgram, 1mg tablets
- For management of diet related Vit B12 deficiency, patients can be advised to purchase cyanocobalamin OTC in line with NHSE guidance.
COVID-19 pandemic - As per BSH advice for Vit B12 replacement there may be situations where oral B12 50-150 micrograms per day may be offered as an alternative to Vit B12 injection. See link below.
|
04.06 |
Cyclizine |
- Tablet 50mg
- Injection 50mg in 1ml
|
21.01.02 |
Cyclizine |
|
21.02.02 |
Cyclizine |
- For nausea and vomiting
- 50mg/ml
- Can be used in syringe drivers check compatibility
- See page 89/90 Wessex Palliative Care Handbook (link at start of chapter)
|
21.03 |
Cyclizine |
- Community Just In Case Boxes
- For nausea and vomiting
|
11.05 |
Cyclopentolate drops |
- 0.5% and 1% ophthalmic drops
- 0.5% and 1% minims
|
08.01.01 |
Cyclophosphamide |
- 500mg,1g and 2g injection
|
08.01.01 |
Cyclophosphamide |
|
18 |
Cyproheptadine Periactin® |
|
08.03.04.02 |
Cyproterone |
|
06.04.02 |
Cyproterone Acetate |
|
08.01.03 |
Cytarabine |
- 100mg/5ml, 500mg/25ml, 1g/10ml, 2g/20ml and 500g/5ml injection
|
02.08.02 |
Dabigatran Pradaxa® |
- Capsules 110mg, 150mg
- The Traffic Light Status for dabigatran depends on the prescribed indication:
Prevention of stroke and systemic embolism in NVAF. (TA249)
Treatment and secondary prevention of DVT and/or PE. (TA327)
Prevention of VTE after elective hip or knee replacement. (TA157)
|
08.01.05 |
Dabrafenib |
|
08.01.05 |
Dacarbazine |
- 500mg and 1g infusion
- 100mg and 200mg injection
|
05.03.03.02 |
Daclatasvir Daklinza® |
|
08.01.02 |
Dactinomycin |
- 500microgram powder for reconstitution
|
02.08.01 |
Dalteparin |
- Note - variation in TLS across trusts and also according to indication. See individual prescribing policies.
- Pre filled syringes 2,500iu/0.2ml, 5000iu/0.2ml, 7,500iu/0.3ml, 10,000iu/0.4ml, 12,500iu/0.5ml, 15,000iu/0.6ml, 18,000iu/0.72ml for subcutaneous injection
|
02.08.01 |
Danaparoid |
- SFT and GWH only and restricted for use on the advice of a haematologist for the treatment/prophylaxis of thromboembolic disease in patients with a history of heparin-induced thrombocytopenia
- Non formulary at RUH
- 750 units/0.6ml solution for injection ampoules
|
10.02.02 |
Dantrolene |
 Swindon and Salisbury
 BaNES
- 25mg and 100mg capsules
- Liver function tests should be performed before commencing dantrolene, and then repeated on discharge from hospital (or 6 weeks after starting therapy) and then at 3 monthly intervals.
|
15.01.08 |
Dantrolene Sodium |
|
06.01.02.03 |
Dapagliflozin |
- 5mg, 10mg tablets
 FOR USE IN COMBINATION WITH OTHER ORAL PRODUCTS FOR THE TREATMENT IF TYPE 2 DIABETES
 IF USED IN COMBINATION WITH INSULIN IN TYPE 2 DIABETES FOLLOWING NICE GUIDANCE ONLY
 IF USED IN COMBINATION WITH INSULIN IN TYPE 1 DIABETES FOLLOWING NICE GUIDANCE ONLY. NOTE: Only the 5mg strength is licensed for this indication. Prescribing should be retained by secondary care although GPs will need to prescribe ketone test strips for type 1 diabetes patients to use whilst on dapagliflozin.
- Nov 2020 – The licence for dapagliflozin now includes the treatment of symptomatic chronic heart failure with reduced ejection fraction. Dapagliflozin is currently NOT included on the BSW formulary for this indication and should not be prescribed for HF. The BSW APC will review the formulary status for this indication once NICE have published their recommendations (expected Feb 2021).
|
05.01.10 |
Dapsone |
 for the treatment of dermatitis herpetiformis for stable patients.
 for unlicensed indications.
- GWH use for the treatment of PCP (Pneumocystis jirovecii pneumonia)
- 50mg
- 100mg
- Needs monitoring as per DMARD shared care agreement on link below
|
13.05.03 |
Dapsone |
 for licensed indications
 for unlicensed indications
- Tablets 50mg, 100mg
- Licensed for the treatment of dermatitis herpetiformis
- Maximum daily dose 300mg
- Restricted for use on dermatology recommendation.
- Tablets disperse in water if needed.
|
05.01.07 |
Daptomycin |
- Use with microbiology advice only
- GWH/RUH only
|
08.01.05 |
Daratumumab |
|
09.01.03 |
Darbepoetin Alfa Non renal indications |
 SFT and RUH
 GWH
- Non renal indications - Haematology / Oncology
- Aranesp®Prefilled syringes 10, 15, 20, 30, 40, 50, 60, 80, 100, 150, 130, 300, 500 micrograms
- SureClick® 20, 40, 60, 80, 100, 150, 300, 500 micrograms
|
05.03.01 |
Darunavir Prezista® |
|
05.03.01 |
Darunavir and Cobicistat Rezolsta® |
- Tablet contains 800 mg of darunavir (as ethanolate) and 150 mg of cobicistat
|
05.03.03.02 |
Dasabuvir Exviera® |
|
08.01.05 |
Dasatinib |
- 20mg, 50mg, 80mg, 100mg and 140mg tablets
|
08.01.02 |
Daunorubicin |
|
09.01.03 |
Deferasirox |
- 90mg,180mg,360mg
- Commissioned by NHS England for iron chelation in thalassaemia and sickle cell anaemia.
|
08.01.05 |
Defibrotide |
- 200mg (80 mg/mL concentrate for solution for infusion)
- For the treatment of veno-occlusive disease in accordance with treatment of possible hepatic veno-occlusive disease as noted in link below
- Formulary at RUH for this indication
|
08.03.04.02 |
Degarelix |
|
09.06.07 |
DEKAs Plus Multivitamin containing vitamins A, D, E and K for patients with CF |
- For Cystic Fibrosis patients only
- Multivitamin containing vitamins A, D, E and K for the dietary management of patients with CF on the specific recommendation of a specialist in CF.
- 1-4yrs DEKAs liquid
- 5-8yrs DEKAs liquid or softgel capsules or chewable tablets
- >9yrs DEKAs softgel capsules or chewable tablets
|
05.01.03 |
Demeclocycline |
- 150mg Capsules
- Only on formulary to treat Syndrome of Inappropriate Anti-Diuretic Hormone (SIADH).
- Not on formulary for treatment of infections.
|
06.05.02 |
Demeclocycline |
- Capsules 150mg
- Used in the treatment of hyponatraemia resulting from inappropriate secretion of antidiuretic hormone (SIADH). Requires specialist initiation.
|
06.06.02 |
Denosumab Prolia® |
- 60mg in 1ml injection
- Indication on formulary: Treatment of osteoporosis in postmenopausal women. In postmenopausal women Prolia significantly reduces the risk of vertebral, non-vertebral and hip fractures. Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.
- New monitoring - check calcium levels: before each dose and, in patients predisposed to hypocalcaemia within two weeks after the initial dose. If any patient presents with suspected symptoms of hypocalcaemia during treatment calcium levels should be measured. Consider monitoring calcium levels more frequently in patients with risk factors for hypocalcaemia (eg, severe renal impairment, creatinine clearance <30ml/min).
- The optimal total duration of antiresorptive treatment for osteoporosis (including both denosumab and bisphosphonates) has not been established. The need for continued treatment should be re-evaluated periodically based on the benefits and potential risks of denosumab on an individual patient basis, particularly after 5 or more years of use
|
06.06.02 |
Denosumab Xgeva® |
- Each vial contains 120 mg of denosumab in 1.7 mL of solution (70 mg/mL).
- Indication on formulary: Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone.
- Not to be prescribed in primary care.
- New monitoring - Monitoring of calcium levels should be conducted (i) prior to the initial dose of XGEVA, (ii) within two weeks after the initial dose, (iii) if suspected symptoms of hypocalcaemia occur Additional monitoring of calcium level should be considered during therapy in patients with risk factors for hypocalcaemia, or if otherwise indicated based on the clinical condition of the patient.
|
07.02.02 |
Dequalinium chloride Fluomizin® |
- 10mg vaginal tablet
- Dequalinium is suitable for initiating in primary care for the treatment of bacterial vaginosis where first line treatment (metronidazole) is not effective or not tolerated, ideally following discussion with a gynaecologist or GUM specialist.
|
13.08.02 |
Dermacolor ® |
- Camouflage Cream and Fixing Powder
|
13.02.01 |
Dermatonics Heel Balm ® cream |
- Use after other emollients have been tried and failed to control symptoms. Expensive emollient.
- 25% urea
- Available as: 75g and 200g pack sizes.
- Preparations containing lauromacrogols and/or urea are useful to stop itching or aid hydration.
|
13.09 |
Dermax® |
- Benzalkonium chloride 0.5% 250ml
|
13.02.01 |
Dermol ® Cream & Lotion |
- CONTAINS ANTIMICROBIALS
- Use long-term if needed to prevent frequent skin infections, or for handwashing for carers with occupational irritant hand dermatitis.
- Use short-term if there is a single episode of infection. Not for repeat prescription.
- Cream 100g, 500g pump
- Contains benzalkonium Cl and chlorhexidine HCL
- Lotion 500ml pump
- Can be used as hairwash and soap substitute
- Contains benzalkonium Cl and chlorhexidine HCL
|
09.01.03 |
Desferrioxamine Mesilate Injection |
- 500mg, 2g powder for solution for injection vials
- Commissioned by NHS England for iron chelation in thalassaemia and sickle cell anaemia.
|
15.01.02 |
Desflurane |
|
02.11 |
Desmopressin |
- SFT only - for the treatment of mild haemophilia A or von Willebrand's disease. Consultant haematologist use only.
- Non formulary at RUH and GWH
- For non-haematology indications, please see chapter 6.5.2
|
06.05.02 |
Desmopressin |
- Injection 4 micrograms in 1ml
|
06.05.02 |
Desmopressin |
 for primary nocturnal enuresis
 for diabetes insipidus, nocturia caused by MS.
- DDAVP® tablets (or generic) 100, 200micrograms
- Desmotabs Tablets (or generic) 200 micrograms
- Note: nasal spray no longer licensed for primary nocturnal enuresis (bed wetting) due to adverse drug reactions including hyponatraemia.
|
06.05.02 |
Desmopressin Desmospray® |
- Nasal spray 10 micrograms per metered spray 60 dose unit
- Nasal spray no longer licensed for primary nocturnal enuresis (bed wetting) due to adverse drug reactions including hyponatraemia.
- DDAVP®/Desmopressin Intranasal Solution is indicated for:
- The diagnosis and treatment of vasopressin-sensitive cranial diabetes insipidus.
- The treatment of nocturia associated with multiple sclerosis where other treatments have failed.
- Establishing renal concentration capacity.
|
07.03.02.01 |
Desogestrel Cerelle® |
- Tablets containing 75 microgram desogestrel
- First line choice of oral progestogen-only contraceptive due to the 12 hour window to take the pill.
- Cerelle is most cost effective generic brand (3 x 28 £3.50 December 2018). Cerazette is non-formulary as not cost effective (3 x 28 £8.68 December 2018)
|
06.03.02 |
Dexamethasone |
- For specific indications
- Tablets 500 microgram, 2mg
- Oral solution 2mg/5ml
- 3.32 mg of dexamethasone (dexamethasone base) in 1 ml solution for injection
- 6.64 mg of dexamethasone (dexamethasone base) in 2 ml solution for injection
- Injection
 (BCAP only) Each ml of solution for injection contains 4.00 mg of dexamethasone phosphate (as 4.37 mg dexamethasone sodium phosphate) equivalent to 3.32 mg of dexamethasone base.
|
11.04.01 |
Dexamethasone |
|
11.04.01 |
Dexamethasone Minims® |
 - Bath & Swindon
- Non formulary - Salisbury
- 0.1% preservative free eye drops in 0.5ml unit doses
|
11.04.01 |
Dexamethasone Ozurdex® |
- 700 micrograms intravitreal implant in applicator
- For the treatment of adults with macular oedema following either branch retinal vein occlusion or central retinal vein occlusion ONLY in line with local commissioning criteria and NICE TA229.
- For the treatment of patients with sight problems caused diabetic macular oedema, in line with NICE TA349.
- For the treatment of patients with non-infectious uveitis, in line with NICE TA460. Only available in specialist centres (not RUH or SFT).
|
21.01.01.04 |
Dexamethasone |
- For specific indications
- Tablets 500 microgram, 2mg
|
21.02.02 |
Dexamethasone |
- 3.32 mg of dexamethasone (dexamethasone base) in 1 ml solution for injection which is equivalent to 4 mg dexamethasone phosphate (or 4.3 mg dexamethasone sodium phosphate)
- For use in syringe pumps following advice from palliative care specialists
- See page 89/90 Wessex Palliative Care Handbook (link at start of chapter)
|
12.01.01 |
Dexamethasone with Antibacterial Otomize® |
- Dexamethasone 0.1%, neomycin sulfate 3250 units/ml, glacial acetic acid 2%
|
12.01.01 |
Dexamethasone with Antibacterials Sofradex® |
- Dexamethasone 0.05%, framycetin sulfate 0.5%, gramicidin 0.005%
|
11.04.01 |
Dexamethasone with Neomycin and Polymyxin B sulphate |
- Dexamethasone 1 mg/gram with neomycin 3500 units/gram and polymyxin B sulfate 6000 unit per 1 gram in 3.5g eye ointment
- Dexamethasone 1 mg/ml with hypromellose 5 mg/ml with neomycin (as neomycin sulfate) 3500 units/ml with polymyxin B sulfate 6000 units/ml in 5ml eye drops
|
11.04.01 |
Dexamethasone with Tobramycin |
- Dexamethasone 1 mg/ml with tobramycin 3 mg/ml eye drops.
- Salisbury only
- Non formulary in BaNES and Swindon
|
16.05 |
Dexamfetamine Sulphate |
- 5mg
- Only for those whose ADHD symptoms are responding to lisdexamfetamine but who cannot tolerate the longer effect profile.
|
15.01.04.04 |
Dexmedetomidine |
- GWH ICU/theatres only
- 100 micrograms/ml concentrate for solution for infusion, various ampoule sizes
|
04.07.02 |
Diamorphine |
- Injection 5mg, 10mg, 30mg, 100mg, 500mg
- For use in Palliative Care see chapter 21
|
21.02.01 |
Diamorphine |
- Currently unavailable (March 2020)
- Use Morphine first line in syringe drivers
- For pain
- 5mg, 10mg, 30mg
- Can be used in syringe drivers
- See page 89/90 Wessex Palliative Care Handbook (link at start of chapter)
|
21.02.01 |
Diamorphine |
- Currently unavailable (March 2020)
- Use Morphine first line in syringe drivers
- For pain relief
- 100mg and more in a syringe driver (where low volume required) on advice of palliative care specialist
|
21.03 |
Diamorphine Injections 10mg /ml |
- Current supply issues - use Morphine first line
- Community Just In Case Boxes
- For pain
|
04.01.02 |
Diazepam |
- Tablets 2mg, 5mg, 10mg
- Oral Solution 2mg in 5ml,
- Suppositories
|
04.08.02 |
Diazepam |
|
04.08.02 |
Diazepam Diazemuls® |
- 5mg/ml Intravenous injection (emulsion) (Diazemuls®)
|
10.02.02 |
Diazepam Muscle relaxant |
- 2mg, 5mg and 10mg tablets
- 10mg/2ml injection
- 2mg/5ml oral suspension
- 2.5mg, 5mg and 10mg rectal tubes
- For short term use only
|
15.01.04.01 |
Diazepam |
- 10mg in 2ml Injection (emulsion - Diazemuls®)
|
21.01.01.04 |
Diazepam |
- Tablets 2mg, 5mg, 10mg
- Oral Solution 2mg in 5ml,
|
21.01.04 |
Diazepam |
- Tablets 2mg, 5mg, 10mg
- Oral Solution 2mg in 5ml,
|
04.01.02 |
Diazepam injection |
- Injection (emulsion - Diazemuls®) 10mg in 2ml
- Injection 5mg/ml
|
06.01.04 |
Diazoxide |
- 50mg
- For the treatment of recurrent or chronic intractable hypoglycaemia caused by insulinoma or other tumour.
|
10.01.01 |
Diclofenac |
- 12.5mg, 25mg, 50mg and 100mg suppositories
- 75mg in 3ml injection
- Cardiovascular risk is higher with diclofenac than other non-selective NSAIDs and similar to selective COX-2 inhibitors.
- Diclofenac should be used for short courses only.
|
10.01.01 |
Diclofenac Akis® |
 GWH ONLY - For the short-term prevention & treatment of post - operative pain.
- Non- formulary at RUH and SFT
- 75mg in 1ml injection.
- Cardiovascular risk is higher with diclofenac than other non-selective NSAIDs and similar to selective COX-2 inhibitors.
- Diclofenac should be used for short courses only.
|
10.01.01 |
Diclofenac |
 - Salisbury & Swindon.
 - RUH - Oral diclofenac is only included on the formulary for maternity services for a short course of inpatient treatment post delivery.
- 25mg & 50mg gastro-resistant tablets
- Cardiovascular risk is higher with diclofenac than other non-selective NSAIDs and similar to selective COX-2 inhibitors.
- Oral diclofenac should be used for short courses only
|
11.08.02 |
Diclofenac |
 Swindon - Pre-operative & immediately post - operatively. For short-term pain relief in episcleritis, cornial abrasion or foreign bodies. Avoid single use except in allergy to preservatives
 RUH (Single use eye drops 0.1%)
- Non formulary in Salisbury
|
13.08.01 |
Diclofenac Solaraze® |
- Gel 3% 50g, 100g Solaraze®
- Prescribe by brand
- Apply thinly twice daily for 60-90 days, maximum 8g daily
|
21.02.01 |
Diclofenac |
- 75mg in 3ml injection
- As recommended by palliative care specialists
- Can be used in syringe drivers
- See page 89/90 Wessex Palliative Care Handbook (link at start of chapter)
|
08.03.01 |
Diethylstilbestrol |
|
13.04 |
Diflucortolone Valerate Nerisone Forte® |
- Very potent steroid
- Oily cream, Ointment 0.3% 15g
- Use for palms and soles. For severe and resistant dermatoses.
|
02.01.01 |
Digoxin |
- Tablets 62.5 micrograms, 125 micrograms, 250 micrograms
- Elixir 50 micrograms/ml
|
02.01.01 |
Digoxin |
- 250 micrograms/ml 2ml ampoule
|
02.01.01 |
Digoxin specific antibody fragments DigiFab® |
- 40mg powder for solution for infusion vials DigiFab®
- Note: For reversal of life-threatening digoxin overdose
|
04.07.02 |
Dihydrocodeine |
- Tablets 30mg
- Oral solution 10mg/5ml
- The efficacy of dihydrocodeine does not increase above a certain dose, but the risks of side effects and dependence increase. Do not prescribe more than a 30mg per dose.
- For post-operative analgesia on discharge.
- Short-term use only.
|
02.06.02 |
Diltiazem Tablets |
- Tablets 60mg
- Although the means of formulation has called for the strict designation ‘modified-release’ the duration of action corresponds to that of tablets requiring administration 3 times daily.
|
02.06.02 |
Diltiazem |
- Different versions of MR preparations containing more than 60 mg diltiazem hydrochloride may not have the same clinical effect. To avoid confusion between these different formulations of diltiazem, prescribers should specify the brand to be dispensed.
- Once daily prep - Viazem XL® available as 120mg, 180mg, 240mg, 300mg, 360mg capsules. Please note Slozem (previous OD preferred brand) discontinued Jan 2020 due to manufacturing issues.
- Twice daily prep - Angitil® SR available as 90mg, 120mg, 180mg capsules.
|
01.07.04 |
Diltiazem 2% Topical |
- 2% ointment.
- 2% cream.
- Please note: This is for use second- line for the treatment of chronic anal fissures, after GTN 0.4% ointment, prior to considering surgery, with maximum duration of use of 8 weeks. (Unlicensed).
- Please note: 2% ointment is more cost-effective in primary care, whilst 2% cream is more cost-effective in secondary care.
|
08.02.04 |
Dimethyl fumarate |
- 120mg and 240mg capsules
- NB Tecfidera brand only licensed for Multiple Sclerosis
- Check full blood counts before prescribing dimethyl fumarate and then every 6 to 12 months. Stop treatment immediately if progressive multifocal leukoencephalopathy is suspected.
|
13.05.02 |
Dimethyl Fumarate Skilarence ® |
- Tablets 30mg, 120mg
- NICE TA 475 guidance Dimethyl fumarate for treating moderate-to-severe plaque psoriasis (Sept 2017)
- The brand Fumaderm was previously used before the licensed product beccame available in the UK. There may still be some existing patients on this imported product, who will be reviewed by their specialist.
|
07.04.04 |
DIMETHYL SULPHOXIDE Bladder Instillation 50% |
- GWH existing patients only
- Not stocked at RUH or SFT
|
07.01.01 |
Dinoprostone |
- Prostin E2® dinoprostone 3mg vaginal tablets
- Prostin E2® dinoprostone 400micrograms per 1ml, 800micrograms per 1ml vaginal gel.
NB Prostin E2 vaginal tablets and vaginal gel are not bioequivalent.
- Propess® dinoprostone 10mg vaginal pessaries with retrieval device.
|
07.01.01.01 |
Dinoprostone |
- GWH and SFT
- note - off label use
|
08.02.04 |
Dinutuximab |
- 20mg/4.5ml infusion
- Only for use in line with NHSE commissioning (see link below)
|
13.02.01 |
Diprobase ® Topical |
- SFT only
- Cream or ointment
- NOT for use in primary care- use epimax as an alternative instead.
|
02.09 |
Dipyridamole |
- 100mg tablet
- 200mg MR capsule
|
11.99.99.99 |
Disodium edetate |
- 0.37% eyedrop Unlicensed
- RUH and GWH - for chelation of cornea for calcific band keratopathy.
- Not on formulary at SFT
|
06.06.02 |
Disodium Pamidronate |
- 15mg, 30mg, 60mg, 90mg
- For multiple myeloma and treatment of hypercalcaemia.
|
02.03.02 |
Disopyramide |
- Capsules 100mg
- Tablets modified release 250mg
|
06.01.01.03 |
Disposable Insulin Syringes |
|
04.10.01 |
Disulfiram |
|
13.05.02 |
Dithranol |
- Restricted: Specialist Prescribing Only. Various forms as per BAD specials list.
- See section 13.14 for BAD specials information
|
13.05.02 |
Dithranol |
 Cream: 0.1% 50g 0.25% 50g , 0.5% 50g (Dithrocream Forte) , 1% 50g (Dithrocream HP)
 2% 50g (Dithrocream 2%) (Prescription only)
- For psoriasis. Increase strength gradually. Stains clothes
|
02.07.01 |
Dobutamine |
- 250mg in 20ml
- 250mg in 50ml
|
08.01.05 |
Docetaxel |
- Various concentrations of infusion
|
01.06.03 |
Docusate Sodium |
- 100mg capsules.
- 50mg in 5ml oral solution SF.
- 120mg micro enema.
- Docusate acts as a softener and also has relatively weak stimulant properties.
|
16.15 |
Docusate Sodium |
- Paediatric 12.5mg/5ml Oral Solution (licensed from age 6months)
- 50mg in 5ml oral solution SF (licensed from age 12years)
- 120mg micro enema (licensed from age 12years)
- 100mg capsules (licensed from age 12years)
|
05.03.01 |
Dolutegravir |
|
05.03.01 |
Dolutegravir & lamivudine Dovato® |
- 50 mg dolutegravir and 300 mg lamivudine
|
05.03.01 |
Dolutegravir, abacavir & lamivudine Triumeq® |
- 50 mg dolutegravir (as sodium), 600 mg of abacavir (as sulfate) and 300 mg of lamivudine
|
04.06 |
Domperidone |
 when used within licensed indication which is SHORT –TERM relief of symptoms of nausea and vomiting in adults and adolescents over 12 years and weighing more than 35 kg. For use in GI pain in palliative care see Chapter 21
 for longer-term or off-label use
- Tablet 10mg
- Suspension 5mg in 5ml
- Prescribe in line with MHRA advice and BSW domperidone guidance (links below)
|
21.01.02 |
Domperidone |
- Tablet 10mg
- Suspension 5mg in 5ml
- Domperidone should be used at the lowest effective dose for the shortest possible duration
- Recommended adult dose for GI pain in palliative care is 10mg TDS. Higher doses should only be considered under specialist palliative care services.
|
04.11 |
Donepezil |
 BaNES
 Swindon
 Wiltshire
- Tablet 5mg, 10mg
|
02.07.01 |
Dopamine |
|
02.07.01 |
Dopexamine |
|
03.07 |
Dornase Alfa Pulmozyme® |
- Nebuliser solution 2500 units in 2.5ml
-
Notes:
- A Jet Nebuliser used exclusively for dornase alfa is required for administration
- To improve pulmonary function in cystic fibrosis patients with a FVC of greater than 40% predicted.
- Use on specialist respiratory advice only.
- Requirement for dornase alfa should be reviewed every 3 days.
|
11.06 |
Dorzolomide |
|
11.06 |
Dorzolomide 2% with Timolol 0.5% |
|
03.05.01 |
Doxapram Dopram® |
|
02.05.04 |
Doxazosin |
- 1mg, 2mg, 4mg
- Use only if diuretics, beta-blockers, CCBs and ACEI fail or are unsuitable.
- Note: Doxazosin m/r is not included as it is less cost-effective
|
07.04.01 |
Doxazosin |
- Tablets 1mg, 2mg, 4mg.
- Only prescribe generic immediate-release formulations.
|
13.03 |
Doxepin Xepin® |
 For eczema associated pruritis only
 for off-label use
- Cream (30g)
- Specialist use only for "off label" urticaria. Apply thin film three or four times a day. Maximum 3g per application
|
08.01.02 |
Doxorubicin |
- 10mg/5ml, 50mg/25ml, 100mg/50ml and 200mg/100ml injection
|
08.01.02 |
Doxorubicin Caelyx® |
|
05.01.03 |
Doxycycline |
|
13.06.02 |
Doxycycline |
- Capsules 100mg
- 100mg once a day for 3 months then review
|
16.09 |
Doxycycline |
|
02.03.02 |
Dronedarone |
- Tablets 400mg
- In line with NHSE guidance (June 2019) prescribers should not initiate dronedarone in primary care for any new patient. If there is a clinical need for dronedarone to be prescribed it must be in line with individual trust Shared Care Agreements - see links below.
|
04.06 |
Droperidol |
- GWH only for short-term peri-operative use on the advice of a consultant anaesthetist
|
06.01.02.03 |
Dulaglutide |
 Bath
 Salisbury and Swindon
- In combination with existing therapy (a sulphonylurea or prandial insulin).
- 0.75mg/0.5ml prefilled syringe, 1.5mg/0.5ml prefilled syringe. The manufacturers have also now received marketing authorisation for two new doses, 3 mg and 4.5 mg weekly (Nov 2020).
- See SPC for further information.
|
04.01.02 |
Duloxetine |
- Capsules 30mg, 60mg
- Useful for mixed anxiety and depression.
- AWP guidance suggests it should not be prescribed except where other treatments are poorly tolerated or ineffective if being used for depression alone.
- Ensure you have chosen the correct product as Duloxetine comes in different strengths and forms which have different license indications.
- Hyponatraemia has been reported with duloxetine, and may be due to a syndrome of inappropriate anti-diuretic hormone secretion (SIADH). The majority of cases of hyponatraemia were reported in the elderly, especially when coupled with a recent history of, or condition pre-disposing to, altered fluid balance. Caution is required in patients at increased risk for hyponatraemia, such as elderly, cirrhotic, or dehydrated patients, or patients treated with diuretics.
|
04.03.04 |
Duloxetine |
- Capsules 20mg, 30mg, 40mg and 60mg
- The starting and recommended maintenance dose is 60 mg once daily with or without food.
- Ensure you have chosen the correct product as Duloxetine comes in different strengths and forms which have different license indications.
- Hyponatraemia has been reported with duloxetine, and may be due to a syndrome of inappropriate anti-diuretic hormone secretion (SIADH). The majority of cases of hyponatraemia were reported in the elderly, especially when coupled with a recent history of, or condition pre-disposing to, altered fluid balance. Caution is required in patients at increased risk for hyponatraemia, such as elderly, cirrhotic, or dehydrated patients, or patients treated with diuretics.
|
04.07.03 |
Duloxetine |
- Capsules 30mg, 60mg
- For the treatment of diabetic peripheral neuropathic pain
- Discontinue if inadequate response after 2 months, review treatment every 3 months.
- Ensure you have chosen the correct product as Duloxetine comes in different strengths and forms which have different license indications.
- Hyponatraemia has been reported with duloxetine, and may be due to a syndrome of inappropriate anti-diuretic hormone secretion (SIADH). The majority of cases of hyponatraemia were reported in the elderly, especially when coupled with a recent history of, or condition pre-disposing to, altered fluid balance. Caution is required in patients at increased risk for hyponatraemia, such as elderly, cirrhotic, or dehydrated patients, or patients treated with diuretics.
|
21.01.01.03 |
Duloxetine |
- Capsules 30mg, 60mg
- For the treatment of neuropathic pain
|
13.05.03 |
Dupilumab |
- 300mg in 2ml solution for injection in a pre-filled syringe
- Use as per NICE TA
|
08.01.05 |
Durvalumab |
- 50 mg/mL concentrate for solution for infusion
|
02.08.02 |
Edoxaban Lixiana® |
- Tablets 15mg,30mg,60mg
- The Traffic Light Status for edoxaban depends on the prescribed indication:
Prevention of stroke and systemic embolism in people with nonvalvular AF. (TA355) For NVAF, choice of DOAC should be based on individual patient characteristics. See here for example decision making tool. If clinically appropriate, edoxaban may be considered first line based on lowest acquisition cost.
Treatment and secondary prevention of DVT and/or PE. (TA354)
OFF-LABEL treatment of cancer associated thrombosis NOTE: Only for patients seen at the RUH. At other trusts, this would be a RED TLS indication currently. See SCA below.
|
10.02.01 |
Edrophonium Chloride |
- Included on formulary as a diagnostic agent for myasthenia gravis.
|
05.03.01 |
Efavirenz Sustiva® |
- Capsules 50mg, 100mg, 200mg
- Tablets 600mg
- Oral solution (SF) 30mg/ml
|
13.09 |
Eflornithine 11.5% |
- SFT only
- Commissioning policy in development (August 2019)
- maximum supply of 30g per month
- Discontinue if no beneficial effects are noticed within four months of commencing therapy
- Hirsutism may be self-managed with mechanical and cosmetic means at no cost to the NHS
- It is important that the patient is properly assessed and underlying causes addressed as hirsutism can result from serious medical conditions or from medication.
- Eflornithine does not offer permanent hair removal, it slows hair growth such that users require less frequent hair removal by other methods (e.g. shaving, plucking, waxing). Hair removal will need to continue (regrowth occurs within 8 weeks).
|
05.03.03.02 |
Elbasvir/Grazoprevir Zepatier® |
|
09.01.04 |
Eltrombopag |
- 25mg, 50mg
- See MHRA Drug Safety Update July 18 for information on reports of interferance with bilirubin and creatinine
- Third line options can be considered for patients with symptoms lasting longer than 12 months in whom first and second line treatment options have failed and there are on-going complications from their thrombocytopenia OR where second-line options are contra-indicated.
|
06.01.02.03 |
Empagliflozin |
- 10mg and 25mg
 FOR USE IN COMBINATION WITH OTHER ORAL PRODUCTS FOR THE TREATMENT OF TYPES 2 DIABETES
 IF USED IN COMBINATION WITH INSULIN IN TYPE 2 DIABETES FOLLOWING NICE GUIDANCE ONLY
|
05.03.01 |
Emtricitabine Emtriva® |
- Capsules 200mg
- Oral solution 50mg/5ml
|
05.03.01 |
Emtricitabine + tenofovir alafenamide Descovy® |
- Emtricitabine/Tenofovir alafenamide 200mg/10mg or 200mg/25mg
|
05.03.01 |
Emtricitabine 200mg, Rilpivirine 25mg and Tenofovir 245mg Eviplera® |
- Emtriciciabine 200mg, rilpivirine 25mg, tenofovir 245mg
|
05.03.01 |
Emtricitabine, rilpivirine, & tenofovir alafenamide Odefsey ® |
- Rilpivirine 25mg, emtricitabine 200mg tenofovir alafenamide (TAF) 25mg
|
13.02.01 |
Emulsifying Ointment BP |
- GREASY MOISTURISER FOR SEVERE DRY SKIN
- Ointment 500g
|
16.01 |
Enalapril |
- 2.5mg, 5mg, 10mg and 20mg
|
02.01.02 |
Enoximone |
- Injection 100mg in 20ml
- SFT and GWH only. Non formulary at RUH.
|
A2.02.01.02 |
Ensure ® Plus Juce |
200 ml bottle.
28 day supply = 56 bottles, 12,320 ml
300 kcals, 10.6 g protein, 71.9 g carbohydrate
NOT SUITABLE FOR PEOPLE WITH COPD OR DIABETES
IDDSI level 1 - Slightly thick fluids |
A2.02.02.01 |
Ensure ® Plus Milkshake style |
220 ml bottle
Provides 330 kcal, 13.8 g protein, 220 ml fluid
IDDSI Level 0 - Thin fluids |
A2.02.02.01 |
Ensure ® Plus Fibre |
Consider for patients with constipation.
200 ml bottle
28 day supply = 56 bottles, 11,200 ml
310 kcals, 13 g protein, 5.0 g fibre, 200ml fluid
IDDSI Level 1 - Thin fluids |
09.04.02 |
Ensure Plus |
- 220ml bottles
- See ONS guidance for full product details (link at top)
|
09.04.02 |
Ensure Plus Fibre |
- Contains fibre, consider for those with constipation
- 200ml bottle
- See ONS guidance for full product details (link at top)
|
04.09.01 |
Entacapone |
- 200mg
- Notes: Entacapone is licensed for use as an adjunct to co-beneldopa or co-careldopa for patients with Parkinson’s disease who experience ‘end-of-dose’ deterioration and cannot be stabilized on these combinations. It is important thtn Entacapone and co-beneldopa or co-careldopa are taken together at the same time of day.
|
05.03.03.01 |
Entecavir Baraclude® |
|
08.01.05 |
Entrecitinib |
- 100mg, 200mg capsules
- Use in line with NICE TA643 and 644
|
08.03.04.02 |
Enzalutamide |
|
02.07.02 |
Ephedrine |
- Injection 30mg in 1ml
- Tablets 30mg for treatment of persistent (12 hours) and orthostatic hypotension, refractory to fluid bolus, during attempts to mobilise patients following spinal anaethesia for total hip or total knee arthroplasty
|
12.02.02 |
Ephedrine |
|
13.02.01 |
Epimax ® Ointment |
- GREASY MOISTURISER FOR SEVERE DRY SKIN
- YSP 30%, LP 40%, emulsifying wax 30%
- 500g or 125g pack sizes available
|
13.02.01 |
Epimax ® ExCetra cream |
- CREAM FOR MILD TO MODERATE DRY SKIN
- Cream 100g and 500g flexi dispenser which can be used instead of a pump by care homes.
- Contains the same ingredients as Cetraben® but is more cost effective choice
March 2020 - EPIMAX® name change
Minor name changes covering part of the EPIMAX® range came into effect in the March 2020 Drug Tariff. For the next 12 months, the products will occupy a dual listing on the drug tariff, such that prescriptions written under both the new and old name can be reimbursed. Despite the new names and associated change in the appearance of the labels, the product itself remains unchanged.
EPIMAX® ExCetra Cream (previously ExCetra Cream) |
13.02.01 |
Epimax ® Original cream |
- CREAM FOR MILD TO MODERATE DRY SKIN
- 500g flexi-dispenser which can be used by care homes. No pump pack available.
- Primary Care Diprobase®alternative
March 2020 - EPIMAX® name change
Minor name changes covering part of the EPIMAX® range came into effect in the March 2020 Drug Tariff. For the next 12 months, the products will occupy a dual listing on the drug tariff, such that prescriptions written under both the new and old name can be reimbursed. Despite the new names and associated change in the appearance of the labels, the product itself remains unchanged.
EPIMAX® Original Cream (previously Epimax Cream)
|
13.02.01 |
Epimax Isomol ® gel |
- VERY LIGHT MOISTURISER FOR MILD DRY SKIN
- 500g flexi dispenser which can be used instead of a pump by care homes
- Low paraffin content (15%)
- Primary care Doublebase® gel alternative
- Useful for dermatitis of the hands and as a light moisturiser for the body
March 2020 - EPIMAX® name change
Minor name changes covering part of the EPIMAX® range came into effect in the March 2020 Drug Tariff. For the next 12 months, the products will occupy a dual listing on the drug tariff, such that prescriptions written under both the new and old name can be reimbursed. Despite the new names and associated change in the appearance of the labels, the product itself remains unchanged.
EPIMAX® Isomol Gel (previously Isomol Gel) |
08.01.02 |
Epirubicin |
- 10mg/5ml and 50mg/25ml injection
- 100mg/50ml, 200mg/100ml infusion
|
02.02.03 |
Eplerenone |
- Tablet 25mg, 50mg
- Use within licensed indication in line with NICE.
- Eplerenone is only indicated as an adjunct in stable patients with left ventricular dysfunction with evidence of heart failure, following acute myocardial infarction. Start within 3-14 days of event.
|
02.08.01 |
Epoprostenol |
- Powder for reconstitution 500 micrograms
|
07.01.01 |
Ergometrine Maleate |
- Injection 500 micrograms in 1ml
|
07.01.01 |
Ergometrine Maleate and Oxytocin Syntometrine® |
- Injection containing ergometrine maleate 500 micrograms and oxytocin 5 units in 1ml
|
08.01.05 |
Eribulin |
- 0.88mg/2ml solution for injection
|
08.01.05 |
Erlotinib |
- 25mg, 100mg and 150mg tablets
|
05.01.02.02 |
Ertapenem |
 for use in acute trusts
 for treatment of multi-resistant UTI in the community. Only available within the BaNES Health Community. The Virgin Care Community IV team provides and administers IV drugs.
- IV infusion 1g vial
|
06.01.02.03 |
Ertugliflozin |
- 5mg and 15mg
 FOR USE IN COMBINATION WITH OTHER ORAL PRODUCTS FOR THE TREATMENT OF TYPE 2 DIABETES
|
05.01.05 |
Erythromycin |
- Tablets 250mg
- Oral suspension (SF) (ethylsuccinate) 125mg/5ml, 250mg/5ml, 500mg/5ml
|
11.03.01 |
Erythromycin |
- 0.5% eye ointment
- GWH only for suspected chlamydia in neonates on the advice of paediatrician
- Non formulary at RUH and SFT
|
13.06.02 |
Erythromycin |
- Tablets 250mg
- First line children less than 12 years of age and in pregnant or breastfeeding women
- 500mg twice a day for 3 months then review (two tablets twice daily)
|
13.06.01 |
Erythromycin 40mg with Zinc Acetate 12mg/mL Topical lotion |
- Topical lotion, powder for reconstitution, erythromycin 40mg/ml, Zinc acetate 12mg/ml 30ml, 90ml
- Apply twice daily
- Note that this product is not in local acne guidance due to high resistance levels. It was on the 3Ts and SFT formularies for children under 12 with acne only.
|
04.01.02 |
Escitalopram |
- Tablets 5mg, 10mg and 20mg
- Licensed option for Generalised Anxiety Disorder (GAD)
- 1st line option
- Escitalopram has been found to cause a dose-dependent prolongation of the QT interval. Cases of QT interval prolongation and ventricular arrhythmia including torsade de pointes have been reported during the post-marketing period, predominantly in patients of female gender, with hypokalemia, or with pre-existing QT interval prolongation or other cardiac diseases. See SPC for further information.
|
04.03.03 |
Escitalopram |
- Tablets 5mg, 10mg, Drops 20mg/ml
- 20 mg for adults;
- 10 mg for patients older than 65 years;
- 10 mg for those with hepatic impairment
- Escitalopram has been found to cause a dose-dependent prolongation of the QT interval. Cases of QT interval prolongation and ventricular arrhythmia including torsade de pointes have been reported during the post-marketing period, predominantly in patients of female gender, with hypokalemia, or with pre-existing QT interval prolongation or other cardiac diseases. See SPC for further detail.
|
04.08.01 |
Eslicarbazepine |
- 200mg, 800mg
- Adjunctive therapy in adolescents and adults Only to be used if other treatments have been ineffective or not tolerated.
- Not approved for monotherapy use.
|
02.04 |
Esmolol |
|
01.03.05 |
Esomeprazole |
 For use in patients with swallowing difficulties, or patients with NG/PEG tubes in-situ.
 - Salisbury & Swindon - For use in patients with treatment- resistant severe GORD, confirmed by endoscopy, who have failed to respond to the use of high doses of generic omeprazole or generic lansoprazole.
- Non-formulary - BaNES - For use in patients with treatment- resistant severe GORD, confirmed by endoscopy, who have failed to respond to the use of high doses of generic omeprazole or generic lansoprazole.
- 20mg & 40mg gastro-resistant tablets.
- Please note: Tablets may be dispersed in non-carbonated water and the resultant suspension swallowed or flushed down a gastric tube immediately (licensed indication).
|
10.01.03 |
Etanercept Benepali®, Enbrel®,Erelzi® |
- 25mg or 50mg solution for injection in pre-filled syringe or pen
- Prescribe by BRAND. Biosimilar should be used 1st line. BENEPALI® is the biosimilar brand used locally in BSW. First-line etanercept brand.
Commissioned by CCG for:
- Rheumatoid arthritis in accordance with NICE TA 375 and local pathway.
- Ankylosing spondylitis in accordance with NICE TA383 and local pathway
- Psoriatic arthritis in accordance with NICE TA199 and local pathway
Commissioned by NHS England from specialist centres only for:
- Juvenile idiopathic arthritis in line with NICE TA373.
- Paediatric patients in line with adult NICE TAs.
- Check Trust contracting arrangements.
|
13.05.03 |
Etanercept Benepali®, Enbrel®Erelzi® |
- Biosimilar available: BENEPALI® is the biosimilar brand used locally in BSW. First-line etanercept brand. Prescribe by brand.
- Originator brand: Enbrel® usually for patients that cannot tolerate or do not respond to Benepali.
- Injection 25mg, 50mg vial, 25mg, 50mg prefilled syringe
|
05.01.09 |
Ethambutol |
|
18 |
Ethanol (alcohol) injection |
|
06.04.01.01 |
Ethinylestradiol |
 Bath
 Swindon and Salisbury
- Tablets 10 micrograms, 50 micrograms, 1mg.
 2 microgram strength is an unlicensed special.
- Licensed for short term use for short term treatment of oestrogen deficiency, female hypogonadism and menstrual disorders.
- Also used for treatment of gender dysphoria
Note: Ethinylestradiol tablets are very expensive consider using estradiol where clinically appropriate as a more cost effective option. |
07.03.01 |
Ethinylestradiol / levonorgestrel phased pill TriRegol®, Logynon® |
- Multiphasic tablets containing ethinylestradiol 30 micrograms, levonorgestrel 50 micrograms; ethinylestradiol 40 micrograms, levonorgestrel 75 micrograms; ethinylestradiol 30 micrograms, levonorgestrel 125 micrograms. 3 x 21 tablets.
|
07.03.01 |
Ethinylestradiol 20 mcg / drospirenone 3 mg Eloine® |
- Tablets containing ethinyloestradiol 20 micrograms and drospirenone 3mg
- Note: third line option where women have struggles with side effects on first and second line combined pills.
|
07.03.01 |
Ethinylestradiol 20mcg / desogestrel 150mcg Gedarel®, Mercilon® |
- Tablets containing ethinylestradiol 20 micrograms and desogestrel 150 micrograms (21 days)
- Gedarel 20/150 Most cost effective choice 3 x 21 £5.08, Mercilon 3 x 21 £8.44 December 2018. Mercilon for existing patients only OR if Gedarel 20/150 unavailable.
|
07.03.01 |
Ethinylestradiol 20mcg / gestodene 75 mcg Millinette 20/75®, Femodette® |
- Tablets containing ethinylestradiol 20 micrograms and gestodene 75 micrograms.
|
07.03.01 |
Ethinylestradiol 30 mcg / drospirenone 3 mg Yasmin®, Lucette® |
- Tablets containing ethinyloestradiol 30 micrograms and drospirenone 3mg
- Lucette most cost effective 3 x 21 £9.35 December 2018. Yasmin only for existing patients 3 x 21 £14.70 December 2018.
- Note: Only for women with mild to moderate acne or symptoms of PMS when first and second choice have failed.
|
07.03.01 |
Ethinylestradiol 30mcg / desogestrel 150mcg Gedarel®, Marvelon® |
- Tablets containing ethinylestradiol 30 micrograms and desogestrel 150micrograms.
- Note: Useful for patients with acne which hasn't improved with Rigevidon.
|
07.03.01 |
Ethinylestradiol 30mcg / gestodene 75 mcg Millinette 30/75®, Femodene®,Sofiperla® |
- Tablets containing ethinylestradiol 30 micrograms and gestodene 75 micrograms.
|
07.03.01 |
Ethinylestradiol 30mcg / gestodene 75 mcg Femodene® ED |
- Each active tablet contains 75 micrograms gestodene and 30 micrograms ethinylestradiol. Each pack also contains seven placebo tablets which are larger.
|
07.03.01 |
Ethinylestradiol 30mcg / levonorgestrel 150mcg Rigevidon®, Microgynon 30®, Levest® |
- Tablets containing ethinylestradiol 30 micrograms and levonorgestrel 150 micrograms (21 days)
- Rigevidon® Most cost effective choice 3 x 21 £1.89 v Microgynon 30, 3 x 21 £2.82 December 2018. Microgynon 30® existing patients only OR if Rigevidon® unavailable.
|
07.03.01 |
Ethinylestradiol 35 mcg / noresthisterone 1mg Norimin® |
- Tablets containing ethinylestradiol 35 micrograms & norethisterone 1mg micrograms
|
07.03.01 |
Ethinylestradiol 35 mcg / noresthisterone 500mcg Brevinor® |
- Tablets containing ethinylestradiol 35 micrograms & norethisterone 500 micrograms x 21 tablets.
- Note: Less progestogenic
|
07.03.01 |
Ethinylestradiol 35 mcg / norgestimate 250 mcg Cilique® |
- Tablets containing ethinylestradiol 35 micrograms and norgestimate 250 micrograms
- Cilique most cost effective £4.65 x 63 tablets (NB Cilest was discontinued in July 2019)
- Note: Useful for irregular bleeding with Rigevidon
|
04.08.01 |
Ethosuximide |
- 250mg capsules
- 250 mg/5 ml oral solution
- Used as per NICE CG137 for absence seizures
|
15.02 |
Ethyl Chloride |
- 100ml
- CAUTION: Extremely flammable liquified gas under pressure. Stable at room temperature 8ºC-20ºC. Use only with good ventilation. Avoid use near electrical equipment, naked flames or high temperature surfaces. Store in a metal cupboard in a ventilated room- never in a refridgerator. All empty or unused containers must be returned to pharmacy for destruction.
|
10.01.01 |
Etodolac |
- Salisbury only
- Non formulary in BaNES and Swindon
- 300mg capsules
- 600mg tablets and 600mg MR tablets
|
15.01.01 |
Etomidate |
|
07.03.02.02 |
Etonorgestrel Nexplanon® |
- Implant containing 68 mg of etonogestrel
- The practitioner fitting (or removing) must be fully trained in the technique.
- Nexplanon is licensed for 3 years.
|
08.01.04 |
Etoposide |
|
08.01.04 |
Etoposide |
- 100mg/5ml, 200mg/10ml and 500mg/25ml infusion
|
10.01.01 |
Etoricoxib |
 - BaNES - Second line for treament of Ankylosing Spondylitis ONLY.
 - Swindon - Reserved for severe inflammatory arthritis unresponsive or intolerant to other NSAIDS.
-
 - GWH ONLY - For the short-term prevention & treatment of post-operative pain in patients with known hypersensitivity to conventional NSAIDs, or patients at high risk of hypersenstivitiy to conventional NSAIDs (e.g. asthmatics).
- Non formulary - Salisbury.
- 30mg, 60mg, 90mg and 120mg tablets.
|
05.03.01 |
Etravirine Intelence® |
|
13.02.01 |
Eucerin ® Intensive 10% Topical |
- SFT only
- Contains Urea
- 250ml lotion or 100ml cream
|
18 |
European Viper Venom Antivenom |
|
08.01.05 |
Everolimus Afinitor® |
- 2.5mg, 5mg and 10mg tablets
- Ensure correct brand is prescribed.
|
08.01.05 |
Everolimus Votubia® |
- Only at RUH
- 2.5mg, 5mg and 10mg tablets
- Ensure correct brand is supplied
- To be prescribed by specialist centres in accordance with NHSE commissioning policies
|
02.12 |
Evolocumab Repatha® |
- 140mg/ml soln for injection Prefilled SureClick pen, 2 x 1ml
- Consultant Lipid specialist only.
- Adjunct to diet in primary hypercholesterolaemia or mixed dyslipidaemia: with a statin when LDL-C response to a statin alone is insufficient, and alone or with other lipid-lowering treatments if statins are contraindicated or not tolerated. With other lipid-lowering treatments in homozygous familial hypercholesterolaemia.
|
08.03.04.01 |
Exemestane |
|
06.01.02.03 |
Exenatide (prolonged release) Bydureon® |
 Bath
 Salisbury and Swindon
- 2mg powder for reconstitution
- Once weekly subcutaneous injection for the treatment of type 2 diabetes
|
02.12 |
Ezetimibe |
- 10mg
- Statin Intolerance - In hypersensitivity, elevated LFTs (ALT > 3 times normal limit) or previous myositis, ezetimibe 10mg daily may be substituted as monotherapy.
- Ezetimibe should only be prescribed to patients with difficult dyslipidaemia or familial hyperlipidaemia who are failing to reach target cholesterol on high doses of statin, or those who experience true adverse effects from high dose statins or in whom statins are contraindicated
|
05.03.02.01 |
Famciclovir |
- SFT only for ophthalmology treatment protocol for keratitis
- 125mg/250mg/500mg tablets
|
10.01.04 |
Febuxostat Adenuric® |
- 80mg and 120mg
- To be prescribed only when patients have failed on Allopurinol in line with NICE TA below.
- SFT Febuxostat guidelines
|
02.12 |
Fenofibrate |
- Only to be prescribed after having had a telephone consultation with a specialist
- Capsules 67mg, 200mg, 267mg
- Tablets 160mg
- NICE. Do not do recomendation: Do not routinely offer fibrates for the prevention of CVD to any of the following: -people who are being treated for primary prevention -people who are being treated for secondary prevention -people with CKD -people with type 1 diabetes -people with type 2 diabetes.
|
04.07.02 |
Fentanyl |
- 12microgram/hour, for 3 days
- 25microgram/hour, for 3 days
- 50microgram/hour, for 3 days
- 75microgram/hour, for 3 days
- 100microgram/hour, for 3 days
- Fentanyl patches are only licensed for chronic intractable pain. For palliative care use.
- Fentanyl patches are not suitable for use in the management of acute / intermittent pain.
- Do not use in opioid-naive patients - see MHRA safety update below. Only to be used in patients who require equivalent dose of at least 60mg morphine daily
- Fentanyl is available both as a reservoir patch and a matrix patch (do not cut either)
- Patients and/or their carers need to be aware that fentanyl patches need to be applied at appropriate 72-hour (three-day) intervals. Remember to remove the old patch before application of new patch
- See BNF for dose conversion information below.
|
15.01.04.03 |
Fentanyl |
- 100 micrograms in 2ml amp
- 500 micrograms in 10ml amp
|
21.01.01.02 |
Fentanyl |
- 100micrograms, 200micrograms, 300micrograms, 400micrograms, 600micrograms, 800micrograms
- Palliative care or pain specialist initiation only
- Patients must be assessed by the palliative care or pain team before commencing treatment. They should be used in the minority of patients with breakthrough pain that fail immediate release morphine or oxycodone. Review weekly.
|
21.01.01.02 |
Fentanyl |
- 12microgram/hour, for 3 days
- 25microgram/hour, for 3 days
- 50microgram/hour, for 3 days
- 75microgram/hour, for 3 days
- 100microgram/hour, for 3 day
- Fentanyl patches are only licensed for chronic intractable pain. For palliative care use.
- Fentanyl patches are not suitable for use in the management of acute / intermittent pain.
- Only to be used in patients who require equivalent dose of at least 60mg morphine daily
- Fentanyl is available both as a reservoir patch and a matrix patch (do not cut either)
- Patients and/or their carers need to be aware that fentanyl patches need to be applied at appropriate 72-hour (three-day) intervals. Remember to remove the old patch before application of new patch
- For dose conversion see BNF link below
|
21.01.01.02 |
Fentanyl |
- 100micrograms, 200micrograms, 400micrograms, 600micrograms, 800micrograms
- Breakthrough cancer pain for patients in whom oral morphine sulphate solution is inappropriate. Under the recommendation of a palliative care specialist only.
- NOT approved for non cancer pain
- Patients must be assessed by the palliative care or pain team before commencing treatment. They should be used in the minority of patients with breakthrough pain that fail immediate release morphine or oxycodone. Review weekly.
- Prescribe by brand name to ensure that the correct product is dispensed.
|
21.02.01 |
Fentanyl |
FOR BaNES Patients ONLY on specialist recommendation
- 100 micrograms in 2ml amp
-
Can be used in syringe drivers for in patients with renal impairment and an eGFR <30ml/min/1.73m2 or declining renal function on the advice of specialist palliative care service.
-
See page 89/90 Wessex Palliative Care Handbook (link at start of chapter)
|
09.01.01.02 |
Ferric Carboxymaltose Ferinject® |
- Please note Ferinject is considerably more expensive than Cosmofer.
- Treatment of iron-deficiency in patients with asthma, allergic eczema or other atopic allergy, when oral iron preparations are ineffective or cannot be used
- 50mg/ml for slow intravenous injection or intravenous infusion
- Anaphylactoid reactions can occur with parenteral administration of iron complexes. Facilities for cardio-pulmonary resuscitation must be at hand.
|
09.01.01.01 |
Ferrous Fumarate |
- Tablets 322mg (equivalent to 100mg ferrous iron per tablet).
- Tablets 210mg (equivalent to 68mg ferrous iron per tablet).
- Oral solution 140mg/5ml (equivalent to 45mg ferrous iron per 5ml)
|
09.01.01.01 |
Ferrous Sulphate |
- Tablets 200mg (equivalent to 65mg ferrous iron per tablet).
|
03.04.01 |
Fexofenadine |
- Tablets 30mg, 120mg, 180mg
- 30mg and 120mg tablets are included on the BSWformulary for symptomatic relief of seasonal allergic rhinitis and should ONLY be prescribed when loratadine/cetirizine have been trialled and failed to control symptoms. Check BNFC for dosing in children.
- 180mg tablet is included on BSWformulary for the treatment of chronic idiopathic urticaria (adults and children >12 yrs) usually initiated by dermatology specialist) in patients not adequately treated with cetirizine/loratadine.
|
20 |
Fibrin Sealant Tisseel® |
- For use within RUH and GWH only
|
05.01.07 |
Fidaxomicin |
- Tablets 200mg
- For the treatment of intractable Clostridium Difficile on microbiologist
advice only.
- See local primary care antibiotic guidance for treatment advice in
primary care or acute trust guidance for treatment in secondary care setting. See PHE management and treatment of Clostridium guidance on link below.
|
09.01.06 |
Filgrastim Accofil® |
- Pre-filled syring 38 million units (300 micrograms)/0.5 mL and 48 million units (480 micrograms)/0.8 mL
- Biosimilar GCSF
- Commissioned by NHS England for neutropenia according to Trust Guidelines.
|
06.04.02 |
Finasteride |
- 5mg
- For treatment of BPH only, not baldness. Women of child-bearing potential should avoid handling crushed or broken finasteride tablets.
|
07.04.01 |
Finasteride |
|
08.02.04 |
Fingolimod |
|
02.03.02 |
Flecainide |
|
02.03.02 |
Flecainide |
|
01.06.05 |
Fleet Phospho-soda ® Solution |
- 24.4g/10.8g oral solution.
|
13.04 |
Flucinolone Acetonide 0.00625% Synalar 1 in 4 Dilution® |
- Moderate potency steroid
- Cream 0.00625%, 50g Synalar 1 in 4®
- Apply sparingly. For short term use. Useful alternative to Eumovate, especially if hydrocortisone allergy
|
13.04 |
Flucinolone Acetonide 0.025% Synalar® |
- Potent steroid
- Cream or gel 0.025% 30g, 60g Synalar
- Useful in many patients including those allergic to hydrocortisone
|
13.04 |
Flucinolone Acetonide 0.025% with Neomycin Sulphate 0.5% Synalar N® |
- Potent steroid
- Cream, Ointment Fluocinolone 0.025%, neomycin 0.5% 30g
|
05.01.01.02 |
Flucloxacillin |
- Capsules 250mg, 500mg.
- Oral solution 125mg/5ml, 250mg/5ml.
- Cholestatic jaundice and hepatitis may occur, very rarely,
up to two months after treatment with flucloxacillin has been stopped. Administration for more than 2 weeks and increasing age are risk factors. See BNF and SPC for further details.
|
05.01.01.02 |
Flucloxacillin |
- 250mg
- 500mg
- 1g
- Cholestatic jaundice & hepatitis may occur, very rarely,
up to two months after treatment with flucloxacillin has been stopped. Administration for more than 2 weeks and increasing age are risk factors. See BNF and SPC for further details.
|
05.02 |
Fluconazole |
- IV infusion 2mg/ml, 25ml bottle, 100ml bottle
|
05.02 |
Fluconazole |
- Capsules 50mg, 150mg, 200mg
- Oral suspension 50mg/5ml, 200mg/5ml
|
07.02.02 |
Fluconazole |
|
05.02 |
Flucytosine |
- Infusion 10mg/ml
- Under the guidance of a consultant mycologist ONLY
|
08.01.03 |
Fludarabine Phosphate Injection |
|
08.01.03 |
Fludarabine Phosphate Tablets |
|
06.03.01 |
Fludrocortisone |
- 100 micrograms
- Review regularly & to use the lowest dose possible to control the postural hypotension
- Fludrocortisone may be given as a mineralocorticoid in combination with hydrocortisone in adrenocortical insufficiency.
- Fludrocortisone may also be used in the treatment of postural hypotension (unlicensed).
|
13.04 |
Fludroxycortide |
- Moderate potency steroid
- Occlusive tape 4micrograms/cm2 50cm x 7.5cm, 200cm x 7.5cm
|
15.01.07 |
Flumazenil |
- 500 micrograms in 5ml amp
- Used to reverse the effects of benzodiazepines. See SPC for full information on safe use.
|
18 |
Flumazenil |
|
12.01.01 |
Flumetasone 0.02% with Clioquinol 1% ear drops |
- Previously Locorten-Vioform® (discontinued)
|
04.07.04.02 |
Flunarazine |
- 5mg capsules (unlicensed)
- RUH for named patients only. Not on formulary at SFT or GWH.
|
11.04.01 |
Fluocinolone Iluvien® |
- For the treatment of chronic diabetic macular oedema after an inadequate response to prior therapy. In line with NICE TA301 Nov 2013. Patients need to have gained 10 or more ETDRS letters of visual acuity between baseline and month 36 to receive a further implant at month 36 according to NICE TA301.
- Note: concurrent treatment to both eyes not recommended (SPC).
- A single implant releases fluocinolone for up to 36 months.
- Implantation may not be repeated more frequently than every 36 months due to lack of evidence base of benefit.
|
13.04 |
fluocinolone acetonide 0.025% with clioquinol 3% Synalar C® |
- Potent steroid
- cream,ointment 15g
|
11.08.02 |
Fluorescein |
- 1% and 2% minims
- Ophthalmic strips
- GWH only
- Non formulary at RUH and Salisbury
|
11.08.02 |
Fluorescein Sodium |
|
09.05.03 |
Fluoride Mouthwash |
- Suitable for self care in most instances.
- Where prescription is required, ONLY for initiation and follow-on prescribing by dentists. Not for GP prescribing - see link below.
|
09.05.03 |
Fluoride Toothpaste |
- Suitable for self care in most instances.
- Where prescription is required, ONLY for initiation and follow-on prescribing by dentists. Not for GP prescribing - see link below.
|
11.04.01 |
Fluorometholone |
|
08.01.03 |
Fluorouracil |
- 250mg/10ml, 500ml/20ml, 500mg/10ml and 1g/20ml injection
- 2.5mg/100ml, 2.5mg/50ml and 5mg/100ml infusion
- For topical cream see chapter 13.8.1
|
11.99.99.99 |
Fluorouracil |
- Swindon only - used in theatre intra-operatively (trabeculectomy) and for needling of trabeculectomy post-op. Special chemotherapeutic agent manufactured for individual patients. 48 hours notice required. Consultant ophthalmologist prescription only.
- For licensed indications for fluorouracil see chapter 8.1.3 and chapter 13.8.1(topical)
- Non formulary at RUH and SFT
|
13.08.01 |
Fluorouracil Efudix® |
- Efudix® cream 5% 40g
- Superficial malignant and pre-malignant skin lesions. Apply thinly to affected area once or twice daily, maximum area of skin treated at one time 500cm (23cm x 23cm); usual duration of inital therapy 3 to 4 weeks. Patients should be warned that skin will become inflamed sore & possibly weepy
|
13.08.01 |
Fluorouracil O.5% salicylic acid 10% Actikerall® |
- Fluorouracil 0.5%, salicylic acid 10%; solution 25ml
- Apply once daily for up to 12 weeks
|
04.03.03 |
Fluoxetine |
- Capsules 20mg, 30mg, 40mg, 60mg
- Liquid 20mg in 5ml
- 10mg tablets and 10mg capsules are available but are prohibitively expensive.
- Note: Long half life, least likely SSRI to cause withdrawal reactions.
|
04.02.02 |
Flupentixol Decanoate Depixol® |
 in south Wiltshire via service commissioned at Fountain Way, Salisbury.
 in rest of Wiltshire, Swindon and BaNES
- Depixol® injection 20mg/ml - 20mg in 1ml, 40mg in 2ml
- Depixol® injection 100mg /ml ("Concentrate") - 50mg in 0.5ml, 100mg in 1ml
- Depixol® injection 200mg/ml ("Low-volume") - 200mg in 1ml
|
04.02.02 |
Fluphenazine Decanoate |
- injection 25mg/ml - 12.5mg in 0.5ml, 25mg in 1ml, 50mg in 2ml
|
04.02.02 |
Fluphenazine Decanoate Modecate® Concentrate |
- injection 100mg/ml ("Concentrate") - 50mg in 0.5ml, 100mg in 1ml
|
12.02.01 |
Fluticasone + Azelastine Nasal spray |
- Azelastine 137 micrograms and Fluticasone propionate 50 micrograms per actuation
- Only to be used 3rd line as per the local allergic rhinitis guidance
|
12.02.01 |
Fluticasone furoate Nasal spray |
- Fluticasone furoate nasal spray, 27.5 micrograms per spray
- Second line for the treatment of allergic rhinitis
|
03.02.02 |
Fluticasone furoate & vilanterol Relvar Ellipta® |
- First choice ICS/LABA DPI for asthma and COPD.
- Use in COPD:
- Combination of fluticasone furoate and vilanterol (92/22)Breath actuated dry powder inhalerApproved for COPD in use with local guidance and in line with NICE FEV1<50%. Once daily administration.
- Use in asthma:
- Combination of fluticasone furoate and vilanterol (92/22, 184/22)Breath actuated dry powder inhaler for uncontrolled asthmatic patients onlyOnce daily administration
|
03.02 |
Fluticasone propionate Flixotide® |
- Existing patients ONLY.
- Flixotide® Accuhaler dry powder for inhalation50,100,250,500 micrograms/dose
- Flixotide® Evohaler aerosol inhalation MDI50,125,250 micrograms/dose
- Restricted to use for adult patients for whom other therapyhas proved unsuccessful and are uncontrolled on over 1000mcgdaily of inhaled beclomethasone or budesonide.
- The evidence for reduced adrenal supression with fluticasone is poor.But, consider use in children of 4 years of age and older, if high dosesof inhaled steroids (30kg 800mcg BD of beclometasone or budesonide)have been used for longer than three months.
- Prescribe fluticasone at half the dose prescribed for beclometasoneor budesonide.
|
12.02.01 |
Fluticasone Propionate nasal drops |
- Nasal drops 400 micrograms/unit dose
- Only for the treatment of nasal polyps and associated symptoms of nasal obstruction.
- Only to be used 3rd line as per the Local allergic rhinitis guidance (see front page for guidance links) March 2018
|
03.02.02 |
Fluticasone propionate and salmeterol Sirdupla®, Airflusal®,Seretide® |
 BaNES and Salisbury
- Non-formulary Swindon(except Seretide 50 Evohaler)
- No new prescribing.
- Review existing patients, to see if could switch to first-line options.
- Airflusal®aerosol inhalation MDI 25/125, 25/250.For asthma >18years of age. NB only to be used for new patients
- Sirdupla ®aerosol inhalation MDI 125/25, 250/25 For asthma >18years of age - NB no lower strength. Prescribe by brand.
- Seretide®Evohaler aerosol inhalation MDI 50/25, 125/25, 250/25
- Notes: The higher doses (125 and 250) are only advised in step 4 of the management of asthma in adults.
- It is envisaged that existing adult patients will be switched to either Sirdupla ®MDI / AirFluSal or Fostair ® MDI, depending on indication, although it is accepted that there may be a very small amount of non-formulary prescribing in the exceptional circumstance that all formulary options have been exhausted.
|
03.02.02 |
Fluticasone propionate and salmeterol Seretide Accuhaler® |
-
 BaNEs & Salisbury
- Non-formulary Swindon
- MDI 100/50, 250/50, 500/50
- No new prescribing
- Review existing patients, to see if could switch to first-line options
- Licensed for COPD but the Evohaler is not-many patients with COPD are using the Seretide 250 Evohaler
- The cost of Seretide Accuhaler 500 (one puff bd) is significantly less than Seretide 250 Evohaler (two puffs bd). It delivers exactly the same medication as for the same number of days but costs £20 less per unit
- NB -Swindon, for use in adults, all strengths have been removed from formulary, it is accepted that there may be a very small amount of non-formulary prescribing in the exceptional circumstance that all formulary options have been exhausted.
|
09.01.02 |
Folic Acid |
- Tablets: 5mg, 400 micrograms
- SF Oral solution: 2.5mg / 5ml
- Refer to BNF for guidance on the use of folic acid for use in pregnancy for the prevention of neural tube defects.
- Women with a BMI ≥30 wishing to become pregnant should be advised to take 5mg folic acid supplementation daily, starting at least one month before conception and continuing during the first trimester of pregnancy. (RCOG)
|
06.05.01 |
Follitropin Alfa Gonal-F® |
- Not on formulary SFT
- Injection powder for reconstitution 450units/0.75ml, 1050units/1.75ml
- prefilled pen 600units/ml 0.5ml, 0.75ml, 1.5ml
|
18 |
Fomepizole |
|
02.08.01 |
Fondaparinux |
RUH and SFT (and GWH for acute coronary syndrome)
at GWH/Swindon for VTE if dalteparin unsuitable
- See individual trust prescribing guidelines
|
A2.02.02.03 |
Foodlink ® Complete |
FIRST LINE CHOICE IN COMMUNITY
28 day supply = 56 sachets, 3192 g, 8 packs of 7
Make up with 200 ml whole milk.
Provides 385 kcal, 18.5 g protein, 200 ml fluid
OR Make with 200 ml juice providing 340 kcal, 12.9 g protein, 200 ml fluid - NOT SUITABLE FOR PEOPLE WITH DIABETES, WOUNDS
IDDSI level 0 - Thin Fluids
|
A2.02.02.03 |
Foodlink ® Complete with Fibre |
Consider for those with constipation
56 g sachet made with 200 ml whole milk
28 day supply = 56 sachets, 3528 g 8 packs of 7
Provides 413 - 421 kcals, 18.5 g - 19.7 g protein, 4.5 - 4.7 g fibre, 200 ml fluid
(depending on flavour)
IDDSI Level 0 - Thin fluids |
09.04.02 |
Foodlink Complete |
- First line option
- 57g sachets
- To be mixed with 200ml full fat milk. Consider whether patient has access to milk and ability to make up the drink with milk. Consider cost to patient. Not suitable for those with lactose intolerance.
- See ONS guidance for full product details
|
09.04.02 |
Foodlink Complete Compact |
- For those who require smaller volumes or with fluid restrictions
- 57g sachets
- See ONS guidance for full product details (link at top)
|
09.04.02 |
Foodlink Complete Powder with Fibre |
- Contains fibre, consider for those with constipation
- 63g sachet
- See ONS guidance for full product details (link at top)
|
03.01.01.01 |
Formoterol Oxis Turbohaler® |
- No new prescribing. Existing patients only - see notes above.
- Oxis®Turbohaler dry powder inhaler MDI 6 micrograms/dose,12 micrograms/dose
- Licensed 6 years +
- Note: Formoterol - licensed for use when adequate treatment with corticosteroids is not sufficient.
- Salmeterol 50 micrograms is roughly equivalent to Formoterol 9 micrograms.
|
03.02.03 |
Formoterol fumarate, beclometasone dipropionate and glycopyrronium bromide Trimbow® |
- Combination of formoterol fumarate, beclametasone diproprionate and glycopyrronium (5/87/9 micrograms per puff) MDI
- 120 doses Two puffs twice a day
- Maintenance treatment in adult patients with moderat to severe chronic obstructive pulmonary disease who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2 agonist.
|
09.04.02 |
Fortijuce |
- Not suitable for people with diabetes, COPD and wounds due to carbohydrate:protein ratio
- 200ml bottle
- See ONS guidance for full product details (link at top)
|
A2.02.01.02 |
Fortijuce ® |
200 ml fluid
28 day supply = 56 bottles, 11,200 ml
300 kcals, 7.8 g protein, 67 g carbohydrate, 200 ml fluid
IDDSI level 0 - Thin fluids
NOT SUITABLE FOR PEOPLE WITH DIABETES |
09.04.02 |
Fortisip |
- 200ml bottle
- See ONS guidance for full product details (link at top)
|
A2.02.02.03 |
Fortisip ® Compact |
125 ml bottle
28 day supply = 56 bottles, 7000 ml
300 kcals, 12 g protein, 125 ml fluid
IDDSI level 1- Slightly thick fluids |
A2.02.02.01 |
Fortisip ® Bottle |
200 ml bottle
28 day supply = 56 bottles, 11,200 ml
300 kcals, 11.8 g protein, 200 ml fluid
IDDSI Level 0 - Thin fluid
|
09.04.02 |
Fortisip Compact |
- For those who require smaller volumes or with fluid restrictions
- 125ml bottle
- See ONS guidance for full product details (link at top)
|
09.04.02 |
Fortisip Compact Protein |
- 125ml bottle
- See ONS guidance for full product details (link at top)
|
A2.02.02.03 |
Fortisip Compact Protein |
125 ml bottle
28 day supply = 56 bottles, 7000 ml
300 kcal, 18 g protein, 125 ml
IDDSI level 2 = mildly thick |
05.01.07 |
Fosfomycin |
- For use on consultant microbiologist advice only
- 2g powder for solution for infusion vials
- 4g powder for solution for infusion vials
- EMA has recommended that fosfomycin medicines given by infusion (drip) into a vein should only be used to treat serious infections when other antibiotic treatments are not suitable. 27/3/2020
|
05.01.13 |
Fosfomycin |
- 3g sachets
- Use if high risk of resistance or penicillin allergy.
- EMA no longer recommends the use of fosfomycin in under 12s as there are insufficient data available to confirm their benefits to patients.
|
06.01.06 |
Freestyle Libre® |
- ONLY to be initiated following specialist recommendation in people with diabetes who fit the NHSE criteria for funding (link below).
- Freestyle Libre should NOT be initiated by non-specialists in primary care.
- Freestyle Libre should not be initiated in people with Type 2 Diabetes (T2D) in line with NHSE policy. Exceptions are people with T2D on dialysis or with Cystic Fibrosis, and people with insulin treated T2D living with a learning disability which is recorded on the GPs learning disability register.
- Specialist teams must provide clinical oversight of a person’s use of Freestyle Libre. Including education for people initiated on Freestyle Libre , a prescribing contract, review of benefits after 6 months and ongoing follow up and review, alongside wider diabetes management.
- Continuing prescription for long-term use of Freestyle Libre post initial 6 months is contingent upon evidence of agreeing with NHSE conditions for use and that on-going use of Freestyle Libre is demonstrably improving an individual’s diabetes self-management. For example improvement of HbA1c or Time In Range; improvement in symptoms such as DKA or hypoglycaemia; or improvement in psycho-social wellbeing.
- A Freestyle Libre Sensor lasts for 2 weeks; one month’s supply is 2 sensors
Freestyle Libre 2 - Jan 2021 Update - NHSE link to follow when published
- The new Freestyle Libre 2 sensor has the added feature of real-time glucose alarms that notify people if glucose goes too low or too high.
- To manage workload & product supply, Freestyle Libre 2 will be offered to patients who meet the eligibility criteria for Flash at their next routine appointment with their specialist diabetic healthcare professional. In the current climate, we respectfully request that people wait until their next routine appointment with their specialist in 2021 to enquire about the FreeStyle Libre 2 system.
- Specialist diabetes teams will support people to use the new features included in Freestyle Libre 2 system to better manage their diabetes by supplying an information booklet and signposting to New Starter Clinic online education and support and will supply those using the old Freestyle Libre scanning device with a new Freestyle Libre 2 scanner. People using the Flash App should check that it is updated to the latest version (version 2.5 or above). Details on device compatibility can be found in the compatibility guide on the Abbott website.
|
16.10 |
Freestyle Libre® |
- ONLY to be initiated following specialist recommendation in people with diabetes who fit the NHSE criteria for funding (link below).
- Freestyle Libre should NOT be initiated by non-specialists in primary care.
- Freestyle Libre should not be initiated in people with Type 2 Diabetes (T2D) in line with NHSE policy. Exceptions are people with T2D on dialysis or with Cystic Fibrosis, and people with insulin treated T2D living with a learning disability which is recorded on the GPs learning disability register.
- Specialist teams must provide clinical oversight of a person’s use of Freestyle Libre. Including education for people initiated on Freestyle Libre , a prescribing contract, review of benefits after 6 months and ongoing follow up and review, alongside wider diabetes management.
- Continuing prescription for long-term use of Freestyle Libre post initial 6 months is contingent upon evidence of agreeing with NHSE conditions for use and that on-going use of Freestyle Libre is demonstrably improving an individual’s diabetes self-management. For example improvement of HbA1c or Time In Range; improvement in symptoms such as DKA or hypoglycaemia; or improvement in psycho-social wellbeing.
- A Freestyle Libre Sensor lasts for 2 weeks; one month’s supply is 2 sensors
Freestyle Libre 2 - Jan 2021 Update - NHSE link to follow when published
- The new Freestyle Libre 2 sensor has the added feature of real-time glucose alarms that notify people if glucose goes too low or too high.
- To manage workload & product supply, Freestyle Libre 2 will be offered to patients who meet the eligibility criteria for Flash at their next routine appointment with their specialist diabetic healthcare professional. In the current climate, we respectfully request that people wait until their next routine appointment with their specialist in 2021 to enquire about the FreeStyle Libre 2 system.
- Specialist diabetes teams will support people to use the new features included in Freestyle Libre 2 system to better manage their diabetes by supplying an information booklet and signposting to New Starter Clinic online education and support and will supply those using the old Freestyle Libre scanning device with a new Freestyle Libre 2 scanner. People using the Flash App should check that it is updated to the latest version (version 2.5 or above). Details on device compatibility can be found in the compatibility guide on the Abbott website.
|
04.07.04.02 |
Fremanezumab Ajovy® |
- 225 mg solution for injection in pre-filled syringe or pre-filled pen
- For use in line with NICE TA631 and BSW migraine pathway below
- Fremanezumab is recommended as an option for preventing migraine in adults, only if:
- the migraine is chronic, that is, 15 or more headache days a month for more than 3 months with at least 8 of those having features of migraine
- at least 3 preventive drug treatments have failed and
- the company provides it according to the commercial arrangement.
- Stop fremanezumab if the migraine frequency does not reduce by at least 30% after 12 weeks of treatment.
|
A2.02.02.01 |
Fresubin ® Energy |
200 ml bottle
300 kcals, 11.2 g protein, 200 ml fluid
IDDSI Level 0 - Thin fluids |
09.04.02 |
Fresubin 3.2 kcal |
- 125ml bottle
- See ONS guidance for full product details (link at top)
|
04.07.04.01 |
Frovatriptan |
- 2.5mg tablets
- Current evidence base supports the use of Frovatriptan as a first-line acute treatment for Menstrual Migraine and for perimenstrual prophylaxis. No triptan is specifically licensed for this indication (off-label).
- For the treatment of menstrual migraine only when other triptans (sumatriptan / zolmitriptan) have proven ineffective. Give 2.5mg twice daily on days when migraine expected.
- Frovatriptan is distinctive from other triptans due to its long elimination half-life of 26 hours, which confers a longer duration of action.
|
08.03.04.01 |
Fulvestrant Faslodex® |
- 250mg/5ml pre-filled syringes
- Commissioned by CDF in in combination with abemaciclib , palbciclib or ribociclib for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA579/593/619). NICE does not recommend for treatment of locally advanced or metastatic breast cancer (TA239/503).
|
02.02.02 |
Furosemide |
- Tablets 20mg, 40mg, 500mg (NOTE: 500mg tablets RED in BaNES)
- Oral solution 20mg in 5ml, 40mg in 5ml, 50mg in 5 ml
|
02.02.02 |
Furosemide Injection |
- Injection 20mg/2ml, 50mg/5ml, 250mg/25ml
|
11.03.01 |
Fusidic Acid |
Fusidic acid eye drops are no longer included in primary care guidance for the management of bacterial conjunctivitis due to high cost (£29.06 per 5g May 2019) and poor activity for a self-limiting condition.
Use should be restricted to people who: - Are pregnant - Have a personal or family history of blood dyscrasias, such as aplastic anaemia - Are intolerant of chloramphenicol - Need a twice-a-day treatment for infective conjunctivitis See CKS topic for more information
|
13.10.01.02 |
Fusidic Acid 2% |
- Cream 2%, 15g, 30g
- Ointment 2% 15g, 30g
- Note: Topical fusidic acid is included for the treatment of impetigo, see primary care antibiotic guidance for further details.
|
04.07.03 |
Gabapentin |
- Capsules 100mg, 300mg, 400mg
- Elderly patients require the lowest possible initial dose of gabapentin.
|
04.08.01 |
Gabapentin |
- Capsule 100mg, 300mg, 400mg (Category 3 MHRA)
- Tablets 600mg, 800mg
- Schedule 3 CD, exempted from safe custody requirements.
- Oral solution 50mg/ml is available but is expensive. Use only if no other option is suitable and there are significant swallowing problems.
|
21.01.01.03 |
Gabapentin |
- Capsules 100mg, 300mg, 400mg
|
04.11 |
Galantamine |
 BaNES and Wiltshire
 Swindon
- Capsules MR 8mg, 16mg, 24mg
- Tablet 8mg, 12mg
|
05.03.02.02 |
Ganciclovir |
|
11.03.03 |
Ganciclovir |
- 0.15% eye gel
 in Salisbury
 in Swindon and BaNES - ONLY for patients with corneal stromal herpes simplex keratitis, aciclovir-resistant herpes simplex keratitis & herpetic keratouveitis on the advice of a Consultant ophthalmologist
|
06.07.02 |
Ganirelix |
- Not on formulary in GWH
- 500micrograms/ml 0.5ml
- Treatment of infertility
|
01.01.02 |
Gaviscon Advance® Oral |
- Liquid (Contains 4.6 mmol of sodium in 10ml, plus 2 mmol of potassium).
- Tablets (Contains 2.25 mmol of sodium per tablet, plus 1 mmol of potassium).
- Licensed for laryngopharyngeal reflux.
|
16.15 |
Gaviscon Infant® |
- 1 dose = half a dual sachet
- Prescribe as doses
|
08.01.05 |
Gefitinib |
|
09.02.02.02 |
Gelatin Gelofusine® |
- GWH only - for endoscopy use only
- RUH/SFT not on formulary
- Gelofusine® Infusion 500ml, 1 litre
|
12.03.01 |
Gelclair ®Oral gel sachet Medical device |
- GWH and RUH
- Contains sodium hyaluronate and polyvinylpyrrolidone
- Used as a mouthwash for oropharyngeal lesions in Oncology patients
|
08.01.03 |
Gemcitabine |
- Various strengths of infusion
|
07.01.01 |
Gemeprost |
|
05.01.04 |
Gentamicin |
 Blood level monitoring is mandatory for continued therapy.
- Used for Non-CF bronchiectasis within RUH (injection nebulised)
 Primary care IM use for prophylaxis during the insertion and removal of catheters. Only use for catheter changes if history of catheter change-associated UTI or trauma.
- 20mg/2ml
- 40mg/2ml - Not in the Drug Tariff do not prescribe on FP10
- 80mg/2ml.
|
11.03.01 |
Gentamicin |
|
11.03.01 |
Gentamicin |
 - GWH.
- Non-formulary - SFT & RUH.
- 1.5 % preservative-free eye drops.
|
12.01.01 |
Gentamicin 0.3% |
|
07.04.04 |
Gepan Instill irrigation solution |
- First line at GWH
- Non formulary at RUH or SFT
|
08.01.05 |
Gilteritinib |
- 40mg tablets
- Use in line with NICE TA642
|
12.03.05 |
Glandosane ® spray |
- ACBS
- 50ml spray
- Lemon, Peppermint or natural
|
08.02.04 |
Glatiramer Acetate |
- 20mg/1ml and 40mg/1ml injection
|
05.03.03.02 |
Glecaprevir / Pibrentasvir Maviret |
- 100mg/40mg tablet
- Chronic hepatitis C genotypes 2,3 and 5/6 non-cirrhotic or with compensated cirrhosis
|
06.01.02.01 |
Gliclazide |
- 80mg (not MR)
- 40mg dose achieved by halving 80mg tablet. See Prescribe Well Spend Less
- Only consider gliclazide MR in exceptional circumstances if there are major compliance issues
|
06.01.02.01 |
Glimepiride |
- 1mg, 2mg, 3mg, 4mg
- Not suitable for use in elderly patients due to its long half-life which increases the risk of precipitating hypoglycaemia.
- To be initiated only with advice of the diabetic team.
|
06.01.04 |
Glucagon GlucaGen® HypoKit |
- 1mg vial
- If glucagon is not effective within 10 minutes, intravenous glucose should be given
|
06.01.04 |
GlucoGel ® Oral |
- Oral ampoule, 23g x 3
- Formerly known as Hypostop
- Glucogel® should be reserved for patients unable to swallow fluids and is designed to be rubbed onto the patient's gums.
|
06.01.01.03 |
GlucoRx ® Finepoint Pen needles |
- To be considered for first line use (compatable with all UK pen devices)
|
06.01.04 |
Glucose Injection 50% |
|
09.02.02.01 |
Glucose Intravenous |
- Glucose 50%: 50ml Min-I-jet
Additional products for infusion available for use in secondary care |
Glucose 5% |
100ml, 250ml, 500ml, 1 litre |
Glucose 10% |
500ml, 1 litre |
Glucose 20% |
500ml |
Glucose 50% |
500ml |
|
13.07 |
Glutaraldehyde |
- Glutaraldehyde 10.0% w/v. 10ml bottle.
- For the topical treatment of warts, especially plantar warts.
|
01.06.02 |
Glycerol |
- 1g, 2g & 4g suppositories.
|
11.99.99.99 |
Glycerol (glycerin) |
|
02.06.01 |
Glyceryl Trinitrate Patch |
- Patches 5mg/24 hours, 10mg/24 hours, 5mg/ 24 hours
- GWH - For use only by nutrition team.
- RUH - Short-term secondary care use only.
- SFT - Non-formulary.
|
02.06.01 |
Glyceryl Trinitrate solution for infusion |
- GWH and SFT only
- Non formulary at RUH
- 1mg/ml, 5mg/ml
|
02.06.01 |
Glyceryl Trinitrate |
- Tablets 300 and 500 micrograms
- Spray 400 micrograms
|
01.07.04 |
Glyceryl Trinitrate 0.4% Rectogesic® |
- 0.4% ointment (Rectogesic®) (Licensed).
- Please note: This is for use first-line for the treatment of chronic anal fissures prior to considering surgery. Max. duration of use 8 weeks. (Licensed).
|
07.04.04 |
Glycine |
|
03.01.04 |
Glycopyrrolate/ indacaterol inhaler Ultibro Breezhaler® |
- Combination of Indacaterol / Glycopyrronium
- Breezehaler device with inhalation powder hard capsules each capsule contains equivalent of 110 micrograms of indacaterol and 50 micrograms of glycopyrronium
|
03.01.02 |
Glycopyrronium Seebri breezhaler® |
- Each capsule contains 63 micrograms of glycopyrronium bromide equivalent to 50 micrograms of glycopyrronium.
- Each delivered dose (the dose that leaves the mouthpiece of the inhaler) contains 55 micrograms of glycopyrronium bromide equivalent to 44 micrograms of glycopyrronium.
|
16.13 |
Glycopyrronium Sialanar® |
- 320micrograms/ml
- Licensed for symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders
- For short term intermittent use
|
13.12 |
Glycopyrronium Bromide Hyperhidrosis |
- Various glycopyrronium products are used:
- 1mg and 2mg tablets
- 3g/5g/10g powder for solution for iontophoresis
unlicensed: Solution 0.05% 500mL and topical cream in various strengths (0.5%-4%) (both unlicensed preparation) for use in iontophoretic threatment of hyperhydrosis
- A specific CCG commissioning policy for the use of this for hyperhydrosis is under development (August 19).
|
15.01.03 |
Glycopyrronium Bromide injection |
- 200 micrograms in 1ml amp
- 600 micrograms in 3ml amp
|
21.02.03 |
Glycopyrronium Bromide injection |
- 200 micrograms in 1ml amp
- 600 micrograms in 3ml amp
- As an alternative to hyoscine butyl bromide for respiratory tract secretions
- Can be used in syringe drivers
- See page 89/90 Wessex Palliative Care Handbook (link at start of chapter)
|
01.05.03 |
Golimumab Simponi® |
- 50mg or 100mg prefilled pens.
- 50mg or 100mg prefilled syringes.
- Please note: Golimumab should be prescribed in accordance with the BSW STP Ulcerative Colitis Biologic / Biosimilar Commissioning Pathway.
|
10.01.03 |
Golimumab Simponi® |
- 50mg or 100mg pre-filled pen or syringe
- Commissioned by NHS England for paediatric indications.
- Commissioned by CCG for:
- Psoriatic arthritis in accordance with NICE TAs and local pathway.
- Rheumatoid arthritis in accordance with NICE TAs and local pathway.
- Ankylosing spondylitis in accordance with NICE TAs and local pathway.
|
06.05.01 |
Gonadorelin |
 For assessment of pituitary function (adults).
- 100 micrograms powder for solution for injection
|
06.07.02 |
Goserelin Zoladex® |
 Endometriosis / fibroids
 RUH/ SFT for fertility
- 3.6mg
For prostate cancer see section 8.3.4.2 |
08.03.04.02 |
Goserelin Acetate |
- 3.6 mg Implant - 1 monthly (Zoladex®)
- 10.8mg Implant - 3 monthly (Zoladex LA ®)
- For locally advanced,non-metastatic prostate cancer, as an alternative to surgical castration, or metastatic prostate cancer within the product licence.
|
13.07 |
Green tea leaves extract 10% ointment |
- Second line option for anogenital warts
|
16.05 |
Guanfacine Intuniv® |
- Use as per NICE NG87
- Offer guanfacine to children aged 5 years and over and young people if:
- they cannot tolerate methylphenidate or lisdexamfetamine or
- their symptoms have not responded to separate 6-week trials of lisdexamfetamine and methylphenidate, having considered alternative preparations and adequate doses.
|
13.05.03 |
Guselkumab |
- Pre-filled syringe 100 mg in 1 mL
|
14.04 |
Haemophilus influenzae type B Combined Vaccine Menitorix® |
|
04.02.01 |
Haloperidol |
- Tablets 500 micrograms, 1.5mg, 5mg, 10mg
- Oral liquidSF 1mg in 1ml
- Notes: Baseline ECG is recommended prior to treatment with haloperidol in all patients, especially in the elderly and patients with a positive personal or family history of cardiac disease or abnormal findings on cardiac clinical examination.
|
04.02.01 |
Haloperidol |
 for palliative care use (see chapter 21)
 for rapid tranquillisation
- Injection 5mg in 1ml for palliative care see guidance for BaNES CCG/RUH patients on link below
- Injection 5mg in 1ml (Rapid traquilisation)
- Notes: Baseline ECG is recommended prior to treatment with haloperidol in all patients, especially in the elderly and patients with a positive personal or family history of cardiac disease or abnormal findings on cardiac clinical examination.
|
21.01.02 |
Haloperidol |
- Tablets 500 micrograms, 1.5mg, 5mg, 10mg
- Oral liquidSF 1mg in 1ml
|
21.02.02 |
Haloperidol |
- 5mg/ml
- For hallucinations and agitation and opioid induced nausea
|
21.02.04 |
Haloperidol |
- 5mg/ml
- For hallucinations and agitation
|
21.03 |
Haloperidol |
- Community Just In Case Boxes
- For hallucinations and agitation
|
04.02.02 |
Haloperidol Decanoate Haldol ® |
 in south Wiltshire via service commissioned at Fountain Way, Salisbury.
 in rest of Wiltshire, Swindon and BaNES
- Haldol® injection 50mg in 1ml
- Haldol®injection 100mg in 1ml
|
20 |
Heavy Liquid (Perfluorodecalin) |
|
02.08.01 |
Heparin |
- Note - variation in TLS across trusts. See individual prescribing policies
- 1000iu/ml 5ml amps, 5ml vials (contains preservative), 10ml amps, 20ml amps
- 25000iu/ml – 5000iu/0.2ml amps, 125000iu/5ml vials (contains preservative)
|
02.08.01 |
Heparin Sodium |
- 50units/5ml and 200units/2ml IV Flushing Solution for maintenance of patency of IV devices
 Prescribing of Heparin Sodium IV flushing solutions should be retained by secondary care except in the instances below.
 In BaNES - Heparin Sodium IV flushing solution 200units/2mL is AMBER TLS when recommended by IV nurse specialist and when prescribed in line with BCAP Safe Prescribing Guidance LINK BELOW
Also AMBER TLS in Swindon when used as per GWH Line Insertion Service. |
14.04 |
Hepatitis A vaccine Single Component Avaxim® |
|
14.04 |
Hepatitis A vaccine Single Component Havrix Monodose® |
|
14.04 |
Hepatitis A vaccine Single Component Vaqta® |
|
14.04 |
Hepatitis A vaccine with Hepatitis B vaccine Twinrix® |
- Adult and Paediatric
- Hepatitis B NOT routinely available on the NHS for the purposes of travel therefore combination vaccine not commissioned locally on the NHS.
|
14.04 |
Hepatitis A vaccine with Hepatitis B vaccine Ambirix ® |
- Hepatitis B NOT routinely available on the NHS for the purposes of travel therefore combination vaccine not commissioned locally on the NHS.
|
14.04 |
Hepatitis A vaccine with typhoid vaccine VIATIM® |
|
14.05.02 |
Hepatitis B immunoglobulin HBIG |
- Advice on the usage and availability can be obtained from the Microbiologist.
|
14.04 |
Hepatitis B vaccine Single Component Engerix B® |
- This vaccine is not available at NHS expense in Wiltshire/Bath/Swindon for Overseas Travel
|
14.04 |
Hepatitis B vaccine Single Component Fendrix® |
- Bath - not on formulary
- This vaccine is not available at NHS expense in Wiltshire/Bath/Swindon for Overseas Travel
|
14.04 |
Hepatitis B vaccine Single Component HBvaxPRO® |
- This vaccine is not available at NHS expense in Wiltshire/Bath/Swindon for Overseas Travel
|
07.04.04 |
Hexaminolevulinate |
- SFT only
- Non formulary at RUH and GWH
|
13.11.02 |
Hibitane Obstetric ® Topical |
- Chlorhexidine gluconate 10 mg per 1 gram
- 250ml
|
13.10.05 |
Histoacryl ® Topical |
- Enbucrilate (Histoacryl®) adhesive 5 x 200mg, 10 x 200mg,5 x 500mg
- Tissue adhesives are used for closure of minor skin wounds and for additional suture support/ This should be applied by a trained healthcare professional
|
06.05.01 |
Human Menopausal Gonadotrophins Menopur® |
- Not on formulary GWH
- powder for reconstitution 75units FSH & 75units LH, 150units FSH & 150units LH, 600units FSH & 600 units LH, 1200units FSH 1200units LH.
|
14.05 |
Human normal immunoglobulin |
- Commissioned by NHS England in line with 'Updated Commissioning Criteria for the use of therapeutic immunoglobulin (Ig) in immunology, haematology, neurology and infectious diseases in England (January 2019)'. For indications not covered by these commissioning criteria, commissioning is in line with the 'DoH Clinical Guidelines for Immunoglobulin Use (second edition update, July 2011)'.
- Note: Guidance from NHS England (October 2017) states that the recommended dose of IVIg for the treatment of ITP is a single dose of 1g/kg. A repeat dose of 1g/kg should only be considered at day 7 if there is a failure to achieve a haemostatically adequate platelet count (approval from the local immunoglobulin approval panel is required if earlier use is contemplated in cases of exceptional clinical circumstances such as active mucosal bleeding or the need for emergency surgery).
- Prescribe by brand. Various brands available.
- NOTE Subgam is the HNIG to use when Tetanus IG is unavailable but indicated as per national guidance. See link below.
|
14.04 |
Human papilloma virus vaccine Gardasil® |
- Vaccine of choice for the national immunisation program (see Green Book)
- a quadravalent vaccine which also covers anal lesions, anal cancer and genital warts
- Gardasil is currently the only HPV vaccine supplied for the national HPV programme (for both adolescents and men who have sex with men).
|
11.08 |
Hyaluronidase |
- 1,500unit powder for solution for injection ampoules
- adjunct to local anaesthesia in ophthalmology
|
02.05.01 |
Hydralazine |
- Tablets 25mg, 50mg
- Injection 20mg ampoule
- Note: Hydralazine may be used in combination with long acting nitrates in moderate to severe chronic congestive cardiac failure when an ACE inhibitor is contra-indicated or not tolerated.
- Note: Hydralazine injection is
 at RUH
|
01.05.02 |
Hydrocortisone Colifoam® |
|
06.03.02 |
Hydrocortisone Alkindi® |
- On formulary in Salisbury and Swindon only - for doses less than 5mg
- High cost medicine
|
06.03.02 |
Hydrocortisone |
- 10mg, 20mg (M/R tablets (Plendaren®) are NOT included in the formulary)
|
13.04 |
Hydrocortisone |
- Mild potency steroid
- Ointment: 0.5%, 15g, 30g, 1% 15g, 30g, 50g, 2.5%, 15g
- Cream: 0.5%, 15g, 30g, 1% 15g, 30g, 50g, 2.5%, 15g
- Apply thinly once or twice a day
- Note: Hydrocortisone ointment & cream (1%) is available over the counter for allergic contact dermatitis, irritant dermatitis, insect bite reactions and mild to moderate eczema. It cannot be sold for application to eyes/face, anogenital region, on broken or infected skin or for use in pregnancy or children under 10 years.
|
10.01.02.02 |
Hydrocortisone acetate Hydrocortistab® |
|
13.04 |
Hydrocortisone 1% with Clotrimazole 1% Canesten HC® |
- Mild potency steroid
- Cream, Hydrocortisone 1%, clotrimazole 1% 30g
- Fungal infections accompanied by inflammation. Apply thinly twice daily for up to 7 days.
|
13.04 |
Hydrocortisone 1% with Miconazole Nitrate 2% Daktacort® |
- Mild potency steroid
- Cream or ointment, Hydrocortisone 1%, miconazole nitrate 2% 30g
- Cream also comes in a 15g size which is more expensive than the 30g size (Aug 19)
- For facial seborrhoeic dermatitis, paronychia, intertrigo
|
13.04 |
Hydrocortisone Acetate 1% with Fusidic Acid 2% Fucidin H ® |
- Mild potency steroid
- Cream, Hydrocortisone 1%, fusidic acid 2% 30g, 60g
- For infected eczema at thin skin sites in infants and children (where S Aureus is fucidin-sensitive).
- Not for long-term use.
|
12.01.01 |
Hydrocortisone Acetate 1% with Gentamicin 0.3% ear drops |
- Previously Gentisone HC (discontinued)
|
13.04 |
Hydrocortisone Butyrate Locoid Lipocream® |
- Potent steroid
- Lipocream 30g, 60g
- Instruct patients not to smoke or go near naked flames - risk of severe burns. Fabric (clothing, bedding, dressings etc) that has been in contact with this product burns more easily and is a serious fire hazard. Washing clothing and bedding may reduce product build-up but not totally remove it.
|
12.03.01 |
Hydrocortisone muco-adhesive buccal tablets |
- 2.5mg (as sodium succinate)
- P medicine can be purchased OTC
|
11.04.01 |
Hydrocortisone sodium phosphate. |
- 3.35mg/ml eye drops 0.4ml unit dose
|
06.03.02 |
Hydrocortisone sodium succinate Solu-Cortef |
 Salisbury and Swindon (and Bath for anaphylaxis )
 Bath in patients with known adrenal insufficiency, hydrocortisone injection is TLS amber.
 Bath - all other indications
- Endocrinology will remain responsible for patient education, training in recognition of an Addisonian crisis and injection technique and the initial supply of an emergency injection kit.
- Primary care can replace supplies of hydrocortisone and water for injection that have been used or expired following clear communication to the GP via a clinic letter.
- Suitable contents of an emergency injection kit include:
- 3-5 vials of hydrocortisone sodium succinate 100mg (Solu-Cortef®) - 3-5 vials of 2mL water for injection - Intramuscular needles and 2mL syringes - 1L Sharps box Further information for patients and prescribers can be found at link below.
- Please see the addisons disease website for videos explaining how to give an emergency injection of hydrocortisone sodium succinate in the event of an adrenal crisis.
- Each vial contains hydrocortisone sodium succinate 133.7 mg equivalent to hydrocortisone 100 mg.
|
12.01.01 |
Hydrocortisone with Antibacterial Otosporin® |
- Hydrocortisone 10 mg /Neomycin sulfate 3400 unit /Polymyxin B sulfate 10000 unit per 1 ml
- 10ml
|
12.03.04 |
Hydrogen Peroxide |
- Use as mouthwash
- 20vols (6%)
- 10vols (3%)
|
13.11.06 |
Hydrogen Peroxide |
- 1% cream 25g tube
- Included for localised non-bullous impetigo as per NICE NG153
- Note: Hydrogen peroxide 1% cream should be prescribed on NHS prescription rather than recommended for purchase over the counter due to the high retail price and the need to reduce any potential financial barriers for appropriate treatment of impetigo.
|
13.02.01 |
Hydromol |
- GREASY MOISTURISER FOR SEVERE DRY SKIN
- Ointment 125g, 500g, 1kg
- Excellent greasy emollient for night time or very dry skin. Prescribe with a less greasy emollient for day time use.
- Can be used as soap substitute
- NOTE: Hydromol CREAM is non-formulary due to cost.
|
09.01.02 |
Hydroxocobalamin |
- 1mg in ml
- Intramuscular injection
COVID-19 - BSW medicines management teams support the BSH advice on B12 replacement during the Covid-19 pandemic. See link below. |
18 |
Hydroxocobalamin Cyanokit® |
|
08.01.05 |
Hydroxycarbamide |
 RUH
 SFT and GWR
- 500mg capsules
|
13.05.03 |
Hydroxycarbamide |
- Dermatology use: off-label.
- Capsules 500mg
|
10.01.03 |
Hydroxychloroquine |
- 200mg tablets
-
 - BaNES, Salisbury & Swindon (except Swindon patients monitored via the DAWN system and provided with prescriptions by GWH)
-
 - Swindon DAWN patients
- Please refer to our DMARD Shared Care and Monitoring Guidance for your respective locality for further information
|
13.05.03 |
Hydroxychloroquine |
 -In Swindon only for DAWN patients.
 In BaNES and Wiltshire oatients
25th March 2020 - MHRA statement on hydroxychloroquine for COVID-19 - Hydroxychloroquine is not licensed to treat COVID-19 related symptoms or prevent infection. Clinical trials are ongoing to test hydroxychloroquine as an agent in the treatment of COVID-19 or to prevent COVID-19 infection. These clinical trials are still not completed, so no conclusions have been reached on the safety and effectiveness of this medicine to treat or prevent COVID-19. Until we have clear, definitive evidence that these treatments are safe and effective for the treatment of COVID-19, hydroxychloroquine should only be used for this purpose within a clinical trial. |
03.04.01 |
Hydroxyzine |
- Tablets 10mg, 25mg
- Hydroxyzine is favoured by the dermatologists for its anti-itch and
sedating effects.
MHRA Drug Safety Update 29th April 2015:
Do not prescribe hydroxyzine to people with a prolonged QT interval
or risk factors for QT interval prolongation. |
21.02.03 |
Hyoscine Butlybromide |
- For respiratory tract secretions
- 20mg/ml
- For colic/reduce secretions in inoperable bowel obstruction
- See SPS website for Stock shortages
- Can be used in syringe drivers
- See page 89/90 Wessex Palliative Care Handbook (link at start of chapter)
|
01.02 |
Hyoscine Butylbromide Tablet & Injection |
- 10mg tablets.
- 20mg/ml injection (Salisbury & Swindon only).
- Please note: Hyoscine butylbromide injection is also available for use in Palliative Care. Please refer to our Palliative Care chapter.
|
21.01.03 |
Hyoscine Butylbromide Tablet |
|
21.03 |
Hyoscine Butylbromide |
- Community Just In Case Boxes
- For respiratory tract secretions
- For colic/reduce secretions in inoperable bowel obstruction
|
04.06 |
Hyoscine Hydrobromide |
 400mcg per ml injection
 for palliative care
|
04.06 |
Hyoscine Hydrobromide |
- 150mcg ,300mcg tablet
- Scopoderm® TTS Patch 1mg/ 72hrs
|
15.01.03 |
Hyoscine Hydrobromide injection |
- 400 micrograms in 1ml amps
|
16.13 |
Hyoscine hydrobromide Scopoderm® |
- 1.5mg patch
- Unlicensed indication
- Only licensed from 10 years for travel sickness.
|
21.01.03 |
Hyoscine Hydrobromide |
- 150mcg tablet
- 300mcg sublingual tablets
- Scopoderm® TTS Patch 1mg/ 72hrs
|
21.02.03 |
Hyoscine Hydrobromide |
- Injection 400mcg/ml
- For respiratory tract secretions
- Can be used in syringe drivers
- See page 89/90 Wessex Palliative Care Handbook (link at start of chapter)
|
21.03 |
Hyoscine Hydrobromide |
- Community Just In Case Boxes
- For respiratory tract secretions
|
03.07 |
Hypertonic Sodium chloride for nebulisation MucoClear®, PulmoClear®, Nebusal® |
- Nebuliser solution, sodium chloride 3%, 6%, 7%
- To be started on Specialist respiratory advice only
|
11.08.01 |
Hypromellose |
- 0.3% drops 10ml
- Evolve is the most cost-effective preservative-free hypromellose preparation in primary care
- Swindon only - use Hydromoor brand in secondary care
|
11.08.01 |
Hypromellose |
|
11.08.01 |
Hypromellose 2% in balanced salt solution (HPMC) |
|
06.06.02 |
Ibandronic Acid |
At RUH and GWH only
- 1mg/ml injection licensed for:
- Prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases
- Treatment of tumour-induced hypercalcaemia with or without metastases
|
06.06.02 |
Ibandronic Acid |
- 150mg tablet licensed for the treatment of osteoporosis in postmenopausal women at increased risk of fracture
- 150mg tablet once a month. The tablet should preferably be taken on the same date each month.
- 3rd line option after risedronate
Note: For use of Ibandronic acid 50mg tablets as an adjuvant bisphosphonate for breast cancer under Shared Care Agreement, see chapter 8.3.4.1
|
08.03.04.01 |
Ibandronic Acid |
- Patients from RUH and GWH only -Adjuvant bisphosphonates for breast cancer (see shared care agreement). Under review for SFT.
- For use by oncology only.
- Ibandronic Acid 'off label' indication
- Tablets 50mg daily
|
08.01.05 |
Ibrutinib |
|
07.01.01.01 |
Ibuprofen Pedea® injection |
- GWH and SFT only
- Non formulary at RUH
|
10.01.01 |
Ibuprofen |
- 200mg, 400mg and 600mg tablets
- Oral suspension
- For minor conditions associated with pain and inflammation, patients should self-care in the first instance.
|
10.03.02 |
Ibuprofen |
- 100g gel containing 5% ibuprofen
- Fenbid brand is most cost effective
- NICE clinical guideline 177 Osteoarthritis: Feb 2014 Paracetamol and/or topical NSAIDs should be offered to patients with knee or hand osteoarthritis before considering oral NSAIDs, COX-2 inhibitors or opioids
|
21.01.01.01 |
Ibuprofen |
- 100g gel containing 5% ibuprofen
- Fenbid brand is most cost effective
|
21.01.01.01 |
Ibuprofen |
- 200mg, 400mg and 600mg tablets
- Oral suspension
|
21.01.01.04 |
Ibuprofen |
- 200mg, 400mg and 600mg tablets
- Oral suspension
|
21.01.01.04 |
Ibuprofen |
- 100g gel containing 5% ibuprofen
- Fenbid brand is most cost effective
|
03.04.03 |
Icatibant Firazyr® |
-
Injection 10mg/ml - 3ml pre-filled syringe
- Non Formulary RUH
- Available from SFT
-
Commissioned by NHS England for Hereditary Angioedema and Acquired Angioedema for acute treatment or short-term prophylaxis prior to planned procedures. See NHS England Policy: B09/P/b.
May only be initiated by (or on advice of) Specialist Centres where:
- C1inh is unsuitable due to adverse effects or administration difficulties the specialist clinician determines that Icatibant is the most suitable or cost-effective preparation for the patient
Drug costs for emergency use in other hospitals will be reimbursed through the Specialist Centre
|
08.01.02 |
Idarubicin |
- 5mg, 10mg and 25mg capsules
- 5mg and 10mg injection
|
02.08.03 |
Idarucizumab |
- 2.5g vial for intravenous injection
- When rapid reversal of dabigatran is required for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding. On Consultant Haematologist advice only.
|
08.01.05 |
Idelalisib |
|
08.01.01 |
Ifosfamide |
|
02.05.01 |
Iloprost injection |
- When used for digitial ischaemia and ulceration in Raynaud's Disease and scleroderma as per NHSE policy below within Specialist Services
|
08.01.05 |
Imatinib Gilvec® |
- 100mg and 400mg tablets
- Ensure correct brand supplied
|
08.01.05 |
Imatinib (Generic) |
- 100mg and 400mg tablets
- Also for treatment of Philadelphia Positive Guidelines ALL as per BCSH Guidelines
|
05.01.02.03 |
Imipenem with Cilastatin Injection |
- Used in GWH and SFT
- RUH – not routinely stocked
- 500mg/500mg powder for solution for infusion
|
04.03.01 |
Imipramine |
- Tablets 10mg
- Liquid SF 25mg/5ml
|
04.07.03 |
Imipramine |
- Not licensed for neuropathic pain but a widely accepted treatment (off-label).
|
13.07 |
Imiquimod |
- Cream 5% 12 sachets
- Genital warts. Apply 3 times a week until lesions resolved (maximum 16 weeks)
- Note: Imiquimod cream is also licensed for the treatment of superficial basal cell carcinoma and actinic keratosis-see seperate entry in 13.8.1 for its traffic light status.
|
13.08.01 |
Imiquimod Aldara® |
 Photodamage/Actinic Keratoses. Apply 3 times a week for 4 weeks.
 Superficial Basal Cell Carcinoma. Apply daily for 5 nights of each week for 6 weeks. (Initiation by consultant dermatologist or GP with special interest in Dermatology)
- See entry in 13.7 for its use in the treatment of anogenital warts
- Cream 5% 12 sachets Aldara®
|
13.02.01 |
Imuderm ® cream |
- Use after other emollients have been tried and failed to control symptoms. Expensive emollient.
- Urea 5%, Glycerine 5%
- Available as 500g pump pack
- Preparations containing lauromacrogols and/or urea are useful to stop itching or aid hydration.
|
03.01.01.01 |
Indacaterol Onbrez Breezhaler® |
- No new prescribing. Existing patients only - see notes above.
- Inhalation powder, hard capsule 150, 300 micrograms (via Onbrez Breezhaler® device)
|
02.02.01 |
Indapamide |
- Tablets 2.5mg
- Note: Indapamide 2.5mg daily is considered the optimal dose for hypertension
|
20 |
Indigo carmine solution |
- For use within RUH
- 'Off label' use of solution for injection as replacement for unlicensed preparation in endoscopy
|
20 |
Indocyanine green Injection 25 mg, 50mg |
|
07.01.01.01 |
Indometacin Indocid PDA® |
- GWH and RUH only
- Non formulary SFT
|
10.01.01 |
Indometacin |
- BaNES and Swindon only
- Non formulary in Salisbury
- 25mg and 50mg
- 100mg suppositories
|
13.11.01 |
Industrial Methylated Spirit BP |
|
14.04 |
Infanrix hexa ® |
- Powder and suspension for suspension for injection.
- Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) and Haemophilus influenzae type b (Hib) conjugate vaccine (adsorbed).
- Infanrix hexa is indicated for primary and booster vaccination of infants and toddlers against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type b.
- (schedule at 2, 3, 4 months)
|
14.04 |
Infanrix IPV ® |
- Infanrix®-IPV, suspension for injection in pre-filled syringe
- Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed) (schedule between 3yrs & 4/12 to 5 years)
|
01.05.03 |
Infliximab Remsima®Inflectra®Remicade® |
- 100mg vials.
- Prescribe BY BRAND. Biosimilar first-line option.
- Please note: Infliximab should be prescribed in accordance with either the BSW STP Ulcerative Colitis Biologic / Biosimilar Commissioning Pathway or the BSW STP Crohn's Disease Biologic / Biosimilar Commissioning Pathway.
|
10.01.03 |
Infliximab Remsima®Inflectra®Remicade® |
- 100mg powder for concentrate for solution for infusion
- All products should be prescribed by brand. Biosimilars should be used 1st line.
- For rheumatoid arthritis in accordance with NICE recommendations TA130 and TA195 and local pathway.
- For ankylosing spondylitis in accordance with NICE TA145 and TA140 and local pathway.
- For psoriatic arthritis in accordance with NICE TA199 and local pathway.
- Commissioned by NHS England for paediatric indications (where adult TA available). According to adult TAs (TA130, TA134, TA140, TA143, TA163, TA199) for the range of arthritis-related indications.
- Check Trust contracting arrangements first before prescribing
- Not routinely commissioned by NHS England for: connective tissue disease - interstitial lung disease, graft versus host disease, renal indications, sarcoidosis, progressive pulmonary sarcoidosis, uveitis or hidradenitis suppurativa.
|
13.05.03 |
Infliximab Remsima®Inflectra® |
- Biosimilar available: Remsima® or Inflectra® used locally.
- Prescribe by brand. Biosimilar first-line option.
- Originator product: Remicade usually used for patients that do not tolerate or do not respond to a biosimilar version.
- Injection 100mg vial
|
14.04 |
Influenza vaccine |
- Brands include: Inactivated Influenza Vaccine (Split Virion), Agrippal CSL, Inactivated Influenz Vaccine Enzira Imuvac Influvac, Fluarix Tetra, Fluad
|
14.04 |
Influenza vaccine ® Fluenz Tetra |
- Primary Care Only : Please note that flu vaccines for children should be ordered via IMMFORM and should NOT be reclaimed via NHS prescription services (PPA).
|
06.01.01.03 |
Injection Device JuniorSTAR® |
|
06.01.01.03 |
Injection Device AllStar Pro® |
- ClikSTAR has been discontinued and replaced with this device
|
06.01.01.03 |
Injection Device NovoPen 5 |
|
06.01.01.03 |
Injection Device NovoPen Echo® |
|
06.01.01.03 |
Injection Device HumaPen Savvio® |
|
06.01.01.03 |
Injection Device Autopen Classic (1 and 2 unit)® |
|
06.01.01.03 |
Injection Device Autopen 24 (1 and 2 unit)® |
|
08.01.05 |
Inotuzumab Ozogamicin Injection |
|
06.01.01.01 |
Insulin Actrapid® |
|
06.01.01.01 |
Insulin Insuman® Rapid |
|
06.01.01.01 |
Insulin Humulin® S |
|
06.01.01.01 |
Insulin Aspart NovoRapid® |
|
06.01.01.01 |
Insulin aspart Fiasp® |
- Type 1 diabetes only
- Specialist recommended only for patients with difficult to manage significant post prandial hyperglycaemia
- The safety and efficacy of Fiasp in children and adolescents below 18 years of age have not been established (see SPC).
- SAFETY INFORMATION: From 1 June 2018, the colour of Fiasp cartridges, pre-filled pens and vials is changing from yellow to red and yellow, following cases where patients have mistakenly injected it instead of Tresiba or vice versa.
|
06.01.01.02 |
Insulin degludec Tresiba® |
100 units per ml format: Please note different prescribing criteria for each locality and ensure correct strength is prescribed.
BaNES/West Wilts - Type 1 diabetes only
- This is reserved as a last resort when all other options have been trialled.
- Criteria for use:
- Treatment limiting recurrent severe hypoglycaemia despite optimized analogue basal bolus insulin treatment
- Have recurrent disabling hypoglycaemia prior to insulin pump therapy
- Patients with recurrent DKA due to delayed/irregular administration due to compliance or lifestyle factors requiring hospital admission
- Review criteria (at 6/12):
- No. of episodes of hypoglycaemia
- Acute unplanned admissions
- Improved blood glucose control
Salisbury
- Only for Type 1 diabetic patients with treatment limiting recurrent hypoglycaemia despite optimal treatment prior to insulin pump therapy, patients with recurrent DKA requiring hospital admission due to delayed administration. Patients receiving insulin form a carer where irregular administration times may contribute to hyper/hypoglycaemia
- Only for Type II diabetic patients with significant insulin resistance requiring over 200units per day and over 80units per injection of basal insulin
Swindon - Type 1 diabetes only
- This is reserved as a last resort when all other options have been trialed
- Criteria for use:
- Treatment limiting recurrent severe hypoglycaemia despite optimized analogue basal bolus insulin treatment
- Have recurrent disabling hypoglycaemia prior to insulin pump therapy
- Patients with recurrent DKA due to delayed/irregular administration due to compliance or lifestyle factors requiring hospital admission
- Review criteria (at 6/12):
- No. of episodes of hypoglycaemia
- Acute unplanned admissions
- Improved blood glucose control
|
06.01.01.02 |
Insulin degludec Tresiba® |
200 units per ml format: Please note different prescribing criteria for each locality and ensure correct strength is prescribed.
Bath - not on formulary at this strength
Salisbury:
Criteria for use:
- Only for Type 1 diabetic patients with treatment limiting recurrent hypoglycaemia despite optimal treatment prior to insulin pump therapy, patients with recurrent DKA requiring hospital admission due to delayed administration. Patients receiving insulin form a carer where irregular administration times may contribute to hyper/hypoglycaemia
- Only for Type 2 diabetic patients with significant insulin resistance requiring over 200units per day and over 80units per injection of basal insulin
Swindon: (This is not a standard choice and use should be minimised).
Criteria for use (in type 2 diabetes only):
- High volume of 100 unit/ml injections of insulin with dose greater than 1.2 units /kg body weight.
- Morbidly obese (BMI >35)
- Severe insulin resistance
- Poor blood glucose control (HbA1c >70)
- Pt must be able to selfadminister
Review criteria (at 6/12):
- Improved blood glucose control
|
06.01.01.02 |
Insulin Detemir Levemir® |
- Type 1 and Type 2 diabetes
- includes Innolet
|
06.01.01.02 |
Insulin Glargine Toujeo® |
300 units per ml HIGH STRENGTH.
- Toujeo (insulin glargine 300units/ml) and Lantus, Abasaglar (insulin glargine 100units/ml) are not bioequivalent and are not interchangeable. See product safety review in links below.
- Bath Criteria for use:
- Pt must be able to self-administer
- High volume of 100 unit/ml injections of insulin with dose greater than 1.2 units /kg body weight.
- Morbidly obese (BMI >35)
- Severe insulin resistance
- Poor blood glucose control HbA1c >70
- Demonstrates improved blood glucose control at 6/12 specialist initiated review criteria
- CAUTION PRODUCT SELECTION:
- Toujeo® Solostar is the only Toujeo® formulation on formulary.
- Toujeo® SoloStar 300units/ml. Each pen contains 450units/1.5ml and uses 1-unit dosage step increments.
- Toujeo® DoubleStar 300units/ml. Each pen contains 900units/3ml and uses 2-unit dosage step increments. Toujeo DoubleStar® is one of the very few insulin devices in the UK which administer 2 units of insulin per click, presenting a risk patients could receive double the dose of insulin glargine if the wrong Toujeo product is dispensed or if DoubleStar® is used incorrectly by assuming one click is equivalent to one unit of insulin. Doublestar is non-formulary currently and should not currently be prescribed. Please ensure that the correct pen is always given to the patient and prescribed by brand name.
|
06.01.01.02 |
Insulin Glargine Lantus® |
- Type 1 and Type 2 diabetes
- EXISTING patients/those with dexterity problems and needing greater than 60 units per dose
|
06.01.01.02 |
Insulin Glargine biosimilar Abasaglar® |
- Formulary choice for new patients needing a basal analogue insulin.
- Type 1 and Type 2
|
06.01.01.01 |
Insulin Glulisine Apidra® |
|
06.01.01.01 |
Insulin Lispro 100 units/ml Humalog® |
|
06.01.01.01 |
Insulin Lispro Sanofi 100 units/ml |
- GWH only
- Type 1 diabetes only
|
08.02.04 |
Interferon Beta Rebif® |
- 22micrgoram/0.5ml and 8.8microgram/0.2ml cartridges and pre-filled pens/syringes
- 44microgram/0.5ml cartridges and pre-filled pens/syringes
|
08.02.04 |
Interferon Beta Extavia® |
- Extavia® 250 microgram/ml powder and solvent for solution for injection
- After reconstitution, each ml contains 250 microgram (8.0 million IU) of recombinant interferon beta-1b
|
08.02.04 |
Interferon Beta |
- 30microgram/0.5ml pre-filled (6 million units) syringes
|
18 |
Intralipid |
|
07.03.02.03 |
Intra-uterine Progestogen Only System Levosert® |
- Intra-uterine system containing 52mg levonorgestrel releasing 20micrograms per 24 hours
|
07.03.02.03 |
Intra-uterine Progestogen Only System Kyleena® |
- Intra-uterine system containing 19.5mg levonorgestrel releasing 17.5micrograms per 24 hours
|
07.03.02.03 |
Intra-uterine Progestogen Only System Jaydess® |
- Intra-uterine system containing 13.5mg of levonorgestrel
|
07.03.02.03 |
Intra-uterine Progestogen Only System Mirena® |
- Intra-uterine system releasing 20 micrograms of levonorgestrel per 24 hours
|
08.01.05 |
Ipilimumab |
|
03.01.02 |
Ipratropium Bromide Atrovent® |
- Inhaler 20 micrograms/dose
|
12.02.02 |
Ipratropium Bromide 0.03% Nasal spray |
- nasal spray 0.03%
- Useful for watery rhinorrhoea
|
03.01.02 |
Ipratropium Bromide Nebuliser Solution Ipratropium Steri-Neb® |
- Nebuliser solution 250 micrograms in 1 ml, 500micrograms in 2ml
|
03.01.04 |
Ipratropium bromide with salbutamol Combivent® |
- Ipratropium bromide 500micrograms & salbutamol sulphate 2.5mg/ 2.5ml Unit Dose Vial (nebulised)
- NB - less suitable for prescribing. Licensed for bronchospasm in patients with COPD. BNF states flexibility of dosing is lost with a compound bronchodilator but it may be appropriate for patients stabilised on the individual components in the same proportion.Consider if compliance an issue.
|
08.01.05 |
Irinotecan hydrochloride Injection |
- 500mg/25ml, 300mg/15ml, 100mg/5ml and 40mg/2ml infusion
|
09.01.01.01 |
Iron and Folic Acid Pregaday® |
- Tablets containing ferrous fumarate 322mg (equivalent to 100mg of ferrous iron)and folic acid 0.35mg
|
09.01.01.02 |
Iron Dextran CosmoFer® |
- SFT and GWH only. Not on formulary at RUH
- 50mg/ml
- Anaphylactoid reactions can occur with parenteral administration of iron complexes. Facilities for cardio-pulmonary resuscitation must be at hand.
|
09.01.01.02 |
Iron Isomaltoside Monofer® |
- Included on formulary for RUH only - Treatment of iron-deficiency when oral preparations are ineffective and cannot be used
- GWH/SFT - Not on formulary
- 100mg/ml for slow intravenous injection or intravenous infusion
- Anaphylactoid reactions can occur with parenteral administration of iron complexes. Facilities for cardio-pulmonary resuscitation must be at hand.
|
05.02 |
Isavuconazole |
- Formulary at RUH only
- Non Formulary GWH SFT
- 100 mg hard capsules
- 200 mg powder for concentrate for solution for infusion
- To treat mucormycosis as per Trust Guidelines
|
15.01.02 |
Isoflurane |
|
05.01.09 |
Isoniazid |
- Tablets 50mg, 100mg
- Elixir (SF) 50mg/5ml (unlicensed)
|
06.01.01.02 |
Isophane Insulin Insulatard® |
|
06.01.01.02 |
Isophane Insulin Humulin® I |
|
06.01.01.02 |
Isophane Insulin Insuman® Basal |
- Type 2 diabetes only
- NOTE - Insuman Basal vials are being discontinued.
|
02.07.01 |
Isoprenaline |
- Available as an unlicensed product
|
13.11.01 |
Isopropyl Alcohol |
|
02.06.01 |
Isosorbide Dinitrate |
- RUH only
- Non formulary at GWH and SFT
- 10mg in 10ml, 25mg in 50ml (half strength)
|
02.06.01 |
Isosorbide Mononitrate Tablet |
- Tablets 10mg, 20mg
- If a once daily Modified Release preparation is required, for example patients who have problems with compliance, specify brand.
- Chemydur® 60XL MR tabs 60mg or Monomax® XL MR tabs 60mg or Monomil® XL MR tabs 60mg are preferred brands of choice in primary care.
|
13.06.02 |
Isotretinoin |
- Capsules 5mg, 10mg, 20mg
- Women of child bearing age must be enrolled in the pregnancy prevention program.
- Note: As a RED TLS drug, isotretinoin should be supplied by secondary care. A local exception to this is for Wiltshire patients under the care of the consultant-led integrated community dermatology service at Spa GP practice, Melksham - Cotswold Surgical Partners (CSP). Wiltshire community pharmacies can dispense FP10s for isotretinoin from CSP where it is clear that the prescription has been issued within the context of a Pregnancy Prevention Programme. Do not dispense 7 days beyond issue date of FP10. Further information on P6 of this newsletter.
|
01.06.01 |
Ispaghula Husk |
|
05.02 |
Itraconazole |
- For use by haematology
- GWH and SFT only
- Please note liquid is expensive
|
05.02 |
Itraconazole |
- Capsules 100mg
- Treatment for most fungal skin and nail infections are a low clinical priority for local CCGs.
|
02.06.03 |
Ivabradine |
- Tablets 5mg, 7.5mg
- To be used only for symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm for whom heart rate control is desirable and for whom beta-blockers and calcium-channel blockers are inappropriate or not tolerated.
- Please see MHRA Drug Safety Update for information on risk of bradycardia.
|
02.06.03 |
Ivabradine |
- Tablets 5mg, 7.5mg
- Use according to NICE TA267 below. In patients with New York Heart Association (NYHA) class II or IV stable chronic heart failure with systolic dysfunction and who are in sinus rhythm with a heart rate of 75 beats per minute (bpm) or more and who are given ivabradine in combination with standard therapy including beta-blocker therapy, angiotensin-converting enzyme (ACE) inhibitors and aldosterone antagonists, or when beta-blocker therapy is contraindicated or not tolerated and with a left ventricular ejection fraction of 35% or less.
-
Ivabradine should only be initiated after a stabilisation period of 4 weeks on optimised standard therapy with ACE inhibitors, beta-blockers and aldosterone antagonists.
-
Ivabradine should be initiated by a heart failure specialist with access to a multidisciplinary heart failure team. Dose titration and monitoring should be carried out by a heart failure specialist or in primary care by either a GP with a special interest in heart failure or a heart failure specialist nurse.
|
03.07 |
Ivacaftor |
|
05.05.06 |
Ivermectin |
- GWH only for filaricide infections
|
13.06 |
Ivermectin |
- Cream 1% 30g
- Treatment of moderate to severe inflammatory lesions of rosacea
- Second line to metronidazole
|
13.10.04 |
Ivermectin |
- GWH for norwegian scabies
- Ivermectin is unlicensed in the UK and can be supplied from 'special order' manufacturers or specialist importing companies.
|
08.01.05 |
Ixazomib |
- 2.3mg, 3mg and 4mg capsules
- To treat relapsed/defractory myeloma in combination with Lenalidomaide and Dexamethasone
- To treat multple myeloma via the Cancer Drugs Fund
|
10.01.03 |
Ixekizumab Taltz® |
- 80mg solution for injection in pre-filled syringe or pen
- CCG commissioned as per NICE TA537 for psoriatic arthritis
|
13.05.03 |
Ixekizumab |
- Pre-filled syringe contains 80 mg ixekizumab in 1 ml.
- Use in accordance with NICE guidance
|
24.01 |
Jaw rehabilitation Therabite® |
- Recommended for patients following head and neck radiotherapy or head and neck surgery when recommended by an appropriate Secondary Care Specialist
- Only on recommendation from maxillofacial surgeon with clear follow up plan by specialist
|
13.08.02 |
Keromask ® |
- Finishing Powder and Masking Cream
|
15.01.01 |
Ketamine |
- 200mg in 20ml vial
- 500mg in 10ml vial
|
13.09 |
Ketoconazole |
- Ketoconazole 2% 120ml
- For seborrhoeic dermatitis apply twice weekly for 2-4 weeks (prophylaxis apply once every 1-2 weeks); treatment of ptyriasis versicolor apply once daily for maximum 5 days
- Can be sold to the public for prevention and treament of dandruff and seborrheic dermatitis of the scalp as a shampoo - see BNF for details
|
11.08.02 |
Ketorolac |
- 0.5% ophthalmic drops
- Note at GWH - For inflammation requiring extended treatment (up to 21 days) following ocular surgery
|
15.01.04.02 |
Ketorolac |
- 30mg in 1ml amp
- Licensed for use in short-term management of moderate to severe post operative pain only.
- Contains a small amount of ethanol per dose (100mg)
- See palliative care section Chapter 21
|
21.02.01 |
Ketorolac |
GWH Only
- 30mg in 1ml amp
- GWH: ONLY for specialist initiation and ongoing prescription by the Palliatve Care team, for the treatment of neuropathic cancer pain and bone pain in palliative care patients by sc injection / sc infusion (off-label use).
|
11.04.02 |
Ketotifen Ketofall® |
 - Salisbury & Swindon - 2nd-line after Olopatidine.
- Non formulary - Bath.
- 0.25mg/ml single dose unit drops SPC here.
|
01.06.05 |
Klean-prep® Oral powder |
- 69g sachet containing polyethylene glycol 3350 59g, potassium chloride 742.5 mg, sodium bicarbonate 1.685g, sodium chloride 1.465g & sodium sulfate anhydrous 5.685g.
|
02.04 |
Labetalol |
- Tablets 100mg, 200mg, 400mg
|
02.04 |
Labetalol |
|
04.08.01 |
Lacosamide |
- Tablets 50mg, 100mg, 150mg, 200mg (Category 3 MHRA)
- For the adjunctive treatment of partial seizures with or without secondary generalisation
|
01.06.04 |
Lactulose |
- 3.1-3.7g/5ml oral solution.
- Please note: Lactulose takes up to 48 hours to work, making it unlikely to produce immediate relief, but is often prescribed “when required”. It can be unpleasant to take and compliance may be a problem. Its main clinical benefit is in the management of hepatic encephalopathy.
|
05.03.03.01 |
Lamivudine |
- Tablets 100mg, 150mg, 300mg
- Oral solution 10mg/ml
|
04.02.03 |
Lamotrigine |
- Tablet 25mg, 50mg, 100mg, 200mg
- Dispersible tablet 2mg, 5mg, 25mg, 100mg
- Prevention of depressive episodes in patients with bipolar I disorder who experience predominantly depressive episodes
|
04.08.01 |
Lamotrigine |
- Tablet 25mg, 50mg, 100mg, 200mg (Category 2 MHRA)
- Dispersible tablet 2mg, 5mg, 25mg, 100mg
|
06.01.01.03 |
Lancets |
|
06.01.01.03 |
Lancets |
|
06.01.01.03 |
Lancets Accu-check Fastclik Lancets ® |
|
08.03.04.03 |
Lanreotide |
 Swindon - relief of symptoms associated with acromegaly
- Commissioned by NHS England, as per agreed Trust Guidelines. Use product with lowest procurement cost.
- 60mg/0.5ml, 90mg/0.5ml and 120mg/0.5ml pre-filled syringe
- Carcinoid Syndrome and Neuroendocrine Tumours
- For the treatment of acromegaly
|
01.03.05 |
Lansoprazole |
- 15mg & 30mg capsules.
- Lansoprazole 15mg & 30mg oro-dispersible tablets are available for use ONLY in those with swallowing difficulties but first consider more cost-effective dispersible PPIs - see BSW PPI guidance for further information.
|
09.05.02.02 |
Lanthanum Fosrenol® |
- Tablets (chewable) 500mg, 750mg, 1g
- For intiation by Renal team only (3rd line treatment) as per relevant SCA
|
11.06 |
Latanoprost |
- 50microgram/ml ophthalmic drops
- Preservative free available if indicated as per BSW glaucoma guidance
|
11.06 |
Latanoprost 0.005% with Timolol 0.5% |
- Latanoprost 50micrograms, Timolol 5mg/ml
- Note: Fixapost® preservative free included on formulary at SFT
|
05.03.03.02 |
Ledipasvir and Sofosbuvir Harvoni® |
|
10.01.03 |
Leflunomide |
-
 - BaNES and Wiltshire
-
 - Swindon DAWN patients
- Please refer to our DMARD Shared Care and Monitoring Guidance below for further information
- 10mg, 15mg, 20mg and 100mg tablets
|
08.02.04 |
Lenalidomide |
|
09.01.06 |
Lenograstim Granocyte® |
- SFT and RUH
- GWH - not on formulary
- Pre-filled syringe 13.4 million-unit (105 micrograms), 33.6 million-unit (263 micrograms)
- Recombinant human granulocyte-colony stimulating factor (rHuG-CSF)
- Commissioned by NHS England for neutropenia according to Trust Guidelines
- RUH Used for the mobilisation of STEM cells.
|
08.01.05 |
Lenvatinib |
- 4mg and 10mg capsules
- Different brand depending upon indication
|
08.01.05 |
Lenvatinib with Everolimus Capsules |
- 4mg and 10mg capsules
- Different brand depending upon indication
|
02.06.02 |
Lercanidipine |
- Swindon only
- Non formulary in BaNES and Salisbury
- 10mg and 20mg tablets
|
08.03.04.01 |
Letrozole |
- 2.5mg tablet
 - For treatment of breast cancer.
 - For the second-line treatment of patients with anovulatory infertility unresponsive to Clomifene at RUH and GWH only. Not included for this indication on the formulary at SFT.
|
06.07.02 |
Leuprorelin Prostap® |
 Endometriosis / fibroids
 RUH and SFT for fertility
For endometriosis:
- Prostap SR DCS prefilled syringe - powder for reconstitution 3.75mg (one month)
- Prostap 3 DCS prefiled syringe - powder for reconstitution 11.25mg (three months)
For prostate cancer see section 8.3.4.2 |
08.03.04.02 |
Leuprorelin Acetate Injection |
- 3.75mg pre-filled syringes (Prostap® SR DCS) - one month injection
- 11.25mg pre-filled syringes (Prostap® 3 DCS) - 3 month injection
- For locally advanced, non-metastatic prostate cancer, as an alternative to surgical castration, or metastatic prostate cancer as per the licensed indication
- Lutrate® has been discontinued (Jun 19)
|
04.08.01 |
Levetiracetam |
- Tablets 250mg, 500mg, 750mg, 1g (Category 3 MHRA)
- Oral solutionSF 100mg/ml
- Granules in sachets, 250mg, 500mg and 1000mg Desitrend (second line use only)
|
04.08.01 |
Levetiracetam |
- Concentrate for I/V infusion 100mg/ml 5ml vial (Category 3 MHRA)
|
16.06 |
Levetiracetam |
- 250mg, 500mg, 750mg and 1g (category 3 MHRA)
- Oral solution SF 100mg/ml
- Granules in sachets 250mg, 500mg and 1000mg Desitrend (second line use only)
|
16.06 |
Levetiracetam |
|
21.02.04 |
Levetiracetam |
- 100mg/ml 5ml vial
- For use in syringe pumps following advice of palliative care specialists
- To be used an alternative to midazolam for the treatment of seizures where sedation is not desirable.
- Can be used in syringe drivers if patient on longterm oral levetiracetam.
- Can be used in syringe drivers
- See page 89/90 Wessex Palliative Care Handbook (link at start of chapter)
|
15.02 |
Levobupivacaine |
- 25mg in 10ml (0.25%) amp
- 50mg in 10ml (0.5%) amp
|
15.02 |
Levobupivacaine with Fentanyl |
|
05.01.12 |
Levofloxacin |
- The EMA’s Pharmacovigilence Risk Assessment Committee has recommended restricting fluoroquinolones following a review of disabling & potentially long-lasting side-effects. See link above for further information.
- 250mg
- 500mg
- Consultant microbiologist recommendation ONLY.
|
05.01.12 |
Levofloxacin |
- The EMA’s Pharmacovigilence Risk Assessment Committee has recommended restricting fluoroquinolones following a review of disabling & potentially long-lasting side-effects. See link above for further information.
- IV infusion 5mg/ml 100ml bottle, 100ml infusion bag
|
11.03.01 |
Levofloxacin |
- 5mg/ml eye drops
 Salisbury
 BaNES and Swindon
|
13.03 |
Levomenthol -Menthol in aqueous cream |
- Prescribe as the brand Dermacool® in primary care.
- Cream 0.5%, 1%, 100g, 500g pump
- For severe pruritus and can be used long term if necessary
|
04.02.01 |
Levomepromazine |
- Tablet 25mg
- For palliative care for the management of pain, associated restlessness, distress or vomiting. See chapter 21, palliative care.
|
21.01.02 |
Levomepromazine |
- 25mg Tablets
- For palliative care for the management of pain, associated restlessness, distress or vomiting
|
21.02.02 |
Levomepromazine |
- For nausea and vomiting
- 25mg/ml
- Can be used in syringe drivers
- See page 89/90 Wessex Palliative Care Handbook (link at start of chapter)
|
21.02.04 |
Levomepromazine |
- For nausea and vomiting
- 25mg/ml
- Can be used in syringe drivers
- See page 89/90 Wessex Palliative Care Handbook (link at start of chapter)
|
21.03 |
Levomepromazine |
- Community Just In Case Boxes
- For nausea and vomiting
|
07.03.05 |
Levonorgestrel |
- Tablet contains 1.5 mg of levonorgestrel
- Licensed to prevent pregnancy when taken within 72 hours of unprotected intercourse or failure of a contraceptive method. Emergency contraceptive pills do not prevent 100% of pregnancies and are more effective the sooner they are taken after unprotected sex.
- Please be aware of the updated FSRH advice (2017) to provide a 3mg dose in patients women weighing >70 kg or with a BMI >26 kg/m2
- FP10s for levonorgestrel should be written generically as levonorgestrel 1.5mg. Levonelle One Step, the pharmacy pack, is significantly more expensive.
- Levonelle One Step pharmacy pack of levonorgestrel 1.5mg is available to purchase from Community Pharmacies. Pharmacist checklist and patient information leaflet here.
|
06.04.01.02 |
Levonorgestrel Intrauterine System |
- Intra-uterine system releasing 20 micrograms of levonorgestrel per 24 hours
- Prescribe by brand name.
- Mirena is effective for 5 years in the indications for contraception and idiopathic menorrhagia so should be removed after 5 years use.
- In the indication for protection from endometrial hyperplasia during oestrogen replacement therapy, clinical data (from clinical trials conducted in women of 18 years and over) beyond 4 years of use are limited. Mirena should therefore be removed after 4 years.
|
06.02.01 |
Levothyroxine |
- 12.5 micrograms, 25 micrograms, 50 micrograms, 75 micrograms, 100 micrograms tablets
|
02.03.02 |
Lidocaine |
- Infusion 1g in 5% Glucose (500ml)
- Injection (prefilled syringe) 100mg in 5ml
|
04.07.03 |
Lidocaine |
|
15.02 |
Lidocaine Xylocaine |
- SFT only
- This product is non-sterile and therefore not recommended for use prior to procedures that require aseptic techniques
- Lidocaine 10 mg/metered dose.
- Used for the prevention of pain related to specific procedures
- Contains ethanol
- 50 ml glass spray bottles (approx. 500 spray doses) with a metering spray pump.
|
21.01.01.04 |
Lidocaine |
- Can be used as per Palliative Care specialist recommendation (off-label) on a case by case basis between specialist and GP. Locally agreed indication (August 2019).
- For all other indications see entry under neuropathic pain 04.07.03
- Medicated plasters lidocaine 5%. Prescribe by the brand name: Ralvo®
|
15.02 |
Lidocaine 2.5% with Prilocaine 2.5% EMLA® |
- Lidocaine 2.5%, Priolocaine 2.5%, 30g, 5g with dressings
|
11.07 |
Lidocaine 4% with Fluorescein 0.25% |
|
15.02 |
Lidocaine 5% and Phenylephrine 0.5% spray |
- Each bottle contains 2.5ml of solution to be used as a spray, equivalent to 125mg lidocaine and 12.5mg phenylephrine hydrochloride.
|
12.03.01 |
Lidocaine 5% ointment mouth |
|
15.02 |
Lidocaine Hydrochloride injection |
- 50mg in 10ml (0.5%) vial
- 20mg in 2ml (1%) amp
- 50mg in 5ml (1%) amp
- 200mg in 20ml (1%) amp
- 200mg in 20ml (1%) vial preserved
- 100mg in 5ml (2%) amp
- 100mg in 5ml (2%) prefilled syringe
- 400mg in 20ml (2%) amp
|
15.02 |
Lidocaine with Adrenaline injection |
- Xylocaine 1% with adrenaline 1:200,000 multi-dose vial, 20ml and xylocaine 2% with adrenaline 1:200,000 multidose vial, 20ml.
 for use in acute trusts
 for use by GPs in primary care undertaking minor procedures/surgery
 for GWH only: Lidocaine dental cartridges -Lignospan Special® (Lidocaine hydrochloride 2% + adrenaline 1:80000).
|
15.02 |
Lidocaine2% with Chlorhexidine 0.25% Instillagel® |
- Lidocaine 20mg/ml and chlorhexidine gluconate 500mcg/ml. 60ml or 110ml
|
01.06.07 |
Linaclotide |
- 290 micrograms capsules.
- Please note: This is ONLY for the treatment of moderate to severe irritable
- bowel syndrome with constipation, in line with our Guidance on the Management of IBS with constipation (IBS-C) in Adults. (Link below)
|
06.01.02.03 |
Linagliptin |
- 5mg
- Note: Licensed as monotherapy, dual therapy with metformin, triple therapy (SU+metformin), Insulin add on (plus or minus metformin).
- No dose reduction in renal impairment
|
05.01.07 |
Linezolid |
- Tablets 600mg
- IV infusion 600mg/300ml
- FBC monitoring (including platelets) should be performed weekly.
|
06.02.01 |
Liothyronine sodium Injection |
- 20 micrograms
- For emergency treatment of hypothyroid coma, OR in patients exhibiting signs and symptoms of hypothyroidism following failure to administer/absorb usual oral replacement therapy (typically after 5-7 days).
- Please note this this a high cost medicine
|
06.02.01 |
Liothyronine sodium Tablet |
- Prescribers in primary care should not initiate liothyronine for any new patient
- Please note - only the 20 microgram strength is on formulary. For lower doses the tablet can be dispersed in water. See SPC for details.
- Liothyronine is non formulary for monotherapy, it should be used with levothyroxine (T4).
- Please note this is a high cost medicine
- The British Thyroid Association (BTA) advise that a small proportion of patients treated with levothyroxine continue to suffer with symptoms despite adequate biochemical correction.
- In these circumstances, where levothyroxine has failed and in line with BTA guidance, endocrinologists providing NHS services may recommend liothyronine for individual patients after a carefully audited trial of at least 3 months duration of liothyronine.
- Liothyronine is used for patients with thyroid cancer, in preparation for radioiodine ablation, iodine scanning, or stimulated thyroglobulin test. In these situations it is appropriate for patients to obtain their prescriptions from the centre undertaking the treatment and not be routinely obtained from primary care prescribers.
|
13.10.05 |
Liquiband® adhesive Topical |
|
13.02.01 |
Liquid and White Soft Paraffin Ointment (50:50) |
- VERY GREASY MOISTURISER FOR SEVERE DRY SKIN &/OR ACUTE FLARES (low risk of sensitivity):
- 50/50 ointment
|
11.08.01 |
Liquid Paraffin eye ointment Lacri-lube® |
- GWH for recurrent erosions only. Not on formulary at RUH/SFT
- Consider Hylo-night (formerly VitA-POS or Hydramed night)
|
06.01.02.03 |
Liraglutide Victoza® |
 Bath
 Salisbury and Swindon
- 6mg/ml prefilled pens
- Dose: 0.6mg OD for 2 weeks, increased to 1.2mg OD. Further increase of dose up to 1.8mg is not advised.
- NB Liraglutide (Saxenda®) for weight loss is not included in this formulary for NHS use.
|
04.04 |
Lisdexamfetamine |
- Capsules 20mg, 30mg, 40mg, 50mg, 60mg, 70mg
- Once daily dosing.
Note: SCA for Adults link below. SCA for Paeds see Chapter 16 |
16.05 |
Lisdexamfetamine Elvanse® |
- 20mg, 30mg, 40mg, 50mg, 60mg and 70mg
- Once daily dosing
|
02.05.05.01 |
Lisinopril |
|
04.02.03 |
Lithium Carbonate Camcolit ® 400mg/ Essential Pharma 250mg |
- 250mg
- 400mg MR
- Prescribed by brand name.
- Monitor lithium levels. Samples should be taken 12 hours after the preceding dose.
- The proprietary (brand) name of “Camcolit 250mg tablets” has changed to “Lithium Carbonate Essential Pharma 250 mg film-coated tablets”, effective from 1st October 2015. The product strength and formulation have not changed, only the name has changed.
- This name change only applies to Camcolit 250mg. Please note, the product name for “Camcolit 400mg prolonged release Lithium carbonate film-coated tablet” is not affected.
- Refer to shared care information on links below. Note the SCAs are old and an updated and aligned version for BSW is expected to be published by Autumn 2020.
|
04.02.03 |
Lithium Carbonate Liskonum® |
- 450mg MR
- Prescribed by brand name.
- Monitor lithium levels. Samples should be taken 12 hours after the preceding dose.
- Refer to shared care information on links below. Note the SCAs are old and an updated and aligned version for BSW is expected to be published by Autumn 2020.
|
04.02.03 |
Lithium Carbonate Priadel® |
- Priadel® M/R tablet 200mg,
- Priadel® M/R tablet 400mg
- Prescribed by brand name.
- Monitor lithium levels. Samples should be taken 12 hours after the preceding dose. Refer to shared care information on links below. Note the SCAs are old and an updated and aligned version for BSW is expected to be published by Autumn 2020.
- Oct 2020 -Priadel (lithium) update (see link below) - Essential Pharma has reversed its decision to discontinue Priadel 200mg and 400mg tablets from the UK market whilst facilitating pricing discussions. There is no longer a need to implement system wide switching of patients until further notice.
|
04.02.03 |
Lithium Citrate Liquid Priadel® |
- Priadel® SF syrup 520mg (equivalent to 5.4mmol Li+) in 5ml
- Li-Liquid® (5ml ≡ 200mg lithium carbonate MR tablets)
- Prescribed by brand name.
- See the National Patient Safety Agency safer lithium therapy alert link below.
- Monitor lithium levels. Samples should be taken 12 hours after the preceding dose.
- Refer to shared care information on links below. Note the SCAs are old and an updated and aligned version for BSW is expected to be published by Autumn 2020.
|
06.01.02.03 |
Lixisenatide |
-
 Bath
-
 Salisbury and Swindon
- 10 microgram, 20microgram - 14 dose pre-filled pen (50 microgram/ml)
- Note: Once daily subcutaneous injection for the treatment of type 2 diabetes within license and in combination with oral hypoglycaemics.
- Dose 10 micrograms OD for 2 weeks, increased to 20micrograms OD.
- First choice GLP1 due to cost in Bath and Swindon
|
04.03.01 |
Lofepramine |
- Tablets 70mg
- Oral suspension 70mg in 5ml
- Probably the safest TCA in overdose
|
08.01.01 |
Lomustine |
|
01.04.02 |
Loperamide |
- 2mg capsules.
- 1mg in 5ml oral syrupSF.
- 2mg tablets (RUH only) Loperamide tablets are restricted to use in patients with feeding tubes, where loperamide liquid has been unsuitable due to hypertonicity. Tablets can be crushed and administered via feeding tube without risk of blocking the tube.
- Please note: The maximum total daily dose of loperamide is 16mg in routine use, although stoma patients may require higher doses.
|
05.03.01 |
Lopinavir and Ritonavir Kaletra® |
- Tablets lopinavir/ritonavir 100mg/25mg and 200mg/50mg
- Oral solution lopinavir 400mg and ritonavir 100mg
|
03.04.01 |
Loratadine |
 Self Care Medicine for primary care.
- Tablets 10mg
- Oral solution 5mg in 5ml
|
04.01.02 |
Lorazepam |
- Injection 4mg in 1ml
- For short term use in status epilepticus or rapid tranquilisation. By intramuscular or slow intravenous injection (into a large vein).
- Note: Only use intramuscular route when oral and intravenous routes not possible. For intramuscular injection it should be diluted with an equal volume of water for injections or physiological saline (but only use when oral and intravenous routes not possible).
- See NICE NG10 (link below).
- Shorter half life and no active metabolites, but carries a greater risk of withdrawal symptoms.
- Also used in chemotherapy antiemetic regimens
|
04.01.02 |
Lorazepam |
- Tablets 1mg
- For short term use . Shorter half life and no active metabolites, but carries a greater risk of withdrawal symptoms.
|
04.08.02 |
Lorazepam |
- 4mg in 1ml
- By slow intravenous injection (into large vein)
|
15.01.04.01 |
Lorazepam |
|
21.01.04 |
Lorazepam |
- Tablets 1mg
- Can be given subligually (off label)
- Not all brands of lorazepam can be absorbed sublingually. Please use Genus, Metwest and Genesis brands
|
02.05.05.02 |
Losartan |
- Tablets 12.5mg, 25mg, 50mg, 100mg
|
11.04.01 |
Loteprednol |
- Salisbury only
- Non formulary at RUH and GWH
|
06.02.02 |
Lugols iodine |
|
09.01.04 |
Lusutrombopag |
- 3mg film-coated tablets
- Short-term use for treating severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure following NICE TA617.
|
08.03.04.03 |
Lutetium (177Lu) oxodotreotide Lutathera |
|
05.01.03 |
Lymecycline |
- 408mg capsules
- More expensive option
|
13.06.02 |
Lymecycline |
- Capsules 408mg
- 408mg once a day for 3 months then review
- Better compliance due to once daily dose.
|
01.01.01 |
Maalox Plus |
- Suspension containing aluminium hydroxide 35 mg & magnesium hydroxide 40 mg per 1 ml.
|
01.06.04 |
Macrogol |
- Sachet containing macrogol 3350 105g, potassium 5.4 mmol, sodium 65mmol, bicarbonate 17mmol & chloride 53mmol per litre.
- Please note: Macrogol use is restricted to faecal impaction, or chronic cases where other laxatives have been ineffective or are unsuitable. It may cause electrolyte disturbances, and there is insufficient evidence to support its routine use before well-established, less expensive drugs.
|
09.05.01.03 |
Magnesium Aspartate Magnaspartate® |
- Magnaspartate Sachets each contain 10mmol magnesium (mix with water)
- Licensed for the treatment and prevention of magnesium deficiency, where clinically indicated in adults, adolescents and children aged 2 years and older.
|
09.05.01.03 |
Magnesium Glycerophosphate Neomag ® |
 SFT,GWH & RUH
- Licensed for the treatment of chronic magnesium loss or hyomagesaemia, where clinically indicated, in adults, adolescents and children aged 4 years and older
- Also licensed for adult patients with hypomagnesaemia due to the concomitant administration of loop and thiazide diuretics or other drugs which cause hypomagnesaemia.
|
01.06.04 |
Magnesium Hydroxide Mixture |
- 7.45-8.35% oral suspension BP (magnesium hydroxide 79 mg per 1 ml).
- Phillip's Milk of Magnesia 415mg/5ml oral suspension.
- Please note: Use with caution in the elderly.
|
09.05.01.03 |
Magnesium Sulphate |
- Injection 10%, 20%, 50% ampoules
- 20% pre-filled syringes (unlic) included on formulary for maternity use (GWH only)
|
13.10.05 |
Magnesium Sulphate Paste BP |
- Paste, dried magnesium sulfate 45g, glycerol 55g, phenol 500mg 25g, 50g
|
01.01.01 |
Magnesium Trisilicate Mixture |
- MixtureSF (Contains about 6mmol of sodium in 10ml).
|
13.10.04 |
Malathion 0.5% |
- aqueous liquid 50ml, 200ml (can be used if permethrin is inappropriate.)
|
02.02.05 |
Mannitol |
|
03.07 |
Mannitol inhalation Osmohale ®/Aridol® |
- For inhalation for mannitol bronchial challenge test
|
03.07 |
Mannitol inhalation Bronchitol ® |
- Non Formulary at RUH and SFT
- Inhalation powder, hard capsule (for use with disposable inhaler device) mannitol 40mg
- Commissioned by NHS England for use in CF as per policy A01/P/b and NICE TA266.
|
05.03.01 |
Maraviroc Celsentri® |
|
14.04 |
Measles, Mumps and Rubella Vaccine, Live (MMR) MMRvaxPro® Priorix® |
|
05.05.01 |
Mebendazole |
- Tablets (chewable) 100mg
- Suspension 100mg/5ml.
- Recommended for all children >6 months and adults. Repeat in 2/52 if infestation persists.
- A prescription for treatment of threadworm should not routinely be offered in primary care as the condition is appropriate for self-care.
|
05.05.02 |
Mebendazole |
|
05.05.04 |
Mebendazole |
|
01.02 |
Mebeverine |
- 135mg tablets.
- Please note: Modified-release preparations are NOT included on our formulary.
|
13.02.02 |
Medihoney® |
- Medihoney barrier cream contains only natural products with the addition of 30% active 100% Pure Medical Grade Manuka Honey. 50g pack size.
- INDICATION: Moderate to severe Incontinence Associated Dermatitis
- Protects at risk skin from breakdown associated with incontinence. Can be used under incontinence pads
- Can be used around wound edges to protect skin from irritation
and breakdown caused by wound exudate
- Suitable for injured skin or areas that are inflamed or excoriated
- Suitable for all ages including paediatrics and neonates
|
06.04.01.02 |
Medroxyprogesterone Acetate |
 Used for endometriosis & dysfunctional uterine bleeding.
 RUH - specialist use only for the treatment of infertility
- 5mg and 10mg tablets
|
07.03.02.02 |
Medroxyprogesterone Acetate Depo-Provera® |
- 150mg in 1ml for administration as deep intramuscular injection every 12 weeks.
|
07.03.02.02 |
Medroxyprogesterone acetate Sayana Press® |
 Patients > 18 years
 Patients and adolescents (12-18 years), use of Sayana Press is only indicated when other contraceptive methods are considered unsuitable or unacceptable, due to unknown long-term effects of bone loss associated with Sayana Press during the critical period of bone accretion. Sayana Press has not been studied in women under the age of 18 years but data is available for intramuscular medroxyprogesterone acetate (MPA) in this population.
- Single-dose container with 104 mg medroxyprogesterone acetate (MPA) in 0.65 mL suspension for injection.
- Licensed for self-administration. Please note company provide sharps bins BUT patients must organise safe disposal of full sharps bins via their local council.
- Dose (no hormonal contraceptive use in previous month) 104 mg within first 5 days of cycle or within 5 days postpartum (delay until 6 weeks postpartum if breast-feeding). For long-term contraception, repeat every 13 weeks (if interval greater than 13 weeks and 7 days, rule out pregnancy before next injection)
- Especially effective in patients with a BMI > 30
|
08.03.02 |
Medroxyprogesterone Acetate Tablets |
- 2.5mg, 5mg, 10mg, 100, 200mg and 400mg tablets
- Specialist initiation only for endometrial cancer
|
10.01.01 |
Mefenamic Acid |
- 500mg tablets
- 250mg capsules
|
05.04.01 |
Mefloquine Lariam® |
- Treatment for Malaria is available on the NHS.
- Patients requiring Malaria prevention must acquire this on a private prescription
- BNF caution: mefloquine and driving - dizziness or a disturbed sense of balance may affect performance of skilled tasks e.g. driving; effects may occur and persist upto several months after stopping mefloquine.
- Tablets 250mg
|
08.03.02 |
Megestrol Acetate |
- 160mg tablets
- Specialist initiation only for endometrial cancer.
|
04.01.01 |
Melatonin Circadin MR 2mg ® |
For short-term treatment of insomnia in ADULTS in the following circumstances:
 In-patient use (maximum 3 weeks treatment) by Consultant Care of the Elderly as short-term treatment of insomnia. Not for continuation in Primary Care.
 GWH and SFT only: For epileptic adults with insomnia, who cannot have Z drugs due to effect on seizure threshold.
- Tablets 2mg m/r
- ONLY prescribe as the brand Circadin®
- Maximum licensed duration of use is 13 weeks.
- For use in paediatrics see paediatric section (chapter 16).
- Please note, the brand Slenyto for paediatric use is not on formulary.
|
16.04 |
Melatonin Circadin MR 2mg® |
- 2mg
- Melatonin MR 2mg tablets are approved for use only to aid sleep cycle synchronisation in children with sensory impairment, autistic spectrum disorder, in other neurodisability/neuropsychiatric/neurodevelopmental disorders (including ADHD when behaviour measures have been insufficient) and also to induce sleep in children undergoing sleep EEG.
- Melatonin MR 2mg tablets are licensed for use in adults over 55 years. Use in children is an 'off label' use.
|
16.04 |
Melatonin 5mg/5ml |
- Melatonin 5mg/5ml oral solution or suspension (alcohol free)
Unlicensed only in line with melatonin policy see here - link to add - 22/02/2020
- Melatonin is approved for use only to aid sleep cycle synchronisation in children with sensory impairment, autistic spectrum disorder, in other neurodisability/neuropsychiatric/neurodevelopmental disorders (including ADHD when behaviour measures have been insufficient) and also to induce sleep in children undergoing sleep EEG.
|
10.01.01 |
Meloxicam |
 - Swindon - Second-line after conventionals NSAIDs.
 - BaNES and Salisbury.
 - GWH ONLY - For the short-term prevention and treatment of post-operative pain in patients at high risk of bleeding with conventional NSAIDs (e.g. adult tonsillectomy, colorectal surgery, etc).
- 7.5mg and 15mg tablets.
|
08.01.01 |
Melphalan |
|
08.01.01 |
Melphalan |
- 50mg powder and solvent for injection
|
04.11 |
Memantine |
 BaNES and Wiltshire
 Swindon
- Tablets 10mg, 20mg
- 10mg/ml oral solution (sugar free)
- Orodispersible tablets (sugar free) 5mg, 10mg, 15mg, 20mg
- NB: As per the SCA, the use of orodispersible or liquid formulations of memantine should be clinically justified by compliance issues. Memantine orodispersible tablets may provide a more cost effective alternative to oral solution
|
09.06.06 |
Menadiol Sodium Phosphate Tablet |
- 10mg
- Menadiol sodium phosphate is water soluble and is included for use where patients have fat malabsorption.
- Water soluble and should be used to prevent vitamin k deficiency in malabsorption syndromes. Not licensed to reverse over anticoagulation with oral anticoagulants.
|
14.04 |
Meningococcal A, C, W135, and Y conjugate vaccine Menveo® |
- Menveo powder and solution for solution for injection
- Meningococcal Group A, C, W-135 and Y conjugate vaccine
- This vaccine is not available at NHS expense in Wiltshire/Bath/Swindon for Overseas Travel
|
14.04 |
Meningococcal group A, C, W-135 and Y conjugate vaccine Nimenrix® |
- This vaccine is not available at NHS expense in Wiltshire/Bath/Swindon for Overseas Travel
|
14.04 |
Meningococcal group B Vaccine Bexsero® |
|
14.04 |
Meningococcal Group C Polysaccharide Conjugate Vaccine Adsorbed NeisVac-C® |
|
14.04 |
Meningococcal polysaccharide A, C, W135 and Y vaccine ACWY Vax® |
- This vaccine is not available at NHS expense in Wiltshire/Bath/Swindon for Overseas Travel
|
03.08 |
Menthol and Eucalyptus Inhalation BP 1980 |
|
01.05.03 |
Mercaptopurine |
 - BaNES & Wiltshire
 - GWH - Swindon DAWN patients. Note: Only the 50mg strength tablets are included on the formulary for gastro indications in adults. The 50mg tablets are licensed but used 'off-label' for gastro indications e.g. severe ulcerative colitis and Crohn’s. 10mg strength tablets are unlicensed specials and prohibitively expensive when sourced in primary care. Alternate dosing using 50mg/100mg should be considered where daily doses between 50 and 100mgs are required for adults. For use in children see paediatric chapter.
- Please refer to our DMARD Shared Care and Monitoring Guidance below for further information.
|
08.01.03 |
Mercaptopurine |
- 50mg tablets
- Note: Only the 50mg strength tablets are included on the formulary for gastro indications in adults. 10mg strength tablets are unlicensed specials. Alternate dosing using 50mg/100mg should be considered where daily doses between 50 and 100mgs are required for adults.
- For use in children see paediatric chapter
- For use in Crohn's disease, see chapter 1
|
16.15 |
Mercaptopurine |
- Note: 10mg strength tablets are unlicensed specials and prohibitively expensive when sourced in primary care.
- 10mg strength tablets are included on the formulary only when used in paediatric patients (alternate dosing using 50mg/100mg should be considered where daily doses between 50 and 100mgs are required for adults).
- Prescribing in paediatric patients should be retained by secondary care.
|
05.01.02.02 |
Meropenem |
|
01.05.01 |
Mesalazine |
- Granules
- Salofalk® 500mg, 1g, 1.5g & 3g gastro-resistant, modified release granule sachets (First- line for all new UC patients, with 1.5g or 3g sachets most cost- effective).
- Pentasa® 1g, 2g & 4g modified-release granule sachets (Salisbury & Swindon ONLY).
- Tablets
- Octasa® 400mg & 800mg MR tablets (Second- line).
- Asacol MR® 400mg & 800mg MR tablets (Existing patients only).
- Salofalk® 250mg, 500mg & 1g gastro-resistant tablets.
- Pentasa® 500mg & 1g MR tablets (Salisbury & Swindon ONLY).
- Pentasa® 500mg MR tablets (BaNES - Existing patient only).
|
01.05.01 |
Mesalazine |
- Suppositories
- Salofalk® 500mg & 1g suppositories (First-line).
- Pentasa® 1g suppositoires.
- Foam Enemas
- Salofalk® 1g/application foam enema.
- Liquid Enemas
- Salofalk® 2g/59ml enema (First- line).
- Pentasa® 1g/100ml enema.
Please note: Asacol suppositories and foam enema have been removed from formulary, as they have been discontinued (2018). See link below for May 2020 supply disruption notice for rectal 5-ASA preparations.
|
08.01 |
Mesna |
- 400mg or 600mg tablets
- Chemotherapy induced neutropenic infection and nephrotoxicity
|
08.01 |
Mesna |
- 1m/10ml solution for injection
- Chemotherapy induced neutropenic infection and nephrotoxicity
|
13.02.02 |
Metanium® Barrier ointment |
- Ointment 30g,
- Contains titanium
|
02.07.02 |
Metaraminol |
|
06.01.02.02 |
Metformin |
- 500mg, 850mg tablets, Oral solution (100mg/ml)
- The EMA has concluded that metformin-containing medicines can now be used in patients with moderately reduced kidney function (GFR [glomerular filtration rate]=30–59 ml/min) for the treatment of type 2 diabetes.
|
06.01.02.02 |
Metformin MR |
- 500mg, 750mg, 1g (Sukkarto SR 500mg, 1g)
- Prescribe by brand
- Note: Metformin MR should only be used where the standard-release tablets have been tried and are not tolerated due to GI problems. Metformin SR tablets are supported purely as an attempt to ensure the largest number of patients are able to stay on metformin therapy, hopefully delaying progression to other new drugs which often have a reduced evidence base and/or additional safety concerns.
|
04.07.02 |
Methadone |
- Tablets 5mg
- Oral Solution 1mg/ml
- For treatment of substance misuse see section 4.10.3
|
04.10.03 |
Methadone |
- Injection 10mg/1ml, 20mg/2ml, 50mg/1ml
|
04.10.03 |
Methadone |
- Oral solution 1mg/1ml
- Oral solutionSF 1mg/1ml
|
21.01.01.02 |
Methadone |
- Tablets 5mg
- Oral Solution 1mg/ml
- Only on recommendation of palliative care specialist
|
05.01.13 |
Methenamine Hippurate Tablet |
- Tablets 1g
- Methenamine can be considered if there is no renal or hepatic impairment.
- Might be recommended by a urologist for prophylaxis in patients with
recurrent UTIs.
|
15.01.01 |
Methohexital |
|
01.05.03 |
Methotrexate |
 - BaNES, Salisbury & Swindon (except Swindon patients monitored via the DAWN system and provided with prescriptions by GWH).
 - GWH - Swindon DAWN patients.
- 2.5mg tablets ONLY.
- Please note: Methotrexate is administered weekly.
- Please refer to our DMARD Shared Care and Monitoring Guidance for your respective locality for further information.
|
08.01.03 |
Methotrexate |
|
10.01.03 |
Methotrexate |
- 2.5mg tablets ONLY. There should be no prescribing of 10mg tablets. Please refer to NPSA guidance on reducing the risks of oral methotrexate. Patients should have patient held records while they are receiving treatment with any DMARD requiring regular monitoring (record cards and GP protocol advice available from rheumatology).
- The label on prescribed/dispensed methotrexate should state the instructions clearly, for example: ‘methotrexate 2.5mg tablets: (number of tablets) to be taken as a single dose ONCE A WEEK on XXX DAY’.
- Note: Folic Acid 10mg is usually given ONCE A WEEK with methotrexate to reduce side effects. It should NOT be taken on the same day as the methotrexate.
-
 - BaNES and Wiltshire
-
 - Swindon DAWN patients.
- Please refer to our DMARD Shared Care and Monitoring Guidance below for further information.
|
10.01.03 |
Methotrexate |
- When self-adminstering subcutaneous methotrexate, patients should be maintained on the product they were initiated / trained on. Local formulary brands listed below:
- Metoject® 50mg/ml Injection prefilled pen 0.15ml (7.5mg), 0.2ml (10mg), 0.3ml (15mg), 0.4ml (20mg), 0.5ml (25mg), 0.6ml (30mg)
Metoject is a pre-filled pen type device Local brand of choice Instruction guide for Metoject
- Zlatal® 25mg/ml Injection prefilled syringe 0.3ml (7.5mg), 0.4ml (10mg), 0.5ml (12.5mg), 0.6ml (15mg), 0.7ml (17.5mg), 0.8ml (20mg), 0.9ml (22.5mg), 1ml (25mg)
Zlatal is a prefilled syringe For those who need to use a syringe and needle Instruction guide for Zlatal
-
 BaNES & Wiltshire patients.
 for Swindon DAWN patients.
- Please refer to our DMARD Shared Care and Monitoring Guidance for further information.
|
13.05.03 |
Methotrexate |
- Tablets 2.5mg
- For severe psoriasis
|
13.05.03 |
Methotrexate |
- Prescribe by brand
- Metoject® 50mg/ml Injection prefilled pen 0.15ml (7.5mg), 0.2ml (10mg), 0.3ml (15mg), 0.4ml (20mg), 0.5ml (25mg), 0.6ml (30mg)
- Zlatal® 25mg/ml Injection prefilled syringe 0.3ml (7.5mg), 0.4ml (10mg), 0.5ml (12.5mg), 0.6ml (15mg), 0.7ml (17.5mg), 0.8ml (20mg), 0.9ml (22.5mg), 1ml (25mg) For patients who need to use a syringe and needle.
- sc injection
- For severe psoriasis in patients unable to tolerate oral methotrexate
|
04.07 |
Methoxyflurane Penthrox® |
- 3 ml inhalation vapour, liquid
RUH ONLY - for emergency relief of moderate to severe pain and to facilitate the treatment of fractures and joint dislocations, in conscious adult patients who have suffered a traumatic injury.
Not on formulary at SFT or GWH |
13.05.02 |
Methoxypsoralen |
- 8-methoxypsoralen 10mg tablets
- 5-methoxypsoralen 20mg tablets
- 8-methoxypsoralen 1.2 % bath solution 30 ml
- Puvasoralen gel 0.005%
- Only for presribing by dermatologists in secondary care. For photochemotherapy combining long-wave ultraviolet A radiation with a psoralen (PUVA) treatment only.
|
01.06.01 |
Methycellulose |
 - BaNES - For use in patient with high output ileostomies.
- Non-formulary - Salisbury & Swindon.
- 500mg tablets.
|
13.08.01 |
Methyl-5-Aminolevulinate Metvix® |
- 160 mg/g cream
- SFT and GWH; Restricted for use by the dermatology treatment centre only as part of photodynamic therapy.
|
02.05.02 |
Methyldopa |
- Tablets 250mg, 500mg
- For the treatment of hypertension in pregnancy only
|
21.01.05 |
Methylnaltrexone |
- 12 mg/0.6 mL
- Opioid induced constipation in terminal illness when response to other laxatives inadequate.
- Formulary status under review
|
16.05 |
Methylphenidate Concerta® XL, Xaggitin XL, Medikinet XL, Equasym® XL |
- Xaggitin® XL Modified release tablet 18mg, 27mg, 36mg, 54mg - First line for new patients as the most cost-effective formulary choice locally
- Concerta® XL Modified release tablet 18mg, 27mg, 36mg,54mg: existing patients only.
- Equasym® XL Modified release capsule 10mg, 20mg, 30mg
- Prescribe by brand Modified release brands provide different release profiles of methylphenidate and switching brands should only be considered following specialist advice.
|
16.05 |
Methylphenidate |
|
04.04 |
Methylphenidate Hydrochloride MR |
- Xaggitin® XL Modified release tablet 18mg, 27mg, 36mg, 54mg - First line for new patients as the most cost-effective formulary choice locally
- Concerta® XL Modified release tablet 18mg, 27mg, 36mg,54mg : existing patients only.
- Equasym® XL Modified release capsule 10mg, 20mg, 30mg
Note: SCA for Adults link below. SCA for Paeds see Chapter 16 |
06.03.02 |
Methylprednisolone |
|
06.03.02 |
Methylprednisolone acetate Depo-Medrone ® |
- Injection (as acetate - Depot-Medrone) 40mg in 1ml, 80mg in 2ml
|
10.01.02.02 |
Methylprednisolone Acetate Depo-Medrone® |
- 120mg/3ml, 40mg/1ml and 80mg/2ml injection
|
06.03.02 |
Methylprednisolone Sodium Succinate Solu-Medrone ® |
- 40mg, 125mg, 500mg, 1g, 2g.
|
18 |
Methylthioninium chloride Proveblue® |
|
01.02 |
Metoclopramide |
 - For short-term use.
 - For long-term use (off-label).
- 10mg tablets.
- 5mg in 5ml SF oral solution (Salisbury & Swindon ONLY).
- Please note: Metoclopramide should be used with caution in patients under 20 years of age due to the risk of extrapyramidal effects.
- Metoclopramide is also available for prevention or treatment of nausea and vomiting. Please refer to Chapter 4 (CNS).
|
04.06 |
Metoclopramide |
 for short-term use (maximum 5 days)
 for long-term use (off-label)
- Tablet 10mg
- Syrup 5mg in 5ml
- Injection 10mg in 2ml
- Metoclopramide and prochlorperazine are associated with a high risk of dystonias and oculogyric crises particularly in children, young adults and the elderly.
- Severe reactions to metoclopramide should be treated with procyclidine injection
- Metoclopramide should not be prescribed for patients with Parkinson's disease.
|
21.01.02 |
Metoclopramide |
- Tablet 10mg
- Syrup 5mg in 5ml
- Metoclopramide and prochlorperazine are associated with a high risk of dystonias and oculogyric crises particularly in children, young adults and elderly.
- Severe reactions to metoclopramide should be treated with procyclidine injection
|
21.02.02 |
Metoclopramide |
- 100mg/20ml, 10mg in 2ml
- Metoclopramide and prochlorperazine are associated with a high risk of dystonias and oculogyric crises particularly in children, young adults and the elderly. Severe reactions to metoclopramide should be treated with procyclidine injection
|
02.02.01 |
Metolazone |
- Tablets 2.5mg
- Metolazone is significantly more potent than bendroflumethiazide and will cause profound diuresis in combination with furosemide. Careful monitoring is required to avoid electrolyte disturbance and dehydration.
|
02.04 |
Metoprolol |
|
02.04 |
Metoprolol |
- Tablets 50mg, 100mg
- Specialist initiation only. Consider changing to alternative beta blocker once stable. See BNF for details.
|
05.01.11 |
Metronidazole |
|
05.01.11 |
Metronidazole |
- Tablets 200mg, 400mg
- Oral suspension 200mg/5ml
- Suppositories 500mg, 1g
|
05.04.02 |
Metronidazole |
|
05.04.04 |
Metronidazole |
|
07.02.02 |
Metronidazole Zidoval® |
- 0.75% vaginal gel
- Antibiotic guidance recommends metronidazole (both vaginally and orally) for the treatment of bacterial vaginosis.
|
13.06 |
Metronidazole 0.75% Cream |
- Cream 0.75% 30g, 40g
- Treatment of pustules and erythema of rosacea
- Notes: Topical metronidazole preparations are licensed for different indications: rosacea (Rozex®) and malodorous tumours and skin ulcers (Anabact®). Therefore, it is important to prescribe the appropriate branded product.
|
13.10.01.02 |
Metronidazole 0.75% Anabact |
- 15g, 30g
- Notes: Topical metronidazole preparations are licensed for different indications: rosacea (Rozex®) and malodorous tumours and skin ulcers (Anabact®). Therefore, it is important to prescribe the appropriate branded product.
|
06.07.03 |
Metyrapone |
- ONLY for short-term use prior to either surgery for adrenal cancer or pituitary surgery for Cushing’s disease (See NHSE Clinical Commissioning Policy for pathway for medical treatment of Cushing’s disease below)
- Note: Metyrapone is used for Cushing’s syndrome, often in a lower dose combination with aminoglutethamide to reduce side effects.
- 250mg capsules
|
07.02.02 |
Miconazole Gyno-Daktarin® |
- 2% vaginal cream 78g
- Patients should be advised that miconazole products might damage latex condoms and diaphragms.
|
12.03.02 |
Miconazole |
|
13.10.02 |
Miconazole 2% |
|
15.01.04.01 |
Midazolam |
- 5mg in 5ml injection
- 10mg/2ml injection
|
21.02.04 |
Midazolam |
- 10mg/2ml
- For restlessness, anxiety and agitation
- Can be used in syringe drivers
- See page 89/90 Wessex Palliative Care Handbook (link at start of chapter)
|
21.03 |
Midazolam |
- Community Just In Case Boxes
- For restlessness, anxiety and agitation
|
04.08.02 |
Midazolam Maleate Epistatus® |
- Epistatus® Oromucosal solution prefilled single syringe 10mg/1ml (licensed in adolescents from 10 years to less than 18 years)
- Epistatus® Oromucosal solution 10mg/ml prefilled syringes: 2.5mg/0.25ml, 5mg/0.5ml, 7.5mg/0.75ml, (unlicensed). Individually wrapped in a pack of 4.
- Do not prescribe Oromucosal solution 10mg/ml multidose 5ml bottle. In primary care, all patients should use the pre-filled syringe format as this is what the specialist primary care nursing team can provide training on for carers/schools/nurseries/after-school clubs etc.
- Prescribe by BRAND (NB Buccolam brand is a different salt, STRENGTH and volume)
|
21.01.04 |
Midazolam Maleate Epistatus® |
- Epistatus® Oromucosal solution prefilled single syringe 10mg/1ml
- Epistatus® Oromucosal solution 10mg/ml prefilled syringes: 2.5mg/0.25ml, 5mg/0.5ml, 7.5mg/0.75ml, (unlicensed). Individually wrapped in a pack of 4.
- Prescribe by BRAND (NB Buccolam brand is a different salt, STRENGTH and volume)
- In the palliative care setting PRN use only
|
16.07 |
Midazolam Maleate Oromucosal Epistatus® |
- Epistatus® Oromucosal solution prefilled single syringe 10mg/1ml (licensed in adolescents from 10 years to less than 18 years)
- Epistatus® Oromucosal solution 10mg/ml prefilled syringes: 2.5mg/0.25ml, 5mg/0.5ml, 7.5mg/0.75ml, (unlicensed). Individually wrapped in a pack of 4.
- Do not prescribe Oromucosal solution 10mg/ml multidose 5ml bottle. In primary care, all patients should use the pre-filled syringe format as this is what the specialist primary care nursing team can provide training on for carers/schools/nurseries/after-school clubs etc.
- Prescribe by BRAND (NB Buccolam brand is a different salt, STRENGTH and volume)
- See Shared Care Guidelines: Use of Oromucosal Midazolam as an intervention for prolonged seizures and prevention od Status Epilepticus in children under 10 years of age
 Swindon only - when used for sedation and pre-med in theatres
|
02.07.02 |
Midodrine |
- 2.5mg, 5mg (licensed alpha agonist)
- For the treatment of orthostatic postural hypotension and intradialytic hypotension
|
08.01.05 |
Midostaurin |
|
08.02.04 |
Mifamurtide |
- 4mg infusion
- When used in line with NICE TA235 (as below) and initiated by specialist centres ONLY
|
07.01.02 |
Mifepristone Mifegyne® |
- ONLY for consultant obstetrician and gynaecologist prescribing AND in accordance with RCOG guidelines.
|
02.01.02 |
Milrinone |
- 1mg/ml solution for injection/infusion.
- Included as adjunct for severe congestive cardiac failure and acute heart failure.
- RUH only. Non formulary at SFT and GWH.
|
07.04.02 |
Mirabegron |
- Tablets MR 25mg, 50mg
- For use where anti-muscarinics have been ineffective or not tolerated or Mirabegron can be used FIRST line in high risk patients (those at risk of falls or have contra-indications to anti-muscarinics e.g.Elderly /Frail /Dementia/Parkinsons. See OAB guidance (below)
- Contraindicated in patients with severe uncontrolled hypertension (systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥110 mm Hg, or both).
COMBINATION USE OF MIRABEGRON PLUS SOLIFENACIN (AMBER TLS): This regimen is not licensed in the UK but might be recommended by a urology specialist after a patient has had urodynamics, with proven detrusor over-activity. Such use may be taken on by a GP if they are happy to take on the prescribing responsibility. See OAB guidance (below). |
04.03.04 |
Mirtazapine |
- Tablets 15mg, 30mg, 45mg
- Orodispersible tablets 15mg, 30mg, 45mg
- Oral solution 15mg/ml
- Mirtazapine soluble tablets are more expensive than standard formulation. They should be reserved for patients with swallowing difficulties only.
- Mirtazepine oral solution is only for use via enteral feeding tubes.
- Mirtazapine appears to be safe in overdose and is thought to cause less insomnia, anxiety and agitation.
- Sexual dysfunction is rare and the likelihood of drug interactions is low. Weight gain may be significant.
|
07.01.01 |
Misoprostol |
- Misoprostol 200micrograms tablets
- Unlicensed indication/route of administration. Such use of misoprostol is supported by the Royal College of Obstetricians and Gynaecologists guideline development group.
|
08.01.02 |
Mitomycin |
|
08.01.02 |
Mitoxantrone |
|
15.01.05 |
Mivacurium |
- GWH only
- Injection 2 mg/ml
|
04.03.02 |
Moclobemide |
- Tablets 150mg, 300mg
- Patients should avoid consuming large amounts of tyramine-rich food (such as mature cheddar, yeast extracts, red wine and fermented soya bean products) and sympathomimetics (such as ephedrine, pseudoephedrine and phenylpropanolamine).
- Patients should be advised to take last dose before 3pm in order to minimise sleep disturbance / insomnia.
- Refer the patient to the patient information leaflet (PIL) supplied with the product for dietary restrictions.
|
04.04 |
Modafinil |
- Tablet 100mg, 200mg
- Narcolepsy should be diagnosed and treatment initiated by a specialist physician.
|
12.02.01 |
Mometasone Furoate |
- Nasal spray 50 micrograms per spray
- First line for treatment of allergic rhinits (prescribe generically)
- For ENT initiation only for the treatment of nasal polyps.
|
13.04 |
Mometasone Furoate 0.1% Elocon® |
- Potent steroid
- Cream, ointment 0.1% 30g, 100g
|
20 |
Monsels Ferris Subsulphate Solution |
- GWH Obstetric and Gynae OP stock
|
03.03.02 |
Montelukast |
- Granules 4mg sachets sugar-free (6 months to 5 years of age)
- Chewable tablets 4mg (2 to 5 years of age)
- Chewable tablets 5mg (6 to 14 years of age)
- Tablets 10mg (>14 years of age)
- NICE guidance (NG80, November 2017) recommends an LTRA as the first add-on maintenance therapy with ICS and SABA inhalers for the treatment in asthma. A LABA is an option (with/without the LTRA) in addition to an ICS if asthma remains uncontrolled. This is a more cost effective model.
- Existing BTS/SIGN continues the long-held view that low dose ICS should be followed by addition of LABA (in line with international guidelines such as GINA).
- Head to head comparisons of ICS/LABA compared to ICS/LTRA have favoured ICS/LABA for effectiveness in adults (inconclusive in children).
Notes:
|
21.02.01 |
Morphine |
- For pain
- 5mg/5ml, 10mg/ml, 15mg/ml, 20mg/ml, 30mg/ml
- Can be used in syringe drivers
- If eGFR known to be less than 30 mL/min please liaise with specialist palliative care
- See page 89/90 Wessex Palliative Care Handbook (link at start of chapter)
|
21.03 |
Morphine Injections 10mg /ml |
- Community Just In Case Boxes
- For pain
- Use first line
|
03.09.01 |
Morphine Hydrochloride |
Non-formulary - RUH
 - SFT (for intractable cough)
Non-formulary - GWH
|
04.07.02 |
Morphine Sulphate Sevredol® |
- 10mg,20mg,50mg immediate release tablets
- Sevredol® tablet - 4 hourly dosing
|
04.07.02 |
Morphine Sulphate |
- Injection 10mg/1ml, 30mg/1ml
|
21.01.01.02 |
Morphine Sulphate Sevredol® |
- 10mg,20mg,50mg immediate release tablets
- Sevredol® tablet - 4 hourly dosing
|
04.07.02 |
Morphine Sulphate 5mg MST Continus |
- 5mg prolonged-release tablets ONLY on formulary to allow dose titration
|
04.07.02 |
Morphine Sulphate M/R Zomorph® |
- m/r capsule 10mg, 30mg, 60mg, 100mg, 200mg
- 12 hourly dosing
- Zomorph can be opened and the contents administered in semi-solid food for patients with swallowing difficulties.
- Zomorph is also licensed for use via gastric or gastronomy tubes (diameter >16F.G.).
- There is no evidence of superior clinical analgesic effect of other opioids over morphine.
- Prescribe by brand name.
|
21.01.01.02 |
Morphine Sulphate M/R Zomorph® |
- m/r capsule 10mg, 30mg, 60mg, 100mg, 200mg
- 12 hourly dosing
- Zomorph can be opened & contents administered in semi-solid food for patients with swallowing difficulties.
- Zomorph also licensed for use via gastric or gastronomy tubes (diameter >16F.G.).
- There is no evidence of superior clinical analgesic effect of other opioids over morphine.
|
21.01.01.02 |
Morphine Sulphate solution Oramorph® |
- 10mg/5ml Schedule 5 (CD Inv)
- 100mg/5ml Schedule 2 (CD)
- 4 hourly dosing PRN
|
04.07.02 |
Morphine Sulphate solution 10mg/5ml Oramorph® |
- 10mg/5ml Schedule 5 (CD Inv)
- 4 hourly dosing PRN
- Oramorph Oral Solution contains ethanol (alcohol). Each 10 ml dose contains contains up to 810 mg of alcohol, which is equivalent to 81 mg/ml (10%v/v). The amount of alcohol in 10 ml of this medicine is equivalent to 20 ml beer or 8 ml wine. To be taken into account in pregnant or breast-feeding women, children and and those addicted to alcohol.
- This product contains 3 g sucrose in each 10 ml dose. This product also contains 1 g corn syrup, which contains glucose, in each 10 ml dose. This should be taken into account in patients with diabetes mellitus. May be harmful to the teeth. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency should not take this medicine.
|
01.06.05 |
Moviprep® Oral Sachet |
- 1 pair of sachets (A+B), providing when reconstituted to 1 litre with water Na+ 181.6 mmol (Na+ 56.2 mmol absorbable), K+ 14.2 mmol & Cl– 59.8 mmol.
|
05.01.12 |
Moxifloxacin |
- GWH only for use by ophthalmology for endophthalmitis and for sexual health indications.
- The EMA’s Pharmacovigilence Risk Assessment Committee has recommended restricting fluoroquinolones following a review of disabling & potentially long-lasting side-effects. See link above for further information.
- 400mg tablets
|
11.03.01 |
Moxifloxacin |
- 400mg tablets
- GWH only - For the treatment of endophthalmitis, 400mg OD for 10 days.
- Non formulary at RUH and SFT
|
02.05.02 |
Moxonidine |
- Tablets 200, 300, 400 micrograms
- The BNF recommends that moxonidine may have a role when thiazides, beta-blockers, ACE inhibitors and calcium channel blockers are not appropriate or have failed to control blood pressure. Use outside these indications is not recommended.
|
09.06.07 |
Multivitamin Renavit® |
- Tablets containing vitamins B1, B2, B3, B5, B6, B8, B9, B12
- For BaNES patients seen by renal specialist team at NBT as per SCA.
- Vitamin deficiencies are common in patients with renal disease due to dietary restrictions, changes to metabolism and vitamin loss during dialysis.
- Renavit® should only be initiated by a renal dietician- ongoing prescribing in primary care is acceptable.
- Haemodialysis: 1 tablet post dialysis 3 times a week Peritoneal Dialysis: 1 tablet daily
|
09.06.07 |
Multivitamin preparations Abidec® |
- Contains less vitamin A than Dalivit®.
- For neo-nates prescribe as per SCBU guidelines.
- Substitute with Dalivit® if Abidec® unavailable - Dalivit® dose should not exceed 0.3ml daily in neo-nates.
|
09.06.07 |
Multivitamin preparations Dalivit® |
- Used for cystic fibrosis patients and adults, as Abidec® is not suitable for anyone > 12years.
|
12.02.03 |
Mupirocin 2% Bactroban ® |
- Mupirocin (Bactroban® nasal) is of value when the carriage of Staphlococcus aureus in the nose or ears has to be cleared.
- To avoid the development of resistance, the treatment course should not exceed 7 days and the course not repeated on more than one occasion
|
13.10.01.01 |
Mupirocin 2% Bactroban® |
- Topical Cream, 2%
- Notes: Mupirocin ointment and cream are not interchangeable - the prescription should specify formulation required.
|
09.06.07 |
Mutivitamin tablets |
|
10.01.03 |
Mycophenolate |
-
 - BaNES & Wiltshire patients
-
 - Swindon DAWN patients
- Please refer to our DMARD Shared Care and Monitoring Guidance below for further information
- 500mg tablets
|
13.05.03 |
Mycophenolate |
- Tablets 500mg
- Severe refractory inflammatory disease and pemphigus (unlicensed use)
|
08.02.01 |
Mycophenolate Mofetil Oral |
- 250mg capsules
- 500mg tablets
|
11.08.02 |
Mydrane Injection |
GWH Eye Theatre Use Only During Post COVID-19
- Intracameral injection
- Added to formulary for 6 months during post COVID-19 (review date Jan 21)
|
06.07.02 |
Nafarelin |
- Not on formulary in SFT
- For fertility treatment.
- 200 micrograms / metered spray
|
02.06.04 |
Naftidrofuryl |
- 100mg
- For the treatment of intermittent claudication in people with peripheral arterial disease in according to NICE TA below.
|
01.06.06 |
Naldemedine |
- 200 microgram tablet
- Note: BSW Guidance on the Management of Constipation in Adults is currently being updated in line with NICE TA 651
|
04.10.01 |
Nalmefene |
 BaNES due to commissioned service
-
 Wiltshire and Swindon
- Tablets 18mg
- NICE recommended for reducing alcohol consumption in people with alcohol dependance- see link below
- Notes: Prescribing should be an adjunct to psychological therapy. Detoxification from alcohol should not take place in isolation and be supported with a post detoxification care plan.
|
01.06.06 |
Naloxegol |
- 12.5mg & 25mg tablets.
- Please note: This may be considered as an option for treatment of opioid- induced constipation in adults, whose constipation has failed to adequately respond to laxatives appropriately escalated in accordance with our BSW Guidance on the Management of Constipation in Adults (2018), and in whom stopping opiates would be clinically inappropriate.
|
21.01.05 |
Naloxegol |
- 12.5mg & 25mg tablets.
- Please note: This may be considered as an option for treatment of opioid- induced constipation in adults, whose constipation has failed to adequately respond to laxatives appropriately escalated in accordance with our BSW Guidance on the Management of Constipation in Adults (2018), and in whom stopping opiates would be clinically inappropriate.
|
04.10.03 |
Naloxone |
- 400 micrograms in 1ml amp
- Reversal of CNS/Respiratory Depression
|
15.01.07 |
Naloxone |
|
04.10.01 |
Naltrexone |
|
04.10.03 |
Naltrexone |
- BaNES and Swindon only
- Tablets 50mg (generic) for AWP / CDAS
-
Notes: Naltrexone should be initiated by a specialist in the field of substance misuse. However, it may be prescribed on an on-going basis by a primary care prescriber for the maintenance of abstinence from opioids (or alcohol or for mild alcohol dependence) following advice from a specialist practitioner.
|
10.01.01 |
Naproxen |
- 250mg and 500mg tablets
- Oral suspension and effervescent tablets available
- No evidence for GI benefit of EC preparation - use standard tablets.
|
21.01.01.01 |
Naproxen |
- 250mg and 500mg tablets
- Oral suspension and effervescent tablets available
- No evidence for GI benefit of EC preparation - use standard tablets.
|
21.01.01.04 |
Naproxen |
- 250mg and 500mg tablets
- Oral suspension and effervescent tablets available
- No evidence for GI benefit of EC preparation - use standard tablets.
|
08.02.04 |
Natalizumab |
|
02.04 |
Nebivolol |
- 2.5 and 5mg tablets
- Note: not on formulary in BaNES
|
A2.03.01 |
Neocate Active |
(AAF) for over one year (can continue with LCP in most cases) |
A2.03.01 |
Neocate Advance |
(AAF) Specialist milk for children over one year who are not having significant amounts of solid foods |
A2.03.01 |
Neocate LCP |
(AAF) from birth to one year |
15.01.06 |
Neostigmine |
|
15.01.06 |
Neostigmine with Glycopyrronium injection |
- 500 micrograms in 1ml amp
|
11.08.02 |
Nepafenac Nevanac |
- Salisbury only
- Non formulary in BaNES and Swindon
|
05.03.01 |
Nevirapine Viramune® |
- Tablets 200mg
- Tablets 400mg M/R
- Suspension 50mg/5ml
|
02.06.03 |
Nicorandil |
- Tablets 10mg, 20mg
- Not to be used as first line treatment for angina; risk of ulcerations and progression to complications - stop treatment if ulceration occurs.
- Treatment of stable angina only in patients whose angina is inadequately controlled by first line anti-anginal therapies or who have contraindications or intolerance to first line anti-anginal therapies such as beta-blockers and/or calcium antagonists.
- Can cause serious skin, mucosal and eye ulceration which persists unless treatment is discontinued.
|
09.06.02 |
Nicotinamide |
- 50mg for dermatology use - see BSWformulary section 13.5.3
- Tablets 500mg (unlicensed) for oncology use (with radiotherapy & carbogen for bladder cancer) as per NICE NG2
|
13.05.03 |
Nicotinamide |
- RUH/GWH only
- Tablets 500mg (Niacinamide)
- For blistering diseases as a safer alternative to prednisolone, usually in combination with tetracycline.
|
04.10.02 |
Nicotine |
- 16 hour transdermal patch 5mg, 10mg, 15mg, 25mg
- 24 hour transdermal patch TTS 10 (7mg), TTS 20 (14mg), TTS 30 (21mg)
- Inhalator 15mg cartridge
- Chewing gum 2mg, 4mg, 6mg
- Lozenge 1mg, 1.5mg, 2mg, 4mg
- Sublingual microtab 2mg
- Nasal spray 10mg/ml, 0.5mg/dose
- Oromucosal spray 1mg per dose
|
02.06.02 |
Nifedipine |
- Immediate Release Capsules 5mg, 10mg. NOTE: for Raynaud’s phenomenon only. Please also note that immediate release brand Adalat is discontinued; Generic version now available from Relonchem but at higher price (Dec 2019 – approx. £60 per 90 capsules).
-
Modified Release capsules 30mg, 60mg (once daily preparation) and Modified Release tablets 20mg, 30mg, 60mg (once daily preparation).
- Different versions of MR nifedipine preparations may not have the same clinical effect. Prescribers should specify the brand to be dispensed.
- Note: Supply problems
|
07.01.03 |
Nifedipine |
- GWH only - For the initial management of preterm labour (off-label indication)
- Non formulary at RUH and SFT
- For use in hypertension or angina and note on supply problems see section 2.6.2
|
08.01.05 |
Nilotinib |
|
02.06.02 |
Nimodipine |
- Infusion 200mg/ml
- Tablets 30mg
- For the prevention and treatment of ischaemic neurological deficits following subarachnoid haemorrhage.
|
08.01.05 |
Nintedanib |
|
08.02.04 |
Niraparib |
|
05.01.13 |
Nitrofurantoin |
Nitrofurantoin may be used with caution if eGFR 30-44ml/min, if potential benefit outweighs risk.
- Tablets 50mg or 100mg.
- Modified release capsules 100mg
- The SPC for nitrofurantoin has been updated to state that doses should always be taken with food, as this increases absorption and increases dose efficacy.
- NB Liquid is very high cost. Drug Tariff June 2020: £525 per bottle.
|
15.01.02 |
Nitrous oxide |
- Nitrous oxide cylinders size D, E, G
|
15.01.02 |
Nitrous oxide 50% with oxygen 50% Entonox ® |
- Nitrous oxide 50% with oxygen 50% (Entonox) cylinders size D,F,G
- Note: MHRA safety notice Neurological and haematological toxic effects can occur with prolonged use of nitrous oxide. Neurological effects can occur without preceding overt haematological changes.
Assessment of vitamin B12 levels should be considered before nitrous oxide anaesthesia in people with risk factors for deficiency.
|
08.02.04 |
Nivolumab |
|
02.07.02 |
Noradrenaline / Norepinephrine |
- 8mg in 50ml pre-filled syringe (unlicensed)
|
06.04.01.02 |
Norethisterone |
- 5mg
- This preparation is not licensed for HRT
|
07.03.02.01 |
Norethisterone Noriday® |
- Tablets containing norethisterone 350 micrograms
- Recommended for patients previously on Micronor - discontinued 2017
- Note: If administration is delayed for 3 hours or more it should be regarded as a ‘missed pill'.
|
08.03.02 |
Norethisterone |
- 350microgram and 5mg tablets
- Specialist initiation only for endrometrial cancer.
|
07.03.02.02 |
Norethisterone enantate Noristerat® |
- 200mg norethisterone enantate in 1ml oily solution
- Noristerat® oily injection provides contraception for 8 weeks. Intended for short-term use when a high level of efficacy independent of possible errors by the patient is required. It has been licensed for short-term use by women whose partners undergo vasectomy, until the vasectomy is effective, and women immunised against rubella, to prevent pregnancy during the period of activity of the virus.
|
04.07.03 |
Nortriptyline |
- Tablets 10mg, 25mg
- 'Off label' use for neuropathic pain
- Specialist initiation
- Should only be used if amitriptyline isn't tolerated or is contra indicated
- More expensive than amitriptyline. NB 1x25mg significantly more cost effective than 3 x 10mg tablets
|
21.01.01.03 |
Nortriptyline |
- Tablets 10mg, 25mg
- 'Off label' use for neuropathic pain
- Should only be used if amitriptyline isn't tolerated or is contra indicated
|
09.03 |
Nutilis Clear® |
|
09.04.02 |
Nutilis Fruit Dessert Level 4 |
- 150g pot
- See ONS guidance for full product details (link at top)
|
A2.02.02.02 |
Nutilis Fruit Dessert Level 4 |
150 g pot
28 day supply = 84 desserts, 12,600 ml
206 kcals, 10.5 g protein
IDDSI Level 4 - Extremely thick |
A2.03.01 |
Nutramigen 1 with LGG |
From birth |
A2.03.01 |
Nutramigen 2 with LGG |
From 6 months |
A2.03.01 |
Nutramigen Puramino |
(AAF) from birth |
09.04.02 |
Nutricrem |
- FIRST LINE for Dysphagia Level 4 ONS
- 125g pot
- See ONS guidance for full product details (link at top)
|
A2.02.02.01 |
Nutricrem® |
DYSPHAGIA LEVEL 4 - Only for those who require level 4 thickened fluids
125 g pot
28 day supply = 84 desserts, 10,500 ml
225 kcals, 12.5 g protein
IDDSI Level 4 - moderately thick |
12.03.02 |
Nystatin |
- Always prescribe by BRANDNAME in primary care to get most cost-effective version.
- 100,000 units/ml 30ml bottle
- Dose: ADULT and CHILD over 2 years, 100 000 units 4 times daily
- Due to the high sucrose content of nystatin suspension, 500mg/1ml, ensure that diabetic patients are aware of this.
- Nystatin is the first line choice, however miconazole may be considered due to the differing formulations.
|
13.04 |
Nystatin 100,000IU/g / Chlorhexidine 1% / Hydrocortisone 0.5% |
- Mild potency steroid
- Previously known as Nystaform HC which is discontinued. Prescribe generically.
- Cream, Ointment x 30g
- Cream Useful for babies and children with recurrently infected eczema on face due to antiseptic content.
- Ointment Useful for babies and very young children with recurrently infected eczema on trunk and limbs due to antiseptic content
|
01.09.01 |
Obeticholic acid Ocaliva® |
- Non- formulary - GWH, RUH & SFT - Not specialist centres.
- 5mg & 10mg tablets.
- Please note: This is ONLY available via specialist tertiary centres, in accordance with NHSE's circular "Technology Appraisal 443: Obeticholic acid for treating primary biliary cholangitis (PBC)" dated 26th June 2017.
|
08.02.03 |
Obinutuzumab |
|
08.02.03 |
Ocrelizumab |
|
13.11.05 |
Octenidine Octenisan® |
- Antimicrobial hair and body wash containing octenidine.
- 150ml or 500ml bottles
- GWH and SFT use as part of MRSA decolonisation protocols
|
08.03.04.03 |
Octreotide Sandostatin Lar® |
 Swindon - relief of symptoms associated with acromegaly
- 10mg, 20mg and 30mg injection
- Commissioned by NHS England, as per agreed Trust Guidelines. Use product with lowest procurement cost
- Carcinoid Syndrome and Neuroendocrine Tumours
- For the treatment of acromegaly
|
08.03.04.03 |
Octreotide |
- 50microgram/1ml, 100microgram/1ml
- Also see palliative care chapter for use in management of high output stomas and fistulas
|
21.02.03 |
Octreotide |
- 50microgram/1ml, 100microgram/1ml
- For the short term management of high output stomas and fistulas and bowel obstructions
- Octreotide is best administered in a separate syringe driver. Please phone palliative care advice lines before mixing in a syringe driver.
|
06.04.01.01 |
Oestrogen only HRT Elleste-Solo® |
- estradiol (1mg, 2mg)
- 1 prescription charge
|
06.04.01.01 |
Oestrogen only HRT Evorel |
- estradiol (25 micrograms, 50 micrograms, 75 micrograms, 100 micrograms)
- Change twice a week.
|
06.04.01.01 |
Oestrogen only HRT Oestrogel |
- 0.06% oestradiol gel
- 0.75mg estradiol per measure, 2 measures=standard regime
|
06.04.01.01 |
Oestrogen only HRT Premarin |
- conjugated oestrogens (300 micrograms, 625 micrograms, 1.25 milligram)
- 1 prescription charge
|
06.04.01.01 |
Oestrogen only HRT Estradot |
- estradiol (25, 37.5, 50, 75, 100 micrograms)
- Change twice a week.
|
06.04.01.01 |
Oestrogens for HRT Progynova® |
- RUH only Specialist use fertility treatment (not HRT)
- Not on formuary in Salisbury or Swindon.
- 1mg or 2mg estradiol valerate
|
06.04.01.01 |
Oestrogens for HRT Elleste-Duet Conti® |
- 2mg estradiol and 1mg norethisterone
- 1 prescription charge.
|
06.04.01.01 |
Oestrogens for HRT Indivina |
- Estradiol valerate 1mg /Medroxyprogesterone 2.5mg
- Estradiol valerate 1mg /Medroxyprogesterone 5mg
|
07.02.01 |
Oestrogens, Topical Estring® |
- Vaginal ring, releasing estradiol approx. 7.5 micrograms/24 hours
|
07.02.01 |
Oestrogens, Topical Imvaggis® |
- Vaginal pessaries containing 0.03 mg estriol
- Local treatment of vaginal symptoms of estrogen deficiency in postmenopausal women. Manufacturer states not to be combined with systemic estrogen preparations.
- BaNES and Wiltshire only - not currently included on formulary for Swindon.
|
07.02.01 |
Oestrogens, Topical Ovestin® |
- Vaginal Cream 0.1% estriol. One applicator-dose is 0.5g cream containing 0.5 mg estriol.
- Licensed for Hormone Replacement Therapy (HRT) for treatment of atrophic vaginitis (due to estrogen deficiency) in peri- and post-menopausal women and
- Licensed as pre-surgery therapy for vaginal operations and during subsequent convalescence.
|
07.02.01 |
Oestrogens, Topical Vagifem® |
- Vaginal tablets containing estradiol hemihydrate equivalent to estradiol 10 micrograms.
|
05.01.12 |
Ofloxacin |
- The EMA’s Pharmacovigilence Risk Assessment Committee has recommended restricting fluoroquinolones following a review of disabling & potentially long-lasting side-effects. See link above for further information.
- Tablets 200mg
|
11.03.01 |
Ofloxacin |
- 0.3% eye drops
 in BaNES and Swindon
 in Salisbury
|
12.01.01 |
Ofloxacin 0.3% |
- Eye drops 0.3% (off label use)
- For chronic otitis media
|
13.02.01 |
Oilatum ® Cream |
- CREAM FOR MILD TO MODERATE DRY SKIN
- Available as 500ml pump or 500g tub
- Exactly the same as Oilatum Junior cream in constituents and price
|
13.02.01.01 |
Oilatum ® Plus emollient bath additive |
- BCAP area only
- This product has been included on formulary for the specific indication of MRSA decolonisation ONLY due to it containing Triclosan.
- See MRSA decolonisation guidance (BCAP) below.
|
04.02.01 |
Olanzapine |
- Injection 10mg/2ml (Rapid tranquilisation)
- Note: Olanzapine has been associated with an increased risk of hyperglycaemia, diabetes mellitus and exacerbations of diabetes. In patients with risk factors for diabetes mellitus, appropriate clinical and blood glucose monitoring should be conducted.
|
04.02.01 |
Olanzapine |
- Tablets 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg
- Orodispersible tablet 5mg, 10mg, 15mg, 20mg
-
Note: Olanzapine has been associated with an increased risk of hyperglycaemia, diabetes mellitus and exacerbations of diabetes. In patients with risk factors for diabetes mellitus, appropriate clinical and blood glucose monitoring should be conducted.
|
21.01.02 |
Olanzapine |
- Orodispersible tablet (Velotab®) 5mg
- For Nausea and Vomiting
|
08.02.04 |
Olaparib |
- 50mg capsules
- NB other strengths exist these are not formulary
|
12.01.03 |
Olive Oil Ear Drops |
- Please note: Patients should self-care in the first instance
|
03.01.01.01 |
Olodaterol Striverdi Respimat® |
- No new prescribing. Existing patients only - see notes above.
- The delivered dose is 2.5 microgram Olodaterol (as hydrochloride) per actuation.
|
11.04.02 |
Olopatadine |
- 1mg/1ml ophthalmic drops.
|
03.04.02 |
Omalizumab Xolair® |
- Injection, 150mg vial
- Commissioned by NHS England (for uncontrolled asthma) in accordance with NICE TA278.
Patients must be assessed and approved for a 16 weeks trial by
- MDT decision. Trial outcome to be assessed at regional MDTto decide if ongoing treatment is appropriate.
- Blueteq registration and approval is necessary for all new initiations and continuations.
|
13.05.03 |
Omalizumab |
- Commissioned by CCG (for chronic spontaneous urticaria) in accordance with NICE TA339
- 150 mg solution for subcutaneous injection in a pre-filled syringe
|
05.03.03.02 |
Ombitasvir/ paritaprevir/ ritonavir Viekirax® |
|
01.03.05 |
Omeprazole |
- 40mg powder for solution for infusion.
|
01.03.05 |
Omeprazole |
- 10mg, 20mg, 40mg capsules
- Note: it is more cost effective to prescribe 2 x 20mg caps than 1 x 40mg
- Omeprazole tablets are not cost-effective. Use caps instead.
- Omeprazole dispersible tablets are available for use ONLY in those with swallowing difficulties but first consider more cost-effective dispersible PPIs - see BSW PPI guidance for further information.
|
16.15 |
Omeprazole |
- Omeprazole 4mg/mL powder for oral suspension (Rosemont)
- RESTRICTED USE - Only for use following specialist recommendation for paediatric patients under 1 year of age or under 10kg whereby dispersible tabs/esomeprazole sachets are not appropriate (i.e. prescribed dose under 5mg or feeding tube in situ).
- To support review process of infants receiving doses ≥5mg or those with feeding tubes in situ at 12 months to transition to more cost effective PPI alternatives see link below.
- Omeprazole suspension is NOT included on the formulary for use outside this cohort (see here).
|
04.06 |
Ondansetron |
- Tablet 4mg, 8mg
- SyrupSF 4mg in 5ml
- Injection 4mg in 2ml, 8mg in 4ml
- Long term treatment is rarely justified or necessary.
- Ondansetron is used for the following groups of patients:
- For the prevention of PONV: in patients classified as ‘high risk’.
- In the treatment of PONV: for patients requiring rescue medicine.
- In general patients: those with protracted nausea and vomiting who have failed to respond to two conventional anti-emetics at full dose. If the symptoms are severe, ondansetron may be prescribed after trying only one conventional anti-emetic.
- See MHRA safety update link below: Recent epidemiological studies suggest exposure to ondansetron during the first trimester of pregnancy is associated with a small increased risk of the baby having a cleft lip and/or cleft palate.
|
21.01.02 |
Ondansetron |
- Tablet 4mg, 8mg
- SyrupSF 4mg in 5ml
|
21.02.02 |
Ondansetron |
|
04.09.01 |
Opicapone |
- Capsules 50mg
- Notes: Opicapone is significantly more expensive than entacapone. Opicapone is included in the formulary as a second line COMT inhibitor for the treatment of Parkinson's disease in patients who have been unable to tolerate a trial of a reasonable duration of entacapone (typically experiencing intolerable GI disturbances or unmanageable isues relating to stained secretions).
|
07.03.02.01 |
Oral Progestogen Only Contraceptives Norgeston® |
- Tablets containing levonorgestrel 30 micrograms.
- Note: If administration is delayed for 3 hours or more it should be regarded as a ‘missed pill'
|
09.02.01.02 |
Oral Rehydration Salts Dioralyte® Electrolade® |
|
12.03.05 |
Oralieve® spray |
- Xylitol/peroxidase and oxidase enzymes
- 50ml
|
16.15 |
Oralvac Compact |
- Unlicensed named patient product
- Consultant Specialist initiation only
- For treatment of severe allergic rhinitis and severe allergic conjunctivitis not responding to standard treatment
|
04.05.01 |
Orlistat |
|
04.09.02 |
Orphenadrine |
- Orphenadrine 50mg/5ml oral solution sugar free
|
24.01 |
Oscillating positive expiratory pressure (OPEP) Flutter®, Acapella®, Cronet® |
- Recommended for cystic fibrosis patients where PEP alone has proved ineffective
- BTS guidelines recommend OPEP should be considered for use with postural drainage and forced expiration when helping patients develop effective mucus clearance techniques
- For Bronchiectasis patients as per BTS. Physios to supply first device and show patients how to use. Replacement devices via FP10 via Physiotherapy ONLY
|
05.03.04 |
Oseltamivir Tamiflu® |
- Endorse SLS
- Capsules 30mg, 45mg, 75mg
- Suspension (SF) 6mg/ml
- Some drugs are restricted to prescribing in certain circumstances under the NHS and a list can be found under Part XVIIIA of the Drug Tariff. The prescriber must endorse any prescription with 'SLS' if the patient and purpose complies with that specified in the list. An example of such is where specific patient criteria are set. The drugs affected are highlighted throughout the formulary and the explanatory notes provide further guidance.
Where prescribing falls outside of the regulations, the drug may not be prescribed on the NHS.
|
08.02.04 |
Osimertinib |
|
08.01.05 |
Oxaliplatin |
- 50mg/10ml, 100mg/20ml and 200mg/40ml infusion
|
04.08.01 |
Oxcarbazepine |
- 150mg,300mg ,600mg tablets
- 60mg/ml oral suspension
|
11.07 |
Oxybuprocaine |
|
07.04.02 |
Oxybutynin |
- Specialist initiation for use in paediatrics or spinal/neurogenic bladder patients only.
- HIGHLY ANTICHOLINERGIC; avoid in >65yrs and frail. Inform of risk of serious side effects incl. cognitive impairment (see PIL below). Stop if not effective.
- Immediate release tablets 2.5mg, 3mg, 5mg - twice daily dosing. Side-effects may limit the use of immediate-release preparation.
- Modified release tablets 5mg, 10mg.
- Patch 36mg applied twice weekly. Restricted for those unable to take oral medicines.
- Liquid 5mg/5ml Cost warning £235.53 per 150mL and oral solution 2.5mg/5ml £214.85 per 150mL (prices Oct 2020).
|
04.07.02 |
Oxycodone |
- For non-cancer pain patients.
- M/R Tablets 5mg, 10mg, 20mg, 40mg, 60mg, 80mg
- Oxycodone may be initiated in preference to morphine for the management of pain by a specialist GP with an interest in pain or with pain team advice when: Dose escalation with morphine is not possible due to opioid toxicity eg. hallucinations, myoclonic jerks and confusion.
- For use in palliative care see chapter 21.
|
21.01.01.02 |
Oxycodone Longtec® |
- M/R Tablets 5mg, 10mg, 20mg, 40mg, 60mg, 80mg Longtec®. Prescribe by brand.
- For the treatment of moderate to severe pain in patients with cancer pain.
- Oxycodone may be initiated in preference to morphine for the management of pain by a GP with experience in palliative care or on the advice of the palliative care team or pain team when: Dose escalation with morphine is not possible due to opioid toxicity eg. hallucinations, myoclonic jerks and confusion.
|
21.01.01.02 |
Oxycodone Shortec® |
- Tablets 5mg, 10mg, 20mg, Shortec®.
- Oral solution 5mg/5ml, or concentrate 10mg/ml
- Prescribe by brand.
- Oxycodone may be initiated in preference to morphine for the management of pain by a GP with experience in palliative care or on the advice of the palliative care team or pain team.
|
21.02.01 |
Oxycodone |
- For palliative care use, specialist initiation
- 10mg/ml, 20mg/2ml, (ONLY on specialist advice prescribe 50mg/1ml)
|
05.01.03 |
Oxytetracycline |
|
13.06.02 |
Oxytetracycline |
- Tablets 250mg
- 500mg twice a day for 3 months then review (two tablets twice daily)
|
13.04 |
Oxytetracycline 3% /Hydrocortisone 1% Terra-Cortil ® |
- Mild potency steroid
- Ointment, Hydrocortisone 1%, oxytetracycline 3%, 30g
- Infected eczema at thin skin sites over the age of 12 years
|
07.01.01 |
Oxytocin Syntocinon® |
- Injection 5 units in 1ml, 10 units in 1ml
|
08.01.05 |
Paclitaxel |
- Various strengths of concentration
|
08.01.05 |
Paclitaxel Abraxane® |
|
08.01.05 |
Palbociclib |
- 75mg, 100mg and 125mg capsules
|
04.02.02 |
Paliperidone |
- AWP use only
- Xeplion® Long Acting Injection (LIA) 50mg, 75mg, 100mg, 150mg once a month after initial loading dose
- Be aware that there is also a Trevicta® Long Acting Injection (LIA) administered once every three months which is currently non-formulary.
|
05.03.05 |
Palivizumab |
- 50mg vial Injection
- 100mg vial Injection
- Note: use in line with JCVI guidance
|
01.09.04 |
Pancreatin Creon® |
- 10,000 unit & 25,000 unit (High Strength) capsules.
- Please note: 40,000 unit capsules were discontinued in June 2019.
- It is important to ALWAYS specify capsule strength on any prescription.
|
01.09.04 |
Pancreatin Pancrex® V |
- Oral powder
- Only for patients requiring pancreatic enzyme supplementation via enteral feeding tubes
|
15.01.05 |
Pancuronium |
|
08.01.05 |
Panitumumab |
- 100mg/5ml and 400mg/20ml infusion
|
08.02.04 |
Panobinostat |
- 10mg, 15mg and 20mg capsules
|
01.03.05 |
Pantoprazole |
GWH, SFT, RUH: Stress ulcer prophylaxis for use in Intensive Therapy Unit only. |
07.04.05 |
Papaverine |
- Injection 25mg, 80mg.
- RUH only
- Non formulary at SFT and GWH
|
04.07.01 |
Paracetamol |
- Tablet 500mg
- Dispersible tablet 500mg
- Oral SuspensionSF 120mg/5ml, 250mg/5ml
- Suppository 60mg, 120mg, 240mg, 500mg, 1g
- Avoid expensive paracetamol capsules, use tablets. If difficulty in taking tablets consider ‘caplets’ before soluble tablets.
Inform patients about the dangers of paracetamol overdose to prevent inappropriate self-medication. Some patients are considered high risk for hepatotoxicity with paracetamol. There is no clear consensus on dose adjustments which must be guided by clinical judgement. Consider dose reduction for patients with one or more of the following risk factors;
- Low body weight (less than 50kg)
- Likely glutathione depleted, i.e. Starvation / cachexia / chronic malnutrition / eating disorders
- Hepatic impairment
- Regular excess alcohol (ethanol) consumption
- Taking enzyme inducing medication (including; carbamazepine, phenobarbital, phenytoin, primidone, rifampicin, St John's Wort).
|
04.07.01 |
Paracetamol |
- Intravenous infusion 1000mg/100ml, 500mg/50ml (Perfalgan)
- Vigilance is advised when prescribing and administering Intravenous Paracetamol 10mg/mL solution for infusion, to ensure that the correct, weight-adjusted dose is ALWAYS given.
|
21.01.01.01 |
Paracetamol |
- Tablet 500mg
- Dispersible tablet 500mg
- Oral SuspensionSF 120mg/5ml, 250mg/5ml
- Suppository 60mg, 120mg, 240mg, 500mg, 1g
|
21.01.01.04 |
Paracetamol |
- Tablet 500mg
- Dispersible tablet 500mg
- Oral SuspensionSF 120mg/5ml, 250mg/5ml
- Suppository 60mg, 120mg, 240mg, 500mg, 1g
|
04.07.01 |
Paracetamol and codeine Co-codamol® 8/500 |
- Tablets 8/500
- Effervescent tablets 8/500
- Effervescent analgesics not generally recommended due to cost and high sodium content. Restricted to patients unable to swallow tablets.
- Low dose weak opioid combinations with paracetamol are not recommended because they offer little additional pain relief compared with regular full dose paracetamol.
|
04.07.01 |
Paracetamol and codeine Co-codamol® 30/500 |
- Tablets 30/500
- Effervescent tablets 30/500
- Effervescent analgesics not generally recommended due to cost and high sodium content. Restricted to patients unable to swallow tablets.
- Combination analgesics are not recommended.
|
04.07.01 |
Paracetamol and dihydrocodeine Co-dydramol® |
- Previously co-dydramol (dihydrocodeine/paracetamol) was available only in the ratio 1:50 (co-dydramol 10/500 mg). Two additional products are now available with a higher strength of dihydrocodeine (codydramol 20/500 mg and 30/500 mg tablets). It is therefore important that co-dydramol products are prescribed and dispensed by strength to minimise dispensing errors and the risk of accidental opioid overdose.
- Low dose weak opioid combinations with paracetamol are not recommended because they offer little additional pain relief compared with regular full dose paracetamol.
|
04.08.02 |
Paraldehyde |
- Consultant neurologist recommendation only
|
09.06.07 |
Paravit CF |
- For Cystic Fibrosis patients only
- Softgel capsules or liquid.
- Paravit-CF is a ‘Food for Special Medical Purposes’ containing vitamins A, D, E and K for the dietary management of patients with CF on the specific recommendation of a specialist in CF.
Paravit CF capsules provide an alternative vitamin supplementation option for CF patients, which offers patients a decreased oral medication load whilst also being a cost-effective option. Paravit CF liquid is only available as an option for patients with swallowing difficulties or young children.
|
04.03.03 |
Paroxetine |
- Tablets 10mg, 20mg, 30mg
- Oral Suspension 10mg/5ml 150ml
- Paroxetine has a place in therapy for anxiety disorder. Caution when stopping, higher risk of withdrawal reactions
|
09.02.01.01 |
Patiromer Sorbitex Calcium Veltassa® |
- 8.4g, 16.8g, 25.2g powder for oral suspension
- For use in line with NICE TA623
|
08.01.05 |
Pazopanib |
|
14.04 |
Pediacel ® |
- Suspension for injection in pre-filled syringe
- Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) and Haemophilus type b conjugate vaccine (adsorbed)
|
08.02.04 |
Pegaspargase |
|
08.02.04 |
Peginterferon Alfa Injection |
- 90microgram/0.5ml, 135microgram/0.5ml and 180microgram/0.5ml pre-filled syringes
|
08.02.04 |
Peginterferon Alfa Injection |
- 90microgram/0.5ml, 135microgram/0.5ml and 180microgram/0.5ml pre-filled syringes
- For the treament of leukaemia and lymphoma in accordance with cancer network guidelines
- For the treatment of Myeloproliferative Neoplasms e.g Essential Thrombocythaemia, Polycythaemia after hydroxycarbamide or anagralide.
|
08.02.04 |
Peginterferon Beta-1a Injection |
- 63microgram/0.5ml, 94microgram/0.5ml and 125microgram/0.5ml pre-filled pens
|
08.01.05 |
Pembrolizumab |
- 100mg/4ml concentration for solution for infusion
- 50mg powder for concentration for solution for infusion
- Also available from NHS England Cancer Drugs Fund
- NICE does not recommend pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650).
|
08.01.03 |
Pemetrexed |
|
10.01.03 |
Penicillamine |
-
 - BaNES, Salisbury & Swindon (except Swindon patients monitored via the DAWN system and provided with prescriptions by GWH)
-
 - Swindon DAWN patients
- 125mg and 250mg tablets
- Please refer to our DMARD Shared Care and Monitoring Guidance for your respective locality for further information
|
11.03.01 |
Penicillin |
- 5000 units in 1ml eye drops
- GWH only. Non formulary at RUH and SFT
|
05.04.08 |
Pentamidine Isetionate Injection |
- 300mg Powder for Solution for Injection/Infusion
- Powder for injection (dissolved in water for injection) may be used for nebulisation. Not licensed for primary prevention of Pneumocystis jirovecii (Pneumocystis carinii) pneumonia by inhalation of nebulised solution.
|
07.04.03 |
Pentosan polysulfate sodium |
Secondary care use only for treating bladder pain syndrome in line with NICE TA610 (link below). |
08.01.05 |
Pentostatin |
|
01.02 |
Peppermint Oil |
- 0.2ml gastro-resistant capsules.
- Please note: Gastro-resistant capsules are more cost effective than MR capsules.
- Please prescribe most cost-effective brand of gastro-resistant capsules BY BRAND. Mintec® or Apercap® are cost-effective brands in primary care.
|
01.02 |
Peppermint water |
|
01.01.02 |
Peptac ® Suspension |
- Suspension SF containing sodium alginate 250mg, sodium bicarbonate 133.5mg & calcium carbonate 80mg per 5ml, with equivalent of 6.2 mmol of sodium per 10ml.
- Please note: Peptac is our first-line option, as it is more cost-effective than Gaviscon Advance.
|
04.08.01 |
Perampanel |
- Tablets 2mg, 4mg, 6mg, 8mg, 10mg, 12mg (Category 2 MHRA)
- Initiated by a specialist for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older who have failed on treatment with all first and second line agents.
- Perampanel oral suspension 500mcg/ml is available but is expensive. Use only if no other option is suitable and there are significant swallowing problems.
|
11.08.02 |
Perflurodecaline Heavy Liquid |
-
 - GWH - For use in Ophthalmology.
- Non-formulary- SFT & RUH.
- 5ml vial.
|
02.05.05.01 |
Perindopril |
- 2mg, 4mg, 8mg
- Prescribe generically as erbumine salt.
|
13.10.04 |
Permethrin 5% |
|
08.01.05 |
Pertuzumab |
|
04.07.02 |
Pethidine |
- 50mg/ml and 100mg/2ml
- Hospital use only: (GWH and RUH) NOT for primary care prescribing.
|
04.03.02 |
Phenelzine |
- Tablets 15mg
- Patients should avoid consuming large amounts of tyramine-rich food (such as mature cheddar, yeast extracts, red wine and fermented soya bean products) and sympathomimetics (such as ephedrine, pseudoephedrine and phenylpropanolamine).Patients should be advised to take last dose before 3pm in order to minimise sleep disturbance / insomnia.Refer the patient to the patient information leaflet (PIL) supplied with the product for dietary restrictions.
|
02.08.02 |
Phenindione |
- 10mg, 25mg, 50mg (Very costly £538 for 28 tablets June 2019)
- Only for patients who are hypersensitive to warfarin.
|
04.08.01 |
Phenobarbital |
- Tablets 15mg, 30mg, 60mg (Category 1 MHRA)
- For existing patients ONLY - maintain patients on existing brands.
|
04.08.02 |
Phenobarbital |
- 30mg/1ml,60mg/1ml,200mg/1ml
|
01.07.03 |
Phenol, Oily |
|
02.05.04 |
Phenoxybenzamine Hydrochloride Oral,injection |
- Capsule 10mg
- Injection- note supply problems
|
05.01.01.01 |
Phenoxymethylpenicillin Oral |
- Tablets 250mg
- Oral solution (SF) 125mg/5ml, 250mg/5ml
|
02.05.04 |
Phentolamine |
|
18 |
Phentolamine |
|
10.01.01 |
Phenylbutazone |
- RUH and GWH - Restricted for prescribing by Consultant Rheumatologist for named patients with ankylosing spondylitis.
- SFT - Restricted for prescribing by Consultant Rheumatologist for named patients with ankylosing spondylitis stabilised on therapy. No new patients.
|
02.07.02 |
Phenylephrine |
|
11.05 |
Phenylephrine 5.4mg and Tropicamide 0.28mg Ophthalmic Insert |
- RUH and Salisbury only
- Non formulary at GWH
|
11.05 |
Phenylephrine Hydrochloride |
- Phenylephrine 2.5% and 10% eyedrops
- GWH only - Phenylephrine 1% injection for consultant/senior ophthalmologist approval
|
04.08.01 |
Phenytoin |
- Capsule 25mg, 50mg, 100mg, 300mg Flynn brand.
- Prescribe by brand (Category 1 MHRA)
- Suspension 30mg in 5ml Epanutin brand (15ml of suspension approx. equal to one 100mg phenytoin sodium capsule).
|
04.08.02 |
Phenytoin |
- Intravenous injection 250mg/5ml
|
03.09.01 |
Pholcodine Linctus, BP |
 - BaNES
 - Salisbury
- Non-formulary -Swindon
|
01.06.04 |
Phosphate |
|
09.05.02.01 |
Phosphate Polyfusor ® |
- IV infusion 500ml (Polyfusor)
- National supply problem with Phosphate Polyfusor® which is anticipated to continue until at least October 2020. There is no direct replacement but Glycophos® can be used to provide parenteral phosphate replacement.
|
09.05.02.01 |
Phosphate supplements Phosphate-Sandoz® |
- Effervescent Tablets: 500mg containing the equivalent of 16.1mmol phosphate
|
02.08.03 |
Phytomenadione |
- 10mg/1ml and 2mg/0.2ml solution for injection ampoules
RUH policy for managing patients with high INR on warfarin in primary care here |
09.06.06 |
Phytomenadione Konakion® MM |
- Injection 10mg in 1 ml
- Fat soluble formula (not malabsorption)
- Can be given orally for patients on warfarin at risk of bleeding with high INR. See reversal guidance in chapter 2.8.3
|
09.06.06 |
Phytomenadione Konakion® MM Paediatric |
- Paediatric preparation
- 2mg in 0.2ml
- Fat soluble formula (not malabsorption)
- Can be given orally for patients on warfarin at risk of bleeding with high INR. See reversal guidance in chapter 2.8.3
|
09.06.06 |
Phytomenadione |
- 10mg tablets
- Note added June 2020: The licensed 10mg tablets have been discontinued by the manufacturer. Unlicensed forms including tablets and casules may be available from special-order manufacturers. Prescribing of these for new patients should be retained by secondary care. Advice for existing patients on phytomenadione in primary care can be discussed with BSW medicines optimisation team bswccg.prescribing@nhs.net
|
01.06.05 |
Picolax ® Sachet |
- 16.1g sachet containing citric acid anhydrous 10.97 gram, magnesium oxide light 3.5 gram & sodium picosulfate 10 mg.
|
11.06 |
Pilocarpine |
- 2% and 4% eyedrops.
- 2% preservative-free minims (Swindon only).
|
12.03.05 |
Pilocarpine Hydrochloride Oral |
- GWH and SFT only
- 5mg tablets
- Useful in refractory sjogrens
|
13.05.03 |
Pimecrolimus |
- Cream 1%: 30g, 60g, 100g
- Apply only until symptoms resolve, as per BNF, in accordance with NICE
- Only on prescription by a Clinician experienced in skin disease
- Short term treatment of mild to moderate atopic eczema (including flares) when topical corticosteroids cannot be used or as advised by a specialist.
|
06.01.02.03 |
Pioglitazone |
- 15mg, 30mg, 45mg
- Use in accordance with NICE NG28.
|
05.01.01.04 |
Piperacillin and Tazobactam Injection |
- Piperacillin 2g/ tazobactam 250mg
- Piperacillin 4g/ tazobactam 500mg
- Piperacillin/Tazobactam 13500mg via surefuser + device over 24hrs
- Usual duration is 5-14 days.
|
16.14 |
Piroxicam |
Swindon only. Third line in children unresponsive to or intolerant of Ibuprofen and Diclofenac.
Non-formulary in BaNES and Salisbury |
05.01.01.05 |
Pivmecillinam |
- Tablets 200mg
- Do NOT use if penicillin allergic.
- See primary care antibiotic guidance for UTI guidance
|
05.01.13 |
Pivmecillinam |
- Tablets 200mg
- Use if 1st line nitrofurantoin is unsuitable and eGFR <45ml/min
- Do NOT use if penicillin allergic
|
08.01.02 |
Pixantrone |
|
16.15 |
Pizotifen |
- 500microgram tablet
- 1.5mg tablet
- Pizotifen is only included for prophylaxis of migraine in paediatrics. See Chapter 4.7.4.2 for BSWformulary choices for migraine in adults.
|
01.06.05 |
Plenvu® |
-
 - BaNES - For use as a second-line bowel cleansing agent, where lower fluid volume is desirable or the taste of MOVIPREP has led to treatment failure.
 - GWH - ONLY for use as a bowel cleansing agent prior to colonoscopy, as part of a 6-month trial, finishing at the end of Jan 2020, at which point formulary status will be reviewed, and may be revoked, unless audit outcome data is favourable.
- SFT - ONLY for use as a bowel cleansing agent prior to colonoscopy, as part of a 6-month trial, at which point formulary status will be reviewed, and may be revoked, unless audit outcome data is favourable.
-
Dose 1 (single sachet), providing when reconstituted to 500mL with water Na+ 160.9 mmol, K+ 13.3 mmol & Cl- 47.6 mmol.
-
Dose 2 (sachets A and B), providing when reconstituted to 500mL with water Na+ 297.6 mmol, K+ 16.1 mmol & Cl- 70.9 mmol.
|
09.01.07 |
Plerixafor |
- RUH and SFT - For use in line with NHS England Policy B04/P/2 January2014
- GWH not on formulary
- 20mg/ml 1.2ml vial
|
14.04 |
Pneumococcal polysaccharide conjugate vaccine (adsorbed) Prevenar 13® |
- Primary Care: at NHS expense for infants as part of the routine childhood immunisation programme (order free of charge via Immform)
|
13.07 |
Podophyllotoxin |
- Solution 0.5% 3ml, Cream 0.15% 5g
- Genital warts. Apply twice daily, morning and evening (every 12 hours) for 3 consecutive days. Stop for next 4 consecutive days then repeat for three days at weekly intervals up to 4 weeks.
- Note on Traffic Light Status: Prescribers should consider the commissioning of local GUM clinics. In some areas this may be supplied directly from a specialist GUM clinic. It has been allocated a GREEN TLS and can be prescribed for anogenital warts in primary care if:
- Supplied under a PGD.
- Referral to a sexual health specialist is not possible (because it is declined or unavailable) and the diagnosis of external genital warts can be confidently made.
- The skills and resources to provide comprehensive assessment and treatment, as well as screening and contact tracing for other sexually transmitted infections are available.
|
13.07 |
Podophyllum |
- Podophyllin in benzoin Compound tincture 25% BP Paint
|
08.01.05 |
Polatuzumab vedotin |
- 140mg powder for concentrate for solution for infusion vials
- For use in combination with rituximab and bendamustine in line with NICE TA649
|
11.03.01 |
Polihexanide |
- 0.02% eye drops
- GWH and RUH only. Non formulary at SFT
|
06.01.06 |
Polycal ® Liquid |
- Bottles 200ml containing Carbohydrate 62g/100ml
- Salisbury - not on formulary
|
14.04 |
Polysaccharide Typhoid Vaccine Typherix® |
|
14.04 |
Polysaccharide vaccine for injection Typhim Vi® |
|
09.02.01.01 |
Polystyrene Sulphonate Resins Calcium Resonium® |
- Powder calcium polystyrene sulphonate.
- Note: Calcium resonium can be taken orally mixed in water (not fruit juice or other potassium containing fluids) or rectally.
|
13.05.02 |
Polytar® |
- Coal tar solution 2.5%, arachis (peanut) oil extract of coal tar 7.5%, tar 7.5%, cade oil 7.5%, light liquid paraffin 35%
- 150ml bottle
|
08.02.04 |
Pomalidomide |
|
08.01.05 |
Ponatinib |
- 15mg, 30mg and 45mg tablets
|
03.05.02 |
Poractant Alfa Curosurf® |
|
05.02 |
Posaconazole |
- Suspension 200mg/5ml
- 100mg tablet
- In accordance with prophylaxis/treatment guidance for neutropenic patients
|
05.02 |
Posaconazole |
- RUH only as per anti-fungal guidance
|
09.02.01.01 |
Potassium Chloride Kay-Cee-L® |
- Potassium chloride 375mg/5ml oral solution sugar free (total potassium 1mmol per mL syrup)
- Contains sorbitol: May cause osmotic diarrhoea
|
09.02.01.01 |
Potassium Chloride Sando-K® |
- Effervescent tablets each containing Potassium chloride 600mg / Potassium bicarbonate 400mg (total potassium 12mmol) per tablet
|
09.02.02.01 |
Potassium Chloride |
- For the administration of IV Potassium infusions available in the Trust, refer to Trust Policy
- Pre-mixed infusion solutions should be used when possible.
- Medical errors involving Sterile Potassium Chloride Concentrate (20mmol/10ml {15%}) can be potentially fatal.
- The use of Sterile Potassium Chloride Concentrate (20mmol/10ml {15%}) is restricted to use in areas that require potassium-containing fluids not available as pre-mixed solutions.
|
13.11.06 |
Potassium Permanganate Permitabs® |
- Permitabs® solution tablets 400mg
- 1 tablet to be dissolved in 4 litres of water to provide a 0.01% (1 in 10,000) solution
- Notes:
- It stains; keep out of contact with clothing, fabrics etc.
- Do not use a ceramic basin or bath as these will stain.
|
13.11.04 |
Povidone-Iodine Betadine® or Videne® |
- Alcoholic solution, povidone-iodine 10% in industrial methylated spirit 95%
- Antiseptic solution, povidone-iodine 10% in aqueous solution
- Surgical scrub, aqueous solution, povidone-iodine 7.5%
|
04.09.01 |
Pramipexole |
- Tablets 88 micrograms, 180 micrograms, 350 micrograms, 700 micrograms (generic)
- Tablets m/r 260 micrograms, 520 micrograms, 1.05mg, 1.57mg, 2.1mg, 2.62mg, 3.15mg
- Abrupt discontinuation of dopaminergic therapy can lead to the development of a neuroleptic malignant syndrome or a dopamine agonist withdrawal syndrome. The Pramipexole should be tapered off as per advice in the SPC. Dopamine agonist withdrawal syndrome could still appear while tapering and a temporary increase of the dose could be necessary before resuming tapering.
|